

Victorian paediatric oncology care pathways

Providing optimal care for children and adolescents

Acute leukaemia, central nervous
system tumours and solid tumours

May 2019

Victorian paediatric oncology care pathways: Providing optimal care for children and adolescents
Acute leukaemia, central nervous system tumours and solid tumours

Published May 2019 (This version supersedes the fundamental of care and acute leukaemia pathway published June 2017 and the central nervous system tumours pathway published June 2018).

Suggested citation: Paediatric Integrated Cancer Service (2019). *Victorian paediatric oncology care pathway: Providing optimal care for children and adolescents – Acute leukaemia, central nervous system tumours and solid tumours*. Paediatric Integrated Cancer Service, Melbourne, Australia.

Administrative Host:

The Royal Children's Hospital
1st Floor South Building
50 Flemington Rd
Parkville, Victoria 3052

Telephone +61 3 9345 4433
Email pics.admin@rch.org.au
Website www.pics.org.au



The Paediatric Integrated Cancer Service is supported by the Victorian Government

Disclaimer: The information in these pathways is considered to be true and correct at the date of publication, however, changes in circumstances after the time of publication may impact on the accuracy of this information. The pathway is intended to support health services to decide how best to organise service delivery to achieve the best outcomes. The pathway is not intended to constitute medical advice or replace clinical judgement.

Contents

Foreword.....	3	Summary: Optimal timeframes.....	26
Background.....	4	STEP 1: Prevention and early detection.....	27
Purpose.....	5	STEP 2: Presentation, initial investigations and referral.....	27
Scope.....	5	STEP 3: Diagnosis, staging and treatment planning.....	28
Critical time points.....	5	STEP 4: Treatment.....	32
How to navigate the paediatric oncology care pathway.....	5	Step 5: Care after completing therapy and survivorship.....	36
SECTION 1. PAEDIATRIC ONCOLOGY CARE PATHWAY – FUNDAMENTALS OF CARE	7	STEP 6: Managing refractory disease or relapse.....	37
Why an oncology care pathway for children and adolescents with cancer?.....	8	STEP 7: End-of-life care.....	39
Safe and quality care.....	8	Ongoing commitment to continuous improvement in the treatment of acute leukaemia.....	39
Principles of care	10	SECTION 3. PAEDIATRIC ONCOLOGY CARE PATHWAY – CENTRAL NERVOUS SYSTEM (CNS) TUMOURS	40
Family-centred care.....	10	Classification of CNS tumours seen in children and adolescents.....	42
Multidisciplinary care.....	10	Distribution of CNS tumours seen in children and adolescents.....	43
Care coordination.....	11	Summary.....	44
Consistency of care.....	11	STEP 1: Prevention and early detection.....	46
Communication.....	11	STEP 2: Presentation, initial investigations and referral.....	46
Place of care.....	11	STEP 3: Diagnostic work-up, staging and treatment planning.....	48
Adolescent care.....	11	STEP 4: Treatment.....	52
Transition from paediatric to adult care.....	12	STEP 5: Care after completing therapy and survivorship.....	57
Fundamentals of paediatric oncology practice	12	STEP 6: Managing refractory disease or relapse.....	59
Evidence-based practice – research and clinical trials.....	12	STEP 7: End-of-life care.....	60
Supportive care.....	13	Ongoing commitment to continuous improvement in the treatment of CNS tumours.....	61
Fertility.....	16	SECTION 4. PAEDIATRIC ONCOLOGY CARE PATHWAY – SOLID TUMOURS.....	62
Complementary and alternative medicine in childhood cancer.....	18	Reporting of solid tumours seen in children and adolescents.....	63
Genetic predisposition to cancer.....	18	Distribution of solid tumours seen in children and adolescents.....	64
Educating the patient and family.....	19		
Coming off treatment.....	19		
Survivorship.....	20		
Relapse.....	20		
End-of-life care.....	21		
SECTION 2. PAEDIATRIC ONCOLOGY CARE PATHWAY – ACUTE LEUKAEMIA.....	22		
Summary.....	24		

STEP 1: Prevention and early detection.....	64
STEP 2: Presentation, initial investigations and referral.....	65
STEP 3: Diagnostics, staging and treatment planning.....	65
STEP 4: Treatment.....	68
STEP 5: Care after completing therapy and survivorship.....	72
STEP 6: Managing refractory disease or relapse.....	73
STEP 7: End-of-life care.....	74
Disease-specific considerations: sarcomas.....	74
Disease-specific considerations: lymphomas.....	78
Disease-specific considerations: embryonal tumours.....	81
Disease-specific considerations: germ cell tumours.....	88
Disease-specific considerations: histiocytic disorders.....	90
Disease-specific considerations: rare paediatric solid tumours.....	92
Ongoing commitment to continuous improvement in the treatment of solid tumours.....	94
Glossary.....	95
Acknowledgements.....	98
References.....	101

Foreword

Childhood cancer is by definition rare, and treatments are complex. Surveillance and follow-up are a lifelong process. Clinical management is characterised by the diversity of disease presentation, lead coordination by tertiary centres with higher case volumes, and the central role of clinical trials. The care experience is profoundly impacted by the patient’s age, developmental stage and disease risk profile as well as the need for parents/guardians to act as decision makers.

Treatment and care for children diagnosed and treated for cancer is complex and challenging for all those involved. It involves multiple professionals and sometimes multiple services that may be close or distant to home. Best outcomes demand a timely, multidisciplinary, collaborative approach.

Documented cancer care pathways map the journey for specific disease/tumour types, aiming to foster an understanding of the whole pathway and its distinct components to promote quality cancer care and patient experiences. These pathways act as a reminder that the patient and family is the constant in the care continuum and that the health system has a responsibility to deliver the care experience in an appropriate and coordinated manner.

To be useful, a paediatric oncology care pathway needs to encompass the specific challenges of childhood cancer management. The Victorian Paediatric Integrated Cancer Service (PICS), supported by the Victorian Department of Health and Human Services, developed these oncology care pathways explicitly tailored for the care of children and adolescents. We acknowledge with gratitude the model provided in the adult cancer sector by the Optimal Care Pathways for Cancer Program, auspiced by the National Cancer Expert Reference Group.

The purpose of the paediatric oncology care pathways initiative is to improve children’s outcomes by facilitating consistent cancer care based on a standardised pathway of care. The principles and the standards of good cancer care are not expected to differ from service to service, even though treatment regimens may vary from patient to patient for a variety of reasons.

A wide range of multidisciplinary clinicians and stakeholders in paediatric cancer were consulted or participated in the care pathway development including parent representatives. We want to thank all involved for their generous contributions. We are sure those providing paediatric cancer care will find the specific pathways useful in deciding how best to organise service delivery to achieve the best outcomes for those we care for. Importantly, readers should note that the pathway is not intended to constitute medical advice or replace clinical judgement.

The PICS is a partnership between the health services that deliver care and treatment to children and adolescents with cancer in Victoria. The paediatric oncology care pathways have been adopted by the PICS partners. Other jurisdictions are invited to adopt and co-badge these for their local use.



Professor Yves Heloury
PICS Medical Director



Jane Williamson
PICS Program Manager

Background

Paediatric oncology care pathways are intended to guide the delivery of consistent, high-quality, evidence-based care for patients with cancer. The pathways align with key service improvement priorities including providing access to coordinated multidisciplinary care and reducing unwarranted variation in practice.

The paediatric oncology care pathways are modelled on the adult Optimal Care Pathways developed by the Victorian Department of Health and Human Services and the Cancer Council Victoria (via the National Cancer Expert Reference Group). These are accessible at www.cancer.org.au/ocp

Each care pathway outlines seven critical steps:



Purpose

Oncology care pathways can be used by health services and professionals as a tool to identify gaps in current cancer services and to inform quality improvement initiatives across all aspects of the care pathway.¹ Clinicians can also use the pathways as an information resource and tool to promote discussion and collaboration between health professionals and families affected by cancer.¹ The pathways can also be very helpful for health professionals who may only have discrete involvement at one step in understanding the whole continuum of care.²

The paediatric oncology care pathways are also intended to provide a reference point for general practitioners (GPs) and paediatricians to guide decision making regarding referral to a paediatric cancer service and supporting shared care arrangements. They also provide guidance for the paediatric cancer service in the referral process to survivorship clinics and transition to adult healthcare.

This document is not intended to be a clinical practice guideline (CPG) and does not replace expert, multidisciplinary professional advice or clinical trial demands.

This document, dated May 2019, includes the Victorian paediatric oncology care pathway fundamentals of care, applicable to all tumour streams, and the oncology care pathways for acute leukaemia, central nervous system tumours and solid tumours.

Scope

The paediatric oncology care pathways are intended as a resource in managing children and adolescents diagnosed with cancer from birth up to 18 years of age.

Critical time points

The blue clock symbol  is used throughout this document to highlight a critical time point that has a specific timeframe attached to it.

A red clock symbol  indicates the time point is part of an **urgent pathway**.

How to navigate the paediatric oncology care pathway

There are unique challenges in caring for children and adolescents with cancer that are distinct from the adult population. These include:

- the different disease types and prevalence
- the rarity and complexity of childhood cancer
- the impact of treatment on the developing child and the risk of significant late effects
- the increased role of clinical trials and need for international collaboration
- the family-centred versus patient-centred model of care.

The 'fundamentals of care' section covers key principles and fundamentals of paediatric oncology practice that underpin the care of all children and adolescents with cancer. Following that, disease/tumour specific pathways are outlined in separate sections. A summary is provided at the beginning of each disease/tumour specific pathway to highlight key aspects of each stage of care and emphasise critical time points.

SECTION 1:

**PAEDIATRIC ONCOLOGY CARE PATHWAY –
FUNDAMENTALS OF CARE**

The ‘fundamentals of care’ section covers key principles and fundamentals of paediatric oncology practice that underpin the care of all children and adolescents with cancer. Following that, disease/tumour specific pathways are outlined in separate sections.

Why an oncology care pathway for children and adolescents with cancer?

- Cancer in children is rare and treatments are often complex.
- The types of childhood cancer differ greatly from those experienced in adults.
- Early diagnosis is important but can be challenging due to the rarity of the disease and diversity of presentations.

Safe and quality care

Health policy in Victoria is firmly anchored in principles of safety and quality. The State government has clearly outlined its vision for delivering better, safer care across the health system. The vision includes the following aspirations:³

- “World-class care patients receive is supported by a world-class system of quality and safety assurance
- Patient views and experiences are heard and shared at every point of the health system to drive continuous improvement
- Frontline healthcare workers have a real say on how to make the system safer and lead the way on improvement and best practice
- Individual safety and quality success is shared and built into the state-wide system”.

The Victorian paediatric oncology community shares this vision for better, safer care and recognises the adoption of care pathways as a tool for achieving service improvement.

Service capability – minimum standards

The paediatric oncology care pathways will be delivered by appropriately trained and credentialed clinicians within hospitals and health services that meet the minimum standards articulated in the Victorian Paediatric Integrated Cancer Service (PICS) documents:^{4,5}

- *Service capability framework: a guide for Victorian health services providing primary treatment and shared care to children and adolescents with cancer (2014)*
- *Service capability framework: a guide for Victorian health services providing radiation therapy to children and adolescents with cancer (2015).*


The objectives of these two frameworks are to:

- describe a coordinated system of state-wide paediatric oncology care
- support a sustainable model of care with efficient use of resources across health services
- support and advocate for patient safety through describing minimum recommended capability while providing care as close to home as possible
- provide clear and consistent language across state-wide services.

The emphasis of these frameworks is to define the minimum level of service capability required of health services across different time points in a child’s care. The frameworks support health services to plan, develop and deliver a high level of safe and effective paediatric cancer care within an agreed scope of practice. By documenting minimum requirements, health services will be assisted to deliver services that meet the local needs of the community and build confidence in shared care referrals between health services.

The *Service capability framework: a guide for Victorian health services providing primary treatment and shared care to children and adolescents with cancer*, identifies six paediatric cancer service levels, as outlined in Figure 1.

Figure 1: The levels of paediatric cancer services



The service capability frameworks are described in terms of the following dimensions:

- time points and level of complexity of care
- infrastructure
- speciality services
- workforce
- education and research
- quality and clinical governance
- service links and networks.

Whilst the frameworks define the minimum requirements for health services, this document builds on these requirements by defining optimal paediatric cancer care.

Principles of care

Family-centred care

In Australia, family-centred care is a philosophy of care endorsed by the paediatric healthcare community.^{6,7} It has been defined across eight elements:⁸

- the family is central and constant in the child's life, while healthcare services change
- the facilitation of family-professional collaboration at all levels of healthcare, including program development, implementation and evaluation
- the exchange of complete and unbiased information between families and professionals, in a supportive manner
- recognition of cultural diversity across and within all families
- provision of developmental, educational, emotional, environmental and financial supports to meet the diverse needs of families
- encouragement of 'family-to-family' support and networking
- ensuring systems for children needing specialised care, and their families, are flexible, accessible and comprehensive
- the appreciation that children and families possess a wide range of strengths.

A family-centred care philosophy is required in the design, promotion, communication and delivery of all aspects of the care pathway for children and adolescents with cancer.

Multidisciplinary care

A centralised multidisciplinary approach to paediatric oncology care forms the basis of leading institutional recommendations^{9,10,11} and has been demonstrated to improve patient outcomes.^{12,13,14} The expertise within a disease-specific multidisciplinary team (MDT), usually located within a tertiary referral centre, is of particular importance in the field of paediatric cancer due to the rarity and complexity of management. The 'high-volume effect' within tertiary referral centres has been shown to improve survival outcomes in the paediatric oncology population.¹⁵

Multidisciplinary care is one of the key areas of reform for the Integrated Cancer Services in Victoria. Effective MDTs can support:

- improved treatment
 - improved communication
 - improved coordination of care
 - improved access to clinical trials
 - reduced service duplication
 - better consideration of patient (and family) needs
 - better promotion of shared learning and professional development.
- It is a requirement that all children with a provisional cancer diagnosis be discussed at a paediatric oncology multidisciplinary meeting (MDM), with definitive diagnosis and prospective treatment planning forming the core themes.
 - Core attendees of the MDM include all experts who are appropriate to the diagnosis.
 - Documentation and dissemination of meeting outcomes are shared with key stakeholders including the family, the child or adolescent's GP and, if applicable, their paediatrician.

Care coordination

Care coordination is a comprehensive approach to achieving continuity of care, ensuring that care is delivered in a logical, connected and timely manner to meet the needs of the patient.¹ In the context of a child or adolescent with cancer, this approach incorporates both the child and their family and includes MDMs, supportive care screening/assessment, referral practices, data collection, clinical trial participation, information provision and individual clinical treatment.

There should be a designated nurse within the MDT allocated to the child or adolescent with cancer with the responsibility to coordinate and communicate care.

Consistency of care

The primary oncologist should provide direct clinical consultation at all critical time points during the child or adolescent's treatment. These time points include:

- at diagnosis
 - following investigations measuring response to treatment
 - prior to each new cycle of treatment defined by the protocol
 - following any significant morbidities
 - at the end-of-treatment
- and, if applicable:
- at relapse
 - during the transition to treatment with a primarily palliative intent
 - during the transition to end-of-life care
 - during bereavement.

Communication

Communication with the child or adolescent with cancer and their family should be:¹

- individualised
- candid and transparent
- consistent
- in plain language (avoiding complex medical terms and jargon)
- culturally sensitive

- active, interactive and proactive
- ongoing
- delivered in an appropriate setting and context
- offered in a variety of means such as printed and electronic media.

For the child or adolescent, information should also be tailored to their age and/or level of cognitive development. Medical play may support the needs of younger children, while opportunities for 'time alone' with the healthcare provider may benefit adolescents.

Place of care

Definitive diagnosis, staging/risk assessment and treatment planning for all children and adolescents aged 15 years or younger is made at a level five or six paediatric cancer service.

Adult health services managing patients with 'paediatric-type' cancers should have links to and advice from a level five or six paediatric cancer service and relevant MDTs.

Children and adolescents with 'adult-type' cancers should have links to and advice from an adult oncology service and relevant MDTs.

The child or adolescent's usual place of residence should be considered when determining the most suitable place of care. For patients living in outer metropolitan and regional areas, efforts should be made to support localised and home-based care when it is safe to do so.

Adolescent care

Adolescence is a time of considerable growth and development. These changes are characterised by physical, psychological, social, emotional and sexual maturational processes and can pose significant challenges.¹⁶ The normal developmental process will be significantly harder for adolescents with a serious illness. Additional challenges include:

- difficulty fostering and maintaining peer relationships
- potential loss of autonomy and independence and the need for increased parental support
- sexual and reproductive health
- potential emerging mental illness
- education and vocation challenges
- the concept of assent and/or consent to treatment.

The health service needs to be cognisant of the needs of adolescents by:¹⁷

- ensuring access to expert adolescent health professionals with knowledge specific to the biomedical and psychosocial needs of the population
- understanding the biology and current management of the disease in adolescence
- considering clinical trials accessibility and recruitment for each patient
- engaging in proactive discussions and management of fertility optimisation and the late effects of treatment
- providing treatment in an adolescent and young adult (AYA) friendly environment
- acknowledging the importance of educational support in this age group
- fostering opportunities in adolescents for ‘time alone’ with health professionals where applicable
- promoting normality.

Transition from paediatric to adult care

Effective transition of adolescent survivors of cancer is an important part of the care continuum. As the incidence of late effects following treatment for childhood cancer has been shown to increase with age,¹⁸ it is important that effective transition to adult care takes place to enable ongoing surveillance and earlier detection and intervention of late effects.

Challenges include the adolescent adhering to ongoing appointments when the focus of those appointments has moved from treatment to surveillance, often in a different healthcare setting¹⁹ and with reduced parent involvement. Oncology services have limited involvement once the adolescent no longer has cancer. These patients may also require expertise from several specialties in the long-term, making the transition more complex.

The model of care for transition will also depend on the availability of resources, the risk stratification of the individual and the complexity of care required. This means that some patients will remain in the tertiary adult healthcare sector rather than with their GP. Regardless of risk, a model that incorporates the patient’s GP will reduce the potential for patients to be ‘lost in transition’ and is recommended.

Core principles for transitioning to survivorship programs should include the following:²⁰

- the survivorship healthcare setting should be appropriate to the patient’s age and cognitive development
- common concerns of young adulthood should be addressed in addition to speciality care. These include fertility, sexual health, contraception, self-management, psychosocial and emotional risk factors and access to healthcare¹⁹
- transition should promote autonomy, personal responsibility, self-reliance and a healthy lifestyle in young adults
- transition programs should be flexible to meet the changing needs of the young adult
- the process should be planned with the young adult and their family.

Fundamentals of paediatric oncology practice

Evidence-based practice – research and clinical trials

As the number of children and adolescents diagnosed with cancer is small, participation in collaborative international clinical trials is essential. This allows patients access to a wide range of trials and also enables the trials to recruit the critical mass of participants needed to deliver outcomes in the shortest possible timeframe. Outcomes may include improvement in overall survival or reduction in therapy, toxicities and/or late effects, as well as improved quality of life. Clinical trials may also enable access to off-label emerging therapies that would otherwise be unavailable to the clinician and patient. It is important to note that as more personalised, individual approaches to treatment increase the number of subpopulations of each disease, the already small disease population will become smaller.

- Eligibility for clinical trial enrolment should be considered for and offered to all children and adolescents diagnosed with cancer.
- For children who do not meet eligibility criteria, where enrolment is declined, or where a clinical trial is not open, the patient should follow the most recently completed and published ‘standard of care’ treatment protocol offering the best possible outcome (this may not be the current open trial).
- The cancer service should maintain a database of clinical trial enrolment for each diagnosis.
- Reasons why eligible patients are not enrolled and why patients come off study should be collated and any identified issues examined.

Trials in other disciplines in child and adolescent cancer care

Participation in clinical trials and research should be encouraged in areas other than primary treatment. These include:

- supportive care – for example, infection control and prevention strategies, palliative care, complications of therapy, nutrition, antiemetic control and fertility²¹
- epidemiology – for example, investigation of genetic causes to develop preventative measures²²
- behavioural science – for example, neurocognitive batteries and assessment, identification of at-risk families and children, and psychological and behavioural interventions²³
- nursing – for example, efficacy of patient and family education and reducing illness-related distress.²⁴

Research and data collection

Other initiatives that should be encouraged include participation in a state-wide approach to trials and participation in national and international cancer registries and survivorship registries.

Supportive care

Supportive care is an umbrella term used to refer to services that may be required by those affected by cancer. Supportive care meets the needs across the following five domains:

- physical needs – for example, symptom management, managing and preventing infection, the impact of therapy on growth and development, physiotherapy, occupational therapy
- psychological needs – for example, the impact on cognition and education, managing stress and anxiety
- spiritual needs – for example, meaning-making in the context of illness
- social needs – for example, the child’s access to their community, school and social networks
- information and communication needs of both the child and family.

Supportive care interventions in the paediatric context

Cancer affects the emotional, financial, social, physical and cognitive vulnerability of children and adolescents and their families.^{25,26} Treatment of childhood cancer occurs in the context of a family and, as such, health services are required to ensure they meet the needs not only of the child or adolescent but of their family as well. This includes parents, siblings, guardians and care providers. Health services are required to provide access to appropriate information for parents and caregivers to effectively participate in treatment decisions with the healthcare team.

Risk groups

Patients and families that have a greater need for supportive care may include:

- infants
- children and adolescents receiving therapy for high-risk disease with significant toxicities from either therapies or underlying cancer
- children and adolescents who develop refractory disease or relapse
- children and adolescents with types of cancer for which there is no curative treatment available
- children and adolescents with pre-existing comorbidities
- single-parent and/or blended families

- families with mental health issues
- families with significant financial distress
- families where there are issues relating to child protection
- families from regional and remote areas
- families with cultural and linguistic diversity.

Ⓛ Supportive care assessments are shared with the MDT, documented and actioned at critical time points during and after treatment, including:

- at diagnosis
- following risk assessment
- during treatment
- at the end-of-treatment
- during the transition to survivorship
- during the transition to the adult healthcare sector
- at relapse
- during the transition to treatment with a primarily palliative intent
- during the transition to end-of-life care
- during bereavement.

Supportive care tools

Recommended tools for supportive care assessment are evidence-based, validated and age-appropriate. Tools may include:

- a validated psychosocial assessment tool for the patient and family (for example, PAT 2.0™)²⁷
- a pre-chemotherapy nursing assessment tool (for example, SISOM or the memorial symptom assessment scale)²⁸
- a performance status tool used prior to each treatment encounter (for example, the Karnofsky or Lanksy score)
- survivorship guidelines in assessing late complications of therapy (for example, the Children's Oncology Group survivorship guidelines)²⁹
- a visual analogue score for chemotherapy-induced nausea and vomiting (for example, the BARF™ scale)
- a visual analogue score for pain assessment (for example, the FACES™ pain scale)
- validated tools for assessing mucositis in children and adolescents (for example, ChIMES)³⁰

- a nutritional screening tool for children with cancer (for example, SCAN)³¹
- an AYA psychosocial screening tool (for example, HEADSS assessment).³²

Clinical practice guidelines

The development and utilisation of CPGs in supportive care is essential to provide optimal care and reduce morbidity and treatment-related mortality.³³ Paediatric cancer services should ensure they are following evidence-based supportive care CPGs and should aim to promote national and international collaboration in their development.³³

Neuropsychological demands

A risk algorithm for managing the neuropsychological effects of childhood cancer, and its treatment, is outlined in the PICS document *A compendium of evidence and framework for neuropsychological services in paediatric cancer (2015)*.³⁴

This compendium was written with the aim to establish a risk algorithm using international guidelines and local data that could inform workforce requirements for neuropsychology services. It is recommended that health services use this framework.

Risk factors for neuropsychological morbidity in children include, but are not limited to:

- diagnosis of a central nervous system (CNS) tumour
- cranial irradiation (with higher intensities correlating with poorer outcomes)
- CNS-directed chemotherapy such as intrathecal chemotherapy
- chemotherapy agents such as high-dose methotrexate
- young age at diagnosis or during treatment
- co-existing neurocognitive morbidities
- perioperative complications related to neurosurgery.

Ⓛ Access to neuropsychology services should be risk-adapted and when required, be performed routinely at diagnosis and again at completion of therapy. Neuropsychology assessments should continue to be undertaken in survivorship.

Psychosocial standards of care

Psychosocial standards for paediatric oncology care are summarised below.³⁵

- Patients and their families should receive routine psychosocial assessments.
- Patients in survivorship should receive yearly psychosocial screening.
- Patients and their families are at high-risk of financial hardship, and targeted referral for supports should be made.
- Parents and carers are a psychosocially at-risk group and should have early and ongoing assessments.
- Siblings are an at-risk group and should be provided with appropriate supportive services.
- Patients and their parents should receive school re-entry and ongoing support to ensure the child remains on track academically.
- Patients should be provided with opportunities throughout treatment for social interaction.
- Patients and their families should be provided with psychoeducation, information and anticipatory guidance related to diagnosis, treatment and adaptation.
- Patients should be referred to pain and palliative care services to reduce suffering throughout the disease process.
- A member of the healthcare team should provide bereavement management support following a child's death.

Ⓛ Every family should be seen by a social worker within one week of diagnosis.

Ⓛ A validated psychosocial screening tool is required to be completed at the time of diagnosis with the results (and ongoing actions) communicated to the MDT and documented in the patient's medical record.

Nutritional needs of children with a cancer diagnosis

For many childhood cancers, there is a risk of malnutrition during therapy.³⁶ In survivorship, there is a risk of obesity and developing metabolic syndrome.³⁷ These risks have the

potential to be controlled with dietary and exercise interventions. Using a nutritional screening tool (both during and after treatment) can provide a way of identifying those patients at risk and offering early intervention.³¹ Health services treating children and adolescents with cancer should adopt a validated tool for nutritional assessment as part of ongoing care during and after therapy, with referral to speciality services for those at risk.

Ⓛ Paediatric cancer services should give consideration for a nutritional assessment to be undertaken for all new diagnoses to guide the number and type of interventions required and further assessments during treatment.

Ⓛ All patients should have a nutritional assessment undertaken at each survivorship consultation.

Infection prevention and management

Infection is one of the most common complications in treating childhood cancer.

Recommendations for infection prevention and management in paediatric oncology are summarised below.

- Patients are required to undergo appropriate infection screening.
- Febrile neutropenia (FN) must be managed according to evidence-based guidelines.
- Families must receive information and education concerning the prevention and management of infection.
- Antimicrobial prophylaxis (viral and fungal) must be prescribed according to trial protocol or institutional guidelines.
- Household contacts should be up to date with vaccinations (including live vaccines).
- Annual influenza vaccinations should be provided to the patient and household contacts.
- The paediatric cancer service is required to demonstrate access to an infectious diseases consultant with experience in paediatric oncology.

Ⓛ In children with FN, antibiotics must be administered within one hour of presentation to hospital, or within 30 minutes for inpatients.

⌚ All patients should be identified as standard or high-risk of FN and be provided with documentation at diagnosis that identifies their risk category to streamline any required emergency care. This documentation should be updated according to the degree of perceived toxicity during each phase of treatment by a member of the MDT.

Palliative care

Palliative care needs should be assessed at all stages of a child's cancer diagnosis. Palliative care can be integrated into the child's management alongside disease-modifying therapy including chemotherapy, radiotherapy, bone marrow transplant and clinical trials. Specialists in palliative care are able to assist the oncology team with advance care planning, symptom management, spiritual care, psychosocial support, linking with community palliative care support services, end-of-life care and bereavement support.

Timely referral to palliative care support services promotes:

- the opportunity to focus on enhancing quality of life and reducing symptoms
- time to develop a tailored palliative care approach to the evolving needs of the individual child and family
- the avoidance of crisis-oriented management, which exacerbates the family's sense of vulnerability and helplessness
- a framework for preventive, proactive interventions and decision making
- support for the family's strengths and capacity to cope.

- When applicable, palliative care should be provided concurrently with active treatment.
- Palliative care should be integrated with care provided by the child's oncologist and other members of the MDT.
- Referral to palliative care support services should be considered in the context of:
 - high-risk diagnoses, where three- to five-year event survival is estimated at less than 30 per cent
 - high-risk disease or multiple relapses
 - disease progression on treatment
 - a history of prolonged (more than seven days) or multiple (three or more episodes in a six-month period) intensive care (ICU) admissions
 - patients without a curative therapeutic approach.

Fertility

Reduced fertility and infertility are potential consequences of many cancer treatments in children and adolescents and can result from:³⁸

- exposure to selected systemic chemotherapy agents or radiation to reproductive organs
- high-dose radiation to the hypothalamic-pituitary axis, causing secondary hypogonadism
- selected pelvic, abdominal or neurosurgeries.

The potential for impaired fertility should be discussed and reinforced at different time points as appropriate throughout the diagnosis, treatment, surveillance and survivorship phases of care. These ongoing discussions will enable the family and, if applicable, the patient to make informed decisions.

Communicating fertility options

Discussing the impact of cancer treatment on fertility is an international standard of care. Infertility is acknowledged as a potential side effect of child and adolescent cancer treatment. Discussions should be standardised and follow institutional guidelines. If a procedure is deemed inappropriate due to medical risk or lack of efficacy in some patients, it is advised to have that discussion prior to treatment.

⌚ Communicating the options and potential risks to fertility should be discussed at diagnosis, coming off treatment and entry into the survivorship program.

Prevalence

Rates and degree of infertility vary greatly and are dependent on a number of risk factors, including the location of the disease, treatment regimen, treatment dose and pubertal status, which should be taken into consideration when discussing fertility options in children and adolescents with cancer.³⁹ Prediction of risk is difficult and outcomes vary amongst individual patients.

High-risk groups

The following interventions place young people at high-risk for infertility:²⁹

- treatment with high-doses of alkylating agents such as cyclophosphamide, busulfan, ifosfamide, carmustine and procarbazine
- high-dose radiation to the pelvis, abdomen or hypothalamic axis, particularly in combination with alkylating agents

- total body irradiation for children and adolescents undergoing transplant conditioning
- testicular and ovarian radiation.

In discussing the late consequences of emerging therapies for childhood cancer such as immunotherapy, patients and families should be advised about the lack of conclusive data of the impact of these treatments on fertility, particularly in sperm production.

Education and information should include the enhanced risk of premature ovarian failure and/or early menopause faced by female survivors of childhood cancer.⁴⁰

These different aspects of impaired fertility should be discussed and reinforced at different time points as appropriate throughout the diagnosis, treatment, surveillance and survivorship phases of care. These ongoing discussions will enable the family and, if applicable, the patient to instigate coping mechanisms and make informed decisions.

Fertility recommendations are outlined below.⁴¹

- An assessment of the risk of infertility is made by the MDT and documented at diagnosis for all patients.
- Families and, where appropriate, the child or adolescent, should be educated on the potential fertility-related effects of the treatment delivered.
- Discussions about fertility optimisation and why it may or may not be deemed appropriate should occur as early as clinically possible and prior to treatment commencing.
- Information should be provided in both verbal and written form regarding potential options, risks and benefits.
- Families who express an interest in fertility optimisation should be referred and, where clinically feasible, be seen by a fertility service.
- In those optimisation techniques where efficacy for future fertility cannot be adequately demonstrated, this should be clearly communicated to the child, adolescent and/or family.
- Families should be aware of the ongoing costs involved in fertility optimisation.
- All discussions should be documented in the patient's medical record.
- Clinical and ethical governance is required in centres offering fertility optimisation.
- Results regarding semen analyses and tissue biopsies should be communicated to the family as soon as possible, in case the potential for a secondary procedure is possible.
- Appropriate follow-up during treatment and survivorship is important to discuss results and legalities regarding tissue storage and to monitor reproductive function.

Complementary and alternative medicine in childhood cancer

Complementary and alternative medicine (CAM) refers to a diverse group of practices and products not considered part of evidence-based conventional medicine. CAM is not a substitute for conventional therapy and is not overseen by any health regulating body. In most situations, CAM is integrated into healthcare.

The ever-growing access to information has made parents, patients and families increasingly aware of CAM. How the role and potential benefits of CAM are presented in social media and online (often with limited objectivity) will drive an increase in its use. Caution must be used in supporting or advocating the use of CAM in children and adolescents with cancer, particularly the use of unproven medicines or supplements during therapy. This requires an open, effective relationship between the patient and the healthcare clinician.

The most common complementary health approaches used in children are:⁴²

- dietary supplements (not including multivitamins)
- chiropractic or osteopathic interventions
- yoga
- deep breathing
- homeopathy
- meditation
- guided imagery
- massage
- special diets.

The main reasons cited for use of CAM in children and adolescents with cancer are to:⁴³

- help fight/cure the child's cancer (with the concurrent use of conventional therapy)
- provide symptomatic relief
- support ongoing use of chemotherapy.

Some of the main reasons cited for CAM by adult cancer patients and their families are to:⁴⁴

- improve physical and emotional wellbeing
- 'boost' the immune system
- reduce the side effects of conventional treatment
- improve quality of life.

- Patients should be encouraged to discuss all CAM with the treating team.
- Health services should have a policy governing the use of CAM.
- All discussions of CAM should be shared with the patient's oncologist and/or pharmacy and documented in the patient's medical file.

Genetic predisposition to cancer

Background

Common genetic variations are associated with a proportion of childhood cancers⁴⁵ and inherited genetic traits (germline mutations) currently account for about 10 per cent of all new diagnoses.⁴⁶ Many cancer predisposition genes continue to be discovered across adult and paediatric cancers⁴⁷ highlighting the need to develop specific services to address and provide reliable information about future risks faced by patients, as well as advice and strategies to lower the risk.

Genetic testing allows children and adolescents with a predisposition to developing cancer to be identified early. The potential clinical utility of identifying cancer predisposition genes in individual patients includes:

- providing an assessment on the likelihood of disease development
- altering treatment
- identifying targeted therapies
- using screening and prevention guidelines.

The number of patients with some underlying level of cancer predisposition is underestimated and under-reported. The addition of a genetic counsellor to the MDT has been shown to significantly increase the identification of such patients who could benefit from genetic evaluation.⁴⁸

Genetic counselling, screening and prevention may greatly improve either the chance of avoiding the further onset of cancer or the outcome of the disease'.⁴⁶ However, health services need to also acknowledge the impact of results on the siblings and other family members, for example, where some germline mutations may be shared within the family.

Children and adolescents with cancer predisposition syndromes should be considered for referral to a genetic service.

- There should be access to a genetic service with experience in oncology.
- There should be access to a genetic counsellor in the health service with experience in oncology.
- All children with cancer should have a complete family history of cancer of at least three generations documented at diagnosis.
- The emerging family history of cancer should continue to be documented as part of the survivorship program, and consideration of referral to a genetic clinic where new family cancer histories in children or young adults are reported.
- The health service should have a management strategy that covers the ethical implications of genetic testing in other family members.
- The genetic clinic should continue to measure the efficacy and yield of findings of referrals to genetic services.

Educating the patient and family

Lack of ready access to information can be a cause of stress and conflict with the healthcare team for families of children with cancer.⁷¹ The family and patient (if appropriate) should be provided with both verbal and written information, tailored to the family's learning needs. Individual education topics are listed under each pathway section.

It is important that patients and their families are given the time to process the initial information about the diagnosis before providing education on supportive and essential care.¹⁹⁴ Other considerations that have shown to facilitate the process include:^{194,195}

- providing a structured teaching method

- having consistency in the message – all members of the healthcare team should be aware of and follow the written information provided to families
 - being cognisant of the emotional state of the family, as well as their educational level
 - providing anticipatory educative content because most families will be unaware of what to ask
 - pacing education over time and not leaving it to the day of discharge
 - providing written, verbal and recorded content
 - ensuring siblings are also provided with age-appropriate education.
- Ⓛ Verbal education to families is paced throughout the initial admission, and time is allowed to process the diagnosis. Education should not be left to the moment of discharge, and families should be aware that education is ongoing and accessible throughout treatment.
- Ⓛ Written and/or audio-visual educational information is provided as part of the discharge plan following diagnosis and should also include information targeted to children and adolescents.

Consideration must be made and strategies put in place for communicating with families from diverse backgrounds, including provision of access to interpreter services and translated educational materials. Age and developmentally appropriate information should be available for children and adolescents. A discussion about contraception should be considered for all adolescent patients.

Advice at home

The paediatric cancer service should be able to demonstrate a process for providing timely and consistent remote symptom monitoring via the telephone for children and adolescents with cancer, and their families.

Coming off treatment

The coming off treatment and surveillance phase has been identified as one of the most difficult periods faced by parents in their child's treatment.⁴⁹ There are significant psychosocial and educational pressures encountered by patients and families during this critical time point.

Some of the major considerations for the cancer service to address with the patient and family coming off treatment include:

- education and learning requirements to be identified and tailored to the specifics of the child's cancer treatment
- that education requires the parent's readiness to learn during this point in care
- that the child's primary oncologist should remain responsible for managing cancer-related issues during the surveillance phase
- discussion with and assistance for the child/adolescent and parents in dealing with the fear of relapse
- education in differentiating significant from non-significant symptoms
- review of the initial diagnosis, the side effects and the follow-up care required
- review of any clinical trial requirements during surveillance
- interventions that meet educational and psychological needs of the child and adolescent not be delayed until referral to survivorship
- referral or reintroduction to psychosocial services.

- All patients should attend a formal, multidisciplinary end-of-treatment review.
- Every patient coming off treatment should be given a full summary of the diagnosis, staging, treatment received and any complications of treatment.
- Every patient should also receive a tailored surveillance roadmap. The roadmap should identify the recommended timings for clinical tests and investigations as well as referrals to the necessary support services. This should be tailor-made to the individual patient and cover the period from the end-of-treatment to entry into a survivorship program.
- Copies should be provided to the child/adolescent and their family, as well as their GP and paediatrician as appropriate.

Survivorship

Currently, more than 80 per cent of Australian children and adolescents diagnosed with childhood cancer will be cured. A substantial proportion will have adverse late effects requiring ongoing medical and psychosocial care.⁵⁰

A system/service should be in place to support survivors of childhood cancer into adulthood and transition into adult healthcare services when necessary.

- All children and adolescents who have been treated for cancer or who have undergone an allogeneic stem cell transplant should be referred to a survivorship program.
- Patients in the survivorship program should follow an approach such as the Children's Oncology Group 2018 *Long-term follow-up guidelines* to ensure access to appropriate services.
- The survivorship program should undertake a risk-adapted approach to all patients entering the service for appropriate allocation of resources for those at higher risk of late effects.
- Paediatric oncology healthcare staff should be available, with access to clinical expertise and resources dependant on the child's risk and current guideline recommendations. This may include representation from areas such as cardiology, endocrinology, fertility, physiotherapy, nutrition, education, psychology, dental, social work, occupational therapy and rehabilitation.
- All patients should receive tailored educational material in a format appropriate to their level of understanding and language type.
- The summaries developed at the end-of-treatment must be updated with new information.
- The surveillance roadmap provided should be updated with new information on entry to the survivorship program, in line with current guidelines and recommendations. This should be made available to the patient and their GP and, if applicable, their paediatrician.

Relapse

Disease recurrence is a distressing experience as survivors and their families once again face the psychosocial effects of cancer: uncertainty, distress and concerns about death.

Treatment protocols for relapse can still provide a realistic chance of cure. However, in some diseases, the prognosis following relapse is poor. Relapsed treatment plans, by nature, are very distinct from the original treatment plan as the initial therapy has failed the patient. The treatment

is generally more complex and intensive and the outcomes are more uncertain.¹⁶

Recommendations for patients with relapsed or refractory disease are summarised below.

- All patients with relapsed disease are required to be discussed at a paediatric oncology MDM to develop appropriate treatment planning, including decisions about potential clinical trial availability and possible referral to other specialty services including palliative care.
- The team should present all the information regarding the success rate of conventional relapse treatment plans, regardless of prognosis, and be available to discuss CAM options.
- The MDT should maintain open and candid communication at all times.
- Information is sensitively provided to the child/family, in plain language and in a supportive environment.
- There should be an increased focus on psychosocial support, including exploration of the family's strengths, a focus on enhancing quality of life, ongoing discussion within a multidisciplinary structure and an awareness of maladaptive behaviour, such as emotional or physical withdrawal and refusal to follow through with medical care.
- Due to the toxicities of many relapse protocols, referral to fertility services should be considered.

End-of-life care

The Victorian Department of Health and Human Services has developed the *Victoria's end of life and palliative care framework: A guide for high-quality end of life care for all Victorians*, available at www.health.vic.gov.au. There is also the National consensus statement on end-of-life care for paediatric patients developed by the Australian Commission on Safety and Quality in Health Care, which should guide practice in this area.⁵¹

Each child dealing with an incurable cancer will have different needs, priorities, goals and wishes as they approach the end of their life. The needs of their families will also differ. Supportive care interventions should aim to

honour and facilitate the individual's preferences, which should be elicited with sensitive, open and candid communication.

Informational needs

Children with incurable cancer, and their families, have a high need for communication and support. Discussion regarding approaching end-of-life is likely to require an iterative approach and should be tailored to the individual and their family. Plain language should be encouraged, and euphemisms avoided. Discussions may encompass:⁵²

- prognosis
- rationale for decisions to change the focus of therapy
- explanation of and plans for addressing and preventing symptoms
- referral to community palliative care support services
- advance care planning including place of care
- explanation of the dying process.

The family should be supported and encouraged to involve the child in discussions and decision making in a developmentally appropriate manner.

Symptom management

Symptoms at end-of-life should be vigorously managed using both pharmacological and non-pharmacological measures. This may include the use of palliative chemotherapy or radiotherapy.

Place of care

As the end-of-life phase approaches, clinicians should elicit the family's preferences for ongoing care and preferred place of death. Some families prefer to continue to have regular hospital visits for support. Others favour exclusive home-based care. Similarly, the choice between death at home, in hospice or in hospital is highly individual and may change as the disease evolves.

The dying process

Families should be guided in preparation for and recognition of the dying process. Signs of approaching death, including increasing fatigue, reduced conscious state, reduction in appetite and changes in temperature and breathing, should be described.

SECTION 2:

PAEDIATRIC ONCOLOGY CARE PATHWAY — ACUTE LEUKAEMIA

This oncology care pathway outlines seven critical steps for children diagnosed with acute leukaemia. While these steps are portrayed in a linear time model, in practice, patient care is rarely straightforward and predictable. The critical steps will require realignment and adjustment to best meet the needs of patients and their families as well as care providers, without undermining the effectiveness of the treatment and supportive care program. The pathway describes the optimal cancer care that should be provided at each step.

The key principles and fundamentals of paediatric oncology practice outlined in the 'fundamentals of care' (section 1) underpin the oncology care pathway for acute leukaemia.

Scope

This oncology care pathway is intended as a resource in managing children and adolescents diagnosed with acute leukaemia.

Critical time points

As mentioned at the beginning of this document the blue clock symbol 🕒 is used to highlight a critical time point that has a specific timeframe attached to it.

A red clock symbol 🕒 indicates the time point is part of an **urgent pathway**. A precis of these time points are found in the summary of optimal timeframes (figure 3, page 24).

Summary

Figure 2: Paediatric oncology care pathway summary – acute leukaemia

Assess supportive and/or palliative care at every step of the pathway and refer to the appropriate health professional	STEP 1 Prevention and early detection	<p>RISK FACTORS. There is currently no known cause of childhood leukaemia. There is a peak in incidence for acute lymphoblastic leukaemia (ALL) in early childhood and some genetic disorders increase the risk of developing leukaemia in childhood.</p>	<p>There is a link between developing acute myeloid leukaemia (AML) and prior chemotherapy exposure. There is no evidence that lifestyle plays a role in developing leukaemia. There are no preventative or screening programs for childhood leukaemia.</p>
	STEP 2 Presentation, initial investigations and referral	<p>SIGNS AND SYMPTOMS. Clinical presentation is dependent on the level of leukaemic infiltration in the marrow and extramedullary sites at the time of presentation, resulting in a wide spectrum of signs and symptoms. Signs and symptoms that warrant a full blood examination and peripheral film include:</p> <ul style="list-style-type: none"> • a persistent unexplained fever • diffuse bone pain with no obvious history of trauma and/or refusal to walk • generalised lymphadenopathy • pallor or unexplained bruising • unexplained bleeding • extreme fatigue • recurrent respiratory tract infections. <p>Signs that warrant an immediate referral to a paediatric tertiary referral centre include:</p> <ul style="list-style-type: none"> • hepatosplenomegaly • unexplained petechiae. 	<p>PARENTAL CONCERN. Escalation for further investigations is also warranted if there have been repeated GP visits or a high level of parental anxiety.</p> <p>REFERRAL. All children and adolescents with a suspicion of leukaemia on clinical or laboratory grounds will be discussed on the same day with a level five or six paediatric cancer service.</p> <p>Paediatric tertiary referral centres should provide clear routes of rapid access for GPs to specialist evaluation.</p>
	STEP 3 Diagnosis, staging and treatment planning	<p>DIAGNOSIS. A diagnosis of leukaemia will require laboratory testing on both peripheral blood and bone marrow and include:</p> <ul style="list-style-type: none"> • assessment of morphology • immunophenotyping, karyotyping and fluorescence in situ hybridisation (FISH) analysis • molecular genetic analysis. <p>Tissue must be collected as a baseline at diagnosis to define markers that can be used for risk stratification, such as minimal residual disease (MRD) testing.</p> <p>A lumbar puncture (LP) must be obtained at diagnosis to check for CNS disease.</p>	<p>TREATMENT PLANNING. Optimal treatment planning includes presentation to and consideration within a paediatric leukaemia MDM when all necessary tests and investigations have been completed.</p> <p>CLINICAL TRIALS. Clinical trial enrolment should be offered to all children and adolescents with leukaemia. For patients who do not meet trial eligibility criteria, the most recent, evidence-based and published study protocol offering the best outcomes must be used.</p> <div style="border: 1px solid #ccc; padding: 5px; margin-top: 10px;"> <p>COMMUNICATION. The lead clinician should discuss the outcomes of the MDM with the patient and family, including the diagnosis, risk assignment, treatment plan and access to clinical trials, if appropriate. The plan should be communicated with the GP and/or paediatrician.</p> </div>
	STEP 4 Treatment	<p>TREATMENT. Treatment protocols used must offer the best curative approach.</p> <p>Chemotherapy is the key component of treatment, prescribed within validated treatment protocols.</p> <p>Targeted therapies are also increasingly being utilised in leukaemia.</p> <p>Radiotherapy. Any consideration for radiotherapy will be discussed within the paediatric leukaemia MDM.</p> <p>Immunotherapy, including haematopoietic stem cell transplant (HSCT), may be required in some circumstances.</p>	<div style="border: 1px solid #ccc; padding: 5px; margin-top: 10px;"> <p>COMMUNICATION. The lead clinician should discuss the treatment protocol, including risks and benefits and supportive care measures, with the patient and family. The care plan should also be communicated with the GP and/or paediatrician.</p> </div>

Assess supportive and/or palliative care at every step of the pathway and refer to the appropriate health professional	STEP 5 Care after completing therapy and survivorship	<p>COMING OFF TREATMENT. All patients will be provided with a surveillance roadmap covering the first three to five years after treatment.</p> <p>SURVIVORSHIP. All patients completing treatment for childhood leukaemia will be referred to a survivorship program following surveillance.</p>	<p>Minimum documentation should include:</p> <ul style="list-style-type: none"> • a treatment summary • a patient-specific roadmap for future tests and investigations. <p>TRANSITION OF CARE. Transition to adult care should be supported by the survivorship program or the cancer service, via a referral and documentation to the patient's GP. In selected patients having specialised therapies such as HSCT, referral to more specialty adult services may be warranted.</p>
	STEP 6 Managing refractory disease or relapse	<p>DETECTION. Most instances of relapse or recurrence are identified through routine clinical examination or laboratory findings.</p> <p>TREATMENT PLANNING. Optimal treatment planning requires presentation to and consideration within a paediatric leukaemia MDM. Early integration with palliative care should be considered.</p> <p>TREATMENT. Children with relapsed ALL are often eligible for enrolment in clinical trials evaluating the effectiveness of chemotherapy alone, or in combinations of therapies including HSCT, chemotherapy and targeted therapies.</p>	<p>For patients with relapsed AML, treatment with chemotherapy followed by HSCT is currently the most common modality. Services should continue actively pursuing new treatment modalities for relapsed and refractory leukaemia such as targeted therapy and immunotherapy.</p> <div style="border: 1px solid #ccc; padding: 5px; margin-top: 10px;"> <p>COMMUNICATION. The lead clinician should discuss the outcomes of the MDM with the patient and family, including treatment options, potential clinical trial enrolment, prognosis and risks and benefits of treatment. The plan should be communicated with the GP and/or paediatrician.</p> </div>
	STEP 7 End-of-life care	<p>PLANNING. Discussion should be held within the paediatric leukaemia MDM to determine those patients for whom no further disease-modifying therapy is warranted and to identify those approaching end-of-life.</p>	<div style="border: 1px solid #ccc; padding: 5px; margin-top: 10px;"> <p>COMMUNICATION of advance care planning, including preferred site of ongoing care and preferred location of death, must be undertaken with all families with primarily palliative goals of care. Referral to palliative care support services must be implemented, if not already undertaken. The plan should also be communicated with the GP and/or paediatrician.</p> </div>

Summary: Optimal timeframes

Figure 3 summarises the recommended timeframes across two pathways at critical time points in the management of acute leukaemia in children and adolescents. All other timings of care for treating acute leukaemia can be found within the document.

Urgent pathway: Some patients may present with oncological emergencies including, but not limited to, hyperleucocytosis, tumour lysis syndrome, mediastinal mass and coagulopathies. Urgent, same day emergency assessment and diagnosis needs to be completed to allow rapid commencement of therapy to manage these emergencies.

Standard pathway: If the patient is stable and/or enrolled in a clinical trial, protocol requirements and institutional resources should guide timing for optimal diagnosis and treatment planning.

Figure 3: Recommended timeframes in managing acute leukaemia

STEP IN PATHWAY	CARE POINT	TIMEFRAME
Presentation, initial investigations and referral	GP investigations and referral	All children and adolescents with a suspicion of leukaemia on clinical or laboratory findings must be discussed on the same day with a paediatric tertiary referral centre and, if required, referred to a level five or six paediatric cancer service within 24 hours.
Diagnosis, staging and treatment planning	Diagnostic interventions	<p>Urgent: Diagnostic investigations need to occur on the day of presentation</p> <p>Standard: Diagnostic investigations need to occur by the next business day in clinically stable patients; however, clinical trial requirements, as well as the level of institutional resources, should also guide timings.</p>
	Central venous access	<p>Urgent: Central venous access should be established on day of presentation when it is safe to do so</p> <p>Standard: A central venous access device should be placed prior to beginning intravenous chemotherapy.</p>
	Multidisciplinary meeting	A referral for discussion at an MDM will be made within a week of diagnosis. Discussion at the MDM will also take place at the end of induction therapy.
Treatment	Chemotherapy	<p>Urgent: Chemotherapy commenced on the day of presentation</p> <p>Standard: Chemotherapy commenced by the next business day in clinically stable patients; however, clinical trial requirements, as well as the level of institutional resources, should also guide timings.</p>

STEP 1: Prevention and early detection

1.1 Prevention

Although risk factors have been identified, the cause of childhood leukaemia remains unknown.

There is no evidence that lifestyle plays a role in childhood leukaemia. It is important to ensure the patient and their family are aware of this to avoid feeling responsible for their child's illness.

1.2 Risk factors

Genetic predisposition

Some genetic disorders may increase the likelihood of developing leukaemia in childhood or adolescence. These include Down syndrome, neurofibromatosis type-1, ataxia telangiectasia^{53,54} and Fanconi's anaemia.

Siblings

Siblings of children and adolescents with leukaemia have an increased risk compared with the general population, although the risk is still very low. In identical twins, the non-affected twin has an increased risk of developing leukaemia, occurring in approximately 15 per cent of cases when the first twin develops leukaemia between two and five years of age.⁵³ Generally when the second twin develops leukaemia, this occurs within six months of the first child.

Environmental factors

There is evidence to suggest that radiation exposure including from medical imaging sources, particularly during pregnancy and early childhood, may increase the risk of childhood cancer, including leukaemia.^{55,56} However, the cumulative absolute risk is very small. Computed tomography (CT) scans in children and adolescents should be limited to situations where there is a definite clinical indication, with every scan using the lowest possible dose of radiation.⁵⁷ Other environmental factors, such as electromagnetic fields, parental smoking habits and paternal workplace exposures, have not been able to yield strong aetiological associations.⁵³

There is a link between the use of chemotherapy (particularly topoisomerase-II inhibitors) for childhood malignancies and secondary leukaemia, particularly treatment-related AML.

1.3 Screening and early detection

There are no effective screening tools for detecting newly diagnosed leukaemia in children and adolescents. Most children present with an array of non-specific symptoms that prompt the parent or guardian to seek medical attention. These signs and symptoms can be quite varied and are listed below in step 2. Screening individual symptoms has been shown to have low positive predictive values for leukaemia in primary care.⁵⁸ Despite this, there is a need to educate GPs to appreciate the potential significance of these symptoms and make appropriate referral. Delays in diagnosis can adversely affect outcomes and have major implications on the acceptance of a cancer diagnosis and a patient and family's subsequent health-seeking behaviour.⁵⁸

Children who have a higher predisposition to develop cancer, such as a genetic risk or previous treatment for cancer, should have regular medical consultations. Children with identified bone marrow failure syndromes should have annual bone marrow evaluations to identify potential leukaemia.⁵⁹

STEP 2: Presentation, initial investigations and referral

Childhood cancer is rare. This represents a major diagnostic challenge for emergency departments and GPs.

This step outlines the process for establishing a provisional diagnosis and appropriate referral for a child or adolescent suspected of having leukaemia.

In isolation, alert symptoms do not have a strong positive predictive value but nevertheless should be used to guide early referral to a level five or six paediatric cancer service. One identifying factor that supports referral is repeated visits with the same symptoms but without a clear diagnosis. Similarly, parental 'insight' and anxiety should be a strongly noted and sufficient reason for referral.^{6,60} This is in line with the National Institute for Health and Care Excellence's (NICE) recommendations.⁹

Specific 'alert symptom' guidelines should be encouraged in primary care to overcome the issue of rarity, including education for adolescents and parents and guardians.⁹

2.1 Presenting signs and symptoms

The clinical manifestations of leukaemia are dependent on the level of leukaemic infiltration into the marrow and extramedullary sites at the time of presentation, resulting in a wide spectrum of signs and symptoms. It is important to recognise parental concern; escalation for investigations should be warranted after repeated visits or high levels of parental anxiety.

- The following symptoms may warrant the consideration of a **full blood examination and peripheral film**: persistent unexplained fever, diffuse bone pain with no obvious trauma and/or refusal to walk, generalised lymphadenopathy, pallor, unexplained bruising, unexplained bleeding or extreme fatigue, persistent respiratory tract infections.
- The following signs warrant **immediate referral and presentation to a paediatric tertiary referral centre**: hepatosplenomegaly and/or unexplained petechiae.

2.2 Referral

All children and adolescents with a suspicion of leukaemia on clinical and/or laboratory findings will be discussed on the same day with a level five or six paediatric cancer service, and if required, referred to the service within 24 hours.

The GP should have a clear and timely process for paediatric referral.

The minimum documentation for referral should include:

- a referral letter, including the patient's demographics, relevant medical history, medications and allergies
- results of clinical investigations (including imaging and pathology reports)
- the need for interpreter services and other recognised significant psychosocial issues.

The GP should aim to provide electronic or printed confirmation of tests and investigations, but availability should not delay the referral or assessment.

STEP 3: Diagnosis, staging and treatment planning

Step 3 outlines the process for confirming the diagnosis, risk stratification and treatment planning of leukaemia in children and adolescents.

It is a requirement that all children and adolescents with leukaemia are managed by a level five or six paediatric cancer service.

Urgent pathway: Some patients may present with oncological emergencies including, but not limited to, hyperleucocytosis, tumour lysis syndrome, mediastinal mass and coagulopathies. For these patients, **urgent, same day emergency assessment and diagnostic interventions** need to be completed to allow early commencement of therapy.

Standard pathway: diagnostic interventions should be planned for the next business day in clinically stable patients; however, clinical trial requirements, as well as the level of institutional resources, should also guide timings.

3.1 Diagnostic work-up and pre-treatment investigations

Physical examination and history

- A thorough physical examination and history is important to identify co-existing organ dysfunction and the extent of infiltration, such as the clinical effects of bone marrow disease and extent of extramedullary disease, as well as potential features of underlying genetic predispositions and pre-existing comorbidities.
 - Once a diagnosis is confirmed, a comprehensive family cancer history of at least three generations' pedigree will help further identify patients and families with potential cancer predisposition or inherited syndromes.⁵⁴ This may in turn help guide treatment or provide support to the extended family.
- All children and adolescents with a suspicion of leukaemia on clinical and/or laboratory findings will be discussed on the same day with a level five or six paediatric cancer service, and if required, referred to the service within 24 hours.

Pre-treatment laboratory examinations

- Full blood examination and film review
- Urea and creatinine, electrolytes, liver function tests
- Uric acid and lactate dehydrogenase
- Blood group, antibody screen and red blood cell phenotype
- Coagulation studies

Pre-treatment medical imaging

A chest x-ray will provide evidence or confirmation of mediastinal masses, particularly in patients with T-cell ALL.

Pre-treatment investigations will be performed on the day of presentation to the level five or six paediatric cancer service.

Diagnostic laboratory investigations

Laboratory diagnostic work-up includes the following tests, performed on bone marrow and, at times, also on peripheral blood:⁶¹

- morphology
- immunophenotyping, karyotyping and FISH analysis
- molecular genetic analysis.

All diagnostic tests should be ordered in such a way as to reduce the number of investigative procedures requiring general anaesthesia, improve workflow and support clinical trial enrolment. One such example may be in the use of upfront flow cytometry on peripheral blood.

A LP is performed to establish whether there is any CNS disease. It is a requirement that the initial LP be performed with adequate platelet cover and performed by an experienced clinician to avoid trauma, and the subsequent need to deliver increased therapeutic lumbar punctures.

A bone marrow aspirate (BMA) and LP should be performed under a general anaesthetic.

Urgent pathway: For urgent cases, if it is safe to do so, the diagnostic BMA and LP should be performed on the day of presentation. Urgent patients include, but are not limited to, those who present with hyperleucocytosis, tumour lysis syndrome, mediastinal mass and coagulopathies.

Standard pathway: The diagnostic BMA and LP should be performed by the next business day; however, clinical trial requirements, as well as the level of institutional resources, should also guide timings.

Infection screening

It is important that infection screening is undertaken at diagnosis and prior to treatment. Screening should include:

- routine serology – HBV, HCV, HIV, HSV, VZV (for all patients prior to receiving blood products)
- EBV, CMV and toxoplasma (as indicated but particularly for patients that may require haematopoietic stem cell transplantation (HSCT))

For patients born or who have travelled overseas, particularly to tropical regions or tuberculosis endemic countries, consultation with infectious diseases must be sought.

Other investigations are as clinically indicated and on discussion with the infectious diseases service.

Infection screening should be performed prior to treatment, particularly prior to transfusion of blood products.

Comorbidities

Due to the toxicities of therapy, baseline organ function should be assessed at diagnosis. A thorough medical history will also help identify any pre-existing comorbidities.

Biobanking

Consent for biobanking of diagnostic material should be sought.⁶¹ In many upfront clinical trials in leukaemia, biobanking is a prerequisite to enrolment.

Minimal residual disease (MRD)

A MRD level is a strong and independent predictor of relapse in childhood leukaemia and widely used for risk stratification.^{62,63} This requires a diagnostic marrow or peripheral blood specimen to enable identification of leukaemia-specific markers.

MRD testing in childhood leukaemia should occur at the time points listed on the next page.⁶⁴

For ALL:

- diagnostic (baseline MRD panel) specimen
- following induction therapy
- end of consolidation for those who are positive at end of induction
- following re-induction therapy in relapse
- prior to a transplant for relapsed patients proceeding HSCT.

For AML:

- diagnostic (baseline MRD panel) specimen
- end of the first course of induction
- consideration at end of subsequent course if positive at end of induction.

These time points will vary according to the protocol and may be overruled by clinical trial requirements.

Clinical trial investigations

Further laboratory tests may be required to enable enrolment onto clinical trials.

3.2 Staging and risk stratification

Stratifying risk according to evidence-based criteria ensures that patients at the highest risk of relapse receive appropriately intensified therapy while those with more favourable prognosis (the lowest risk of relapse) receive therapy of reduced intensity to reduce complications.

Risk stratification at diagnosis must be assessed by a current, internationally recognised, peer-reviewed classification tool.

Acute lymphoblastic leukaemia^{60,65,66}

There are four main pillars that underpin risk stratification in ALL: host factors, disease presentation, disease biology and, most importantly, response to treatment.

ALL favourable prognosis:

- Host factors – for example, age older than one year and younger than 10 years
- Presentation – for example, peripheral white cell count at diagnosis of less than 50,000/ μ L
- Biology – for example, favourable genetic and biological features such as hyperdiploidy or ETV6-RUNX1 (TEL-AML1) positive
- Response – for example, negative MRD at the end of induction therapy.

ALL unfavourable prognosis:

- Host factors – for example, age younger than one year and older than 10 years
- Presentation – for example, peripheral white cell count greater than 50,000/ μ L at diagnosis, presence of extramedullary disease (CNS and testicular)
- Biology – for example, hypodiploidy and BCR/ABL
- Response – for example, positive MRD following first cycle of therapy.

Acute myeloid leukaemia^{56,67,68}

Risk stratification in AML is primarily related to the disease biology and response to treatment.

AML favourable prognosis:

- Down syndrome-associated less than four years of age
- Acute promyelocytic leukaemia (these patients generally have translocation (15:17))
- Negative MRD at the end of induction chemotherapy
- Specific genetic and biological features such as translocation (8:21).

AML unfavourable prognosis:

- Extremely high or low body mass index at diagnosis
- Positive MRD at the end of induction therapy
- Specific genetic and biological features of the leukaemic blast cell such as FLT3 mutations and monosomy 5 and 7.

Application of new diagnostic techniques in the biology of childhood leukaemia continue to develop at a great pace.^{69,65} The MDT needs to be aware of these changes and advances and ensure they are translated to the bedside.

3.3 The multidisciplinary team and treatment planning

Optimal treatment planning includes presentation at a paediatric leukaemia MDM.

It is a requirement that the MDT include all the experts required for the diagnosis and treatment planning of childhood leukaemia including:

- paediatric oncologist with a subspecialty in leukaemia*
- haematopathologist with experience and expertise in paediatric haematological malignancies*
- nurse consultant with experience and expertise in paediatric haematological malignancies*
- paediatric clinical trials coordinator
- paediatric oncology pharmacist
- paediatric infectious diseases consultant
- social worker with experience in paediatric oncology.

*Core members of the MDT who will be represented in person or remotely at the time of the meeting

Administrative support should also be sought for documentation and dissemination of meeting recommendations.

- 🕒 Discussion at an MDM should occur within one week of diagnosis.
- 🕒 All patients will be discussed at the MDM at the completion of induction therapy.
- 🕒 All new diagnoses are reported to the state cancer registry.

3.4 Supportive care considerations

Supportive care demands in all children and adolescents with cancer is discussed in the 'fundamentals of care' section. The success in childhood leukaemia over the past 40 years has led to a stronger emphasis on health status and health-related quality of life. Enhancements in supportive care and better measures of short- and long-term health-related quality of life are essential and are increasingly being embedded into the primary aims of new leukaemia clinical trials.⁷⁰

Supportive care requirements in the context of children and adolescents with leukaemia include:

- managing acute symptoms in newly diagnosed patients (including coagulopathies), providing blood product support and managing electrolyte abnormalities, including preventing tumour lysis syndrome
- managing other clinical symptoms at diagnosis due to extramedullary disease
- nutritional assessment at diagnosis and for all patients requiring HSCT as part of their treatment, though the risk of malnutrition in leukaemia is much less than in other types of childhood cancers³⁶ (there is a risk of obesity both during treatment and in survivorship)
- physiotherapy support in managing chemotherapy-induced peripheral neuropathy
- management and prevention of infection
- neuropsychology supports – referral to neuropsychology should be made for children who have experienced potential neurocognitive insult from triggers such as CNS-directed therapy (cranial radiation and intrathecal chemotherapy), those patients receiving high-dose methotrexate and patients who experience any significant CNS morbidity during treatment such as cerebral bleed, stroke, acute meningitis and encephalopathies
- consideration of palliative care referrals for patients with a high symptom burden.

3.5 Educating the patient and family

Lack of access to information has been identified as a cause of stress and conflict with the healthcare team for families of children with cancer.⁷¹ The family and patient (if appropriate) will be provided with both verbal and written information, specifically for consumers, on the following topics as a minimum:⁷²

- diagnosis, treatment plan and prognosis
- management of fever and neutropenia
- side effects of treatment
- who/how to call their hospital and/or treating team
- clinical trials
- managing medications and compliance at home
- central line care

Continued next page

- caring for the child at home
- supportive care
- orientation to the hospital and overview of the healthcare team (key members)
- preventing infection
- blood counts
- follow-up appointments
- fertility optimisation options (if applicable)
- psychosocial issues.

Information specifically targeted to children with acute leukaemia immediately following diagnosis include:⁷²

- neutropenia precautions
- medication adherence
- steroid side effects
- chemotherapy side effects
- bleeding precautions
- managing procedures
- nutrition
- anaemia.

L Verbal education to families is paced throughout the initial admission, and time is allowed to process the diagnosis. Education should not be left to the moment of discharge, and families should be aware that education is ongoing and accessible throughout treatment.

L Written and/or audio-visual educational information is provided as part of the discharge plan following diagnosis and should also include information targeted to children and adolescents.

Considerations must be made and strategies put in place for communicating with families with cultural and linguistic diversity, including providing access to interpreter services and translated educational materials.

Age and developmentally appropriate information should be available for children and adolescents.

A discussion about contraception should be considered for all adolescent patients.

The paediatric cancer service should be able to demonstrate a process for providing timely and consistent remote support and monitoring via the telephone for patients and their families at home.

STEP 4: Treatment

Step 4 outlines a framework for delivering treatment for leukaemia in children and adolescents.

Effective strategies to improve overall survival in childhood leukaemia are identified through international collaborative clinical trials.

4.1 Treatment intent

The intent at diagnosis for all children and adolescents with leukaemia is cure. Children who develop refractory or relapsed disease are discussed in step 6.

4.2 Timing of therapy

L Urgent pathway: Treatment must begin on the day of presentation immediately following diagnostic interventions. Urgent patients include, but are not limited to, those who present with hyperleucocytosis, tumour lysis syndrome, mediastinal mass and coagulopathies.

L Standard pathway: Treatment for leukaemia should commence by the next business day following diagnosis. In clinically stable patients, clinical trial requirements and the level of institutional resources available on the day to provide optimal care should guide timings.

4.3 After-hours admission of newly diagnosed patients

In some settings, paediatric patients admitted with newly diagnosed acute leukaemia on a weekend have been shown to have prolonged length of stay, increased time to chemotherapy and higher risk of organ failure.⁷³ The timing of diagnostic and therapeutic interventions should be flexible and reflect clinical need, particularly for patients who present with oncological emergencies.

4.4 The role of clinical trials and research in childhood leukaemia

The five-year overall survival rate in ALL for children and adolescents has increased to 92 per cent in 2013.⁷⁰ There has also been an improvement in AML survival, with current overall survival at 70 per cent.⁷⁴ In 1960 nearly all children with AML and ALL succumbed to their disease. To date, this dramatic reduction in mortality has largely been a result of collaborative research.⁷⁵

The low incidence of childhood leukaemia in the general population requires active participation in national and international clinical trials to achieve statistically significant numbers for research.

Clinical trial enrolment should be offered to all children and adolescents with a leukaemia diagnosis where open trials are available. For children who do not meet eligibility criteria, or where a clinical trial is not open, the patient should be treated according to the most recent, evidence-based and completed study protocol (this may not be the current open trial).

Clinical trials for leukaemia are risk-stratified and coordinated and managed within international collaborative studies.

4.5 Chemotherapy

Chemotherapy is the key component for treating childhood leukaemia. Due to the complexity and toxicity of administering cytotoxic agents to children, adherence to medication safety standards (such as mini-bag vincristine infusions) and the demands for supportive care, intravenous chemotherapy should be delivered via a central venous access device.

L Urgent pathway: Central venous access should be established on the day of presentation.

L Standard pathway: Insertion of a CVAD should be undertaken prior to initial treatment.

- Chemotherapy should be prescribed with the use of validated protocols within an electronic prescribing system.
- A documented procedure that is strictly followed on the prescribing, dispensing and administering of chemotherapy must be used.

Minimum requirements for delivering chemotherapy are defined in the *Service capability framework: a guide for Victorian health services providing primary treatment and shared care to children and adolescents with cancer*.⁴

4.5.1 Treatment for acute lymphoblastic leukaemia (ALL)

Most treatments for patients with standard-risk leukaemia are delivered in the outpatient setting. At this point in time, treatment lasts between two and three years and is dependent on risk stratification.

TREATMENT (includes CNS directed therapy throughout)
INDUCTION Goal: Achieve rapid remission. Length: 4 weeks (high-risk period)
CONSOLIDATION Goal: Strengthen depth of remission and systemic treatment for sanctuary sites. Length: variable, weeks to months
DELAYED INTENSIFICATION Goal: Strengthened pulse of intense therapy. Length: 8–12 weeks (high-risk period)
MAINTENANCE/CONTINUATION THERAPY Goal: Provide a prolonged period of low-risk treatment to eliminate MRD. Length: 2–3 years

4.5.2 Treatment for acute myeloid leukaemia (AML)

All treatment for AML is intensive and is delivered within the inpatient setting. At this point in time, total duration is four to six months, dependant on risk stratification. Some children may progress to HSCT as part of the protocol.

TREATMENT (includes CNS-directed therapy throughout, cycles may be repeated)
INDUCTION I Goal: Achieve rapid remission. Length: 4 weeks
INDUCTION II Goal: Achieve rapid remission. Length: 4 weeks
CONSOLIDATION/INTENSIFICATION I Goal: Strengthen pulse of intense therapy. Length: 4 weeks
CONSOLIDATION/INTENSIFICATION I Goal: Strengthen pulse of intense therapy. Length: 4 weeks

4.5.3 Treatment for infant leukaemia

Infants diagnosed with ALL remain a high-risk subset with significantly inferior outcomes. Current event-free survival remains at 50 per cent, despite best-practice international collaborative trials.⁷⁰ Treatment is intensive and predominantly inpatient-based. New therapies are examining the addition of specific targeted therapies, as current treatment regimens have reached dose-limiting toxicities.⁷⁶

It is important that infants with a leukaemia diagnosis are enrolled in clinical trials to provide optimal therapy.

4.5.4 Acute promyelocytic leukaemia (APML)

Although paediatric APML is rare, many children at diagnosis develop significant coagulopathy. Because of this, these patients are managed at diagnosis in the inpatient setting with ready access to intensive care. At this point in time, following induction, treatment is outpatient-based and specific to these patients, including the use of all-trans retinoic acid and arsenic trioxide.

4.5.5 Targeted therapy

The addition of tyrosine kinase inhibitors (a targeted therapy for specific high-risk subsets of ALL) has improved outcomes in recent international studies from a three-year survivorship of 35 per cent to 80 per cent.⁷⁰

Cancer services should continue to search new targets in treating childhood leukaemia, particularly in the high-risk groups. Personalised medicine should stay within the framework of robust collaborative clinical trials.

4.6 Radiotherapy

The use of radiotherapy (RT) for CNS prophylaxis has been one of the most important advances in the treatment of leukaemia. Intrathecal prophylaxis and intensified systemic chemotherapy have now reduced the need for RT without any impact on long-term outcomes,^{77,78,79} reducing the incidence of late neurological sequelae traditionally associated with cranial RT.

Currently, the use of cranial radiotherapy (CRT) in treating leukaemia is generally restricted to patients with overt CNS disease at diagnosis, and prophylaxis CRT is used in some patients with T-cell disease and other high-risk features. Internationally, protocols have drastically reduced the incidence of CRT and continue to do so.⁷⁹

Radiotherapy also has a place in some patients for the treatment of testicular disease, salvage treatment in patients with isolated CNS relapse, as well as a part of the conditioning regimen for some children undergoing HSCT (total body irradiation). It can also be very useful in palliating symptomatic masses in advanced disease.

Patients receiving radiotherapy are usually treated outside of the level five or six paediatric cancer service. It is important that these patients are managed under the recommendations outlined in the *Service capability framework: a guide for Victorian health services providing radiation therapy to children and adolescents with cancer*, which describes the minimum service requirements for providing a coordinated, sustainable and consistent model of care for delivering radiotherapy to children and adolescents with cancer.⁵

 Referral to radiotherapy services should be made once the treatment plan is confirmed.

4.7 Place of care

Treatment for childhood leukaemia is managed by a level five or six paediatric cancer service, in line with the *Service capability framework: a guide for health services providing primary treatment and shared care to children and adolescents with cancer*.⁴ Consideration for supportive care and some aspects of treatment such as administering chemotherapy in shared care centres outside the level five or six paediatric cancer service should be made after consultation with the patient's MDT. Shared care centres are required to adhere to the standards outlined in the framework. Episodes of chemotherapy in regional shared care centres should be conducted with the use of telehealth between the local health service and the child's oncologist.

The child or adolescent's usual place of residence should also be considered when determining the most suitable place of care. For children living in outer metropolitan and regional areas, efforts should be made to support localised and home-based care, when it is safe to do so.

At a time when cure is agreed not to be the primary goal of care, the child and family's preferences for site of ongoing care and site of end-of-life care should be explored.

4.8 Managing and preventing infection

Treatment-related mortality in AML in children and adolescents has been shown to be as high as 10 per cent.⁷⁴ Time to antibiotics greater than one hour in managing FN in high-risk groups has been shown to have negative outcomes in paediatric studies.^{80,81} Children and adolescents with Down Syndrome ALL are also at increased risk of treatment-related mortality and morbidity.⁸² In addition to the infection recommendations in the 'fundamentals of care' section, strategies to mitigate infection risk in children or adolescents with leukaemia are identified below.

- **Mandatory hospitalisation should be considered for all patients with AML and those patients with Down Syndrome-ALL during induction and periods of neutropenia.**
- **Consideration for hospitalisation during induction for non Down Syndrome-ALL should be made based on clinical and social/ compliance factors.**
- **Patients undergoing HSCT or treatment for AML must be treated in facilities appropriate to provide sufficient isolation from airborne pathogens, particularly fungal disease (such as HEPA filtration and positive pressure rooms).**
- **Strategies and policies should be in place for the management of infectious patients within the oncology clinical environment and waiting areas.**
- **For patients with FN, antibiotics must be administered within an hour of presentation to hospital, or within 30 minutes for inpatients.**
- **Patients with AML/ALL during the induction and intensification phases of treatment or those immediately (+ 30 days) post HSCT are at high-risk of sepsis. They must be identified as such and follow a high-risk pathway for FN.**

4.9 Role of haematopoietic stem cell transplantation and other cell therapies

HSCT is an established treatment regimen for haematological malignancies in children. HSCT should be considered in selected patients at greatest risk of relapse where there is evidence that this modality improves outcome. As the understanding of the biology of leukaemia and treatment with chemotherapy and targeted therapy has improved, the indication for HSCT has reduced. HSCT is more widely used as a salvage where primary treatment has failed.

4.9.1 Indications for haematopoietic stem cell transplantation in leukaemia

The indications for HSCT in leukaemia should be reassessed continuously by the cancer service.⁸³ At this point in time, consideration for HSCT may include:

- ALL with high-risk features, for example, t(4:11), hypodiploidy and/or induction failure
- AML patients with high-risk features
- Mixed-phenotype acute leukaemia
- infant leukaemia with poor prognostic criteria
- relapse during or shortly after first remission
- persistent positive minimal residual disease.

All patients being considered for HSCT will be discussed at a leukaemia MDM.

4.10 Adherence and compliance to treatment for leukaemia

Treatment for childhood leukaemia lasts two to three years, with much of the treatment (oral chemotherapy) delivered in the home. The rate of medication errors in the home for children with cancer have been shown to be very high.^{84,85} Non-adherence to oral chemotherapy in ALL has been demonstrated to occur due to practised restrictions placed upon families.⁸⁶ Cancer services are required to demonstrate strategies to support patients, families and caregivers in adhering to the treatment plan, particularly the role of long-term oral chemotherapy in the home.

The cancer service should have in place a mechanism to measure and record compliance with home-based oral medication administration, including how changes to oral chemotherapy doses are communicated to families in both written and verbal forms.

Step 5: Care after completing therapy and survivorship

5.1 Coming off treatment and surveillance in leukaemia

- All patients are required to attend an end-of-treatment consultation following completion of treatment for leukaemia. This should be a multidisciplinary episode of care, including their primary oncologist, nurse consultant (with expertise in managing childhood leukaemia) and, if enrolled in a clinical trial, their study coordinator.
- A referral to a survivorship program should occur at completion of treatment with the view of transition to the survivorship program at the completion of surveillance.
- All patients with a leukaemia diagnosis should be provided with a treatment summary, surveillance roadmap and educational material specific to coming off treatment at their end-of-treatment consultation. The summary should also be sent to the child's GP and if applicable to the paediatrician.

The surveillance roadmap is sourced from the study protocol delivered for that individual disease and should be strictly followed, regardless of clinical trial enrolment. This roadmap should be prepared in collaboration with the survivorship program.

Surveillance includes:

- full blood examination and peripheral film
- Alanine Aminotransferase (ALT) and Urea, Electrolytes and Creatinine (UEC) testing on blood until normal recovery
- physical examination and history.

Echocardiograms will be undertaken routinely during surveillance for patients treated with chemotherapy for AML and ALL, as defined by the clinical trial protocol.

- At this point in time, planned episodes of surveillance following treatment for leukaemia are, at a minimum:
 - first year – every four to six weeks
 - second year – every eight weeks
 - third year – every 12 weeks
 - fourth year – every six months.

For patients enrolled on clinical trials, timings will be determined by the study protocol.

The length of surveillance for leukaemia usually lasts between three and five years. The medical management during the surveillance period should be directed by the primary paediatric oncologist. However, if provided with the adequate information and escalation criteria, consideration of the GP or paediatrician undertaking a portion of this under a shared care arrangement should be considered. Families from regional centres should be encouraged to conduct reviews under a telehealth model with the regional healthcare team, as deemed appropriate by the MDT. The demands for managing children enrolled in a clinical trial should be met prior to shared care being discussed.

5.2 Haematopoietic stem cell transplant

Children and adolescents who received a HSCT as part of therapy for leukaemia should follow a specific evidence-based surveillance roadmap, including routine bone marrow evaluation, designed by the transplant team, tailored to the patient's level of immunocompetence.

5.3 Survivorship

- All patients who have been treated for leukaemia should be referred to a survivorship program at the completion of treatment with the view of transition to the survivorship program at the completion of surveillance.
- All patients who have been treated for leukaemia should be participating in a survivorship program from three to five years after completing treatment.
- All patients should be given an updated treatment summary and a roadmap for late effects surveillance on entering the survivorship program.

Patients and their families should also be provided with educational material about survivorship, including adopting a healthy lifestyle.

Large cohort studies show there is a low prevalence for significant adverse long-term outcomes in ALL and recommend regular, primary care consultations.⁸⁷

Late complications specifically related to childhood leukaemia may include:

- deficits in neurocognitive functioning, particularly with CNS-directed therapy
- impaired cardiac function due to the use of anthracycline chemotherapy
- neuropathy
- risk of obesity and metabolic syndrome, particularly in those patients treated with cranial radiation.

Increased support in survivorship is necessary for children with AML, particularly due to the risk of cardiotoxicity, secondary to the use of anthracyclines.

Increased surveillance and monitoring is also necessary for those who have undergone a transplant due to the increased toxicities of therapy, particularly during conditioning and any graft versus host disease.

See the 'fundamentals of care' section under 'survivorship' for more information.

5.4 Transition from paediatric to adult care

Most survivors of childhood leukaemia will be transitioned to a GP with a treatment summary and roadmap outlining investigations and surveillance required. For patients who have undergone a transplant, transition to an adult transplantation service may be appropriate. See the 'fundamentals of care' section for more information on transition.

STEP 6: Managing refractory disease or relapse

Despite approximately 90 per cent of children with ALL being cured of their disease, relapse remains the most common cause of treatment failure, occurring in 15–20 per cent of all patients.⁸⁸ Of those children who relapse, cure only occurs in about 50 per cent of patients.⁸⁹

In AML, 30 per cent of all patients will relapse, and recent studies show only 30–40 per cent of those patients survive.⁹⁰

6.1 Signs and symptoms

Most cases of disease recurrence or relapse are identified through routine investigations or follow-up. Relapse may be discovered by peripheral blood examination (ordered during or after treatment) or via routine examination of bone marrow at critical time points during the child's treatment. Extramedullary relapse may be made during physical examination (such as testicular relapse or hepatosplenomegaly) or via routine cerebrospinal fluid examination during therapy.

Factors contributing to prognosis in relapsed ALL include:¹⁶

- marrow relapse less than three years from diagnosis (poor)
- extramedullary relapse (for example, CNS) less than 18 months from diagnosis (poor)
- marrow relapse longer than three years since diagnosis (favourable)
- extramedullary relapse longer than 18 months since diagnosis (favourable)
- response to initial therapy.

In AML, the length of time from the first remission is a major predictor of survival (with longer periods more favourable).

6.2 Multidisciplinary team

- There should be an immediate referral to a leukaemia MDT at a level five or six paediatric cancer service for all children with suspected or confirmed relapse.

6.3 Treatment

Children with relapsed ALL are often eligible for enrolment in relapsed protocols, often involving the delivery of systemic chemotherapy and the use of HSCT for selected patients. Transplant remains an option in relapsed ALL where chemotherapy resistance has been established, particularly if there is a matched sibling donor available.

In relapsed AML, achieving rapid remission via systemic chemotherapy followed by HSCT is currently the most effective curative strategy.⁵⁹

Immunotherapy

New immunotherapy agents continue to show promise in early clinical trials in refractory leukaemia.⁸⁸ The health service should continue to look to enrol patients in early clinical trials investigating immunotherapy agents in children and adolescents with refractory leukaemia where standard therapy has failed the patient or the patient has been unable to meet eligibility criteria.

Chimeric antigen receptor T-cell therapy

Despite significant risk of morbidity during treatment requiring high dependency or intensive care, this emerging therapy has shown promising results.⁹¹ Chimeric antigen receptor T-cell therapy should continue to be investigated in children and adolescents with refractory or very high risk leukaemia.

6.4 Supportive care in relapsed leukaemia

Treatment for relapsed leukaemia is associated with a high-risk of treatment-related morbidity and mortality, particularly infectious complications. HSCT, novel agents and cell therapies used in refractory leukaemia may also be associated with significant treatment-related side effects.

Families from regional centres may need to reside near the level five or six paediatric cancer service due to the toxicity of therapy.

Support of the patient and family, including access to information, should be managed under the family-centred care principles discussed in the 'fundamentals of care' section. Further information on relapse in children and adolescents is discussed in the 'fundamentals of care' section.

6.5 Palliative care in relapsed leukaemia

Therapies such as HSCT, treatment for high-risk AML and targeted therapies within the context of clinical trials can result in high levels of physical, psychological and existential distress, despite having curative intent. Children and adolescents with an uncertain prognosis and high symptom burden should be able to access palliative care support alongside curative-intent therapies.

Cases of relapse should trigger a referral to palliative care services, unless there are strong, family-centred reasons to decline referral. The principles of a palliative care approach need to be documented and shared with the team. The decision should be made in collaboration with the child or adolescent, and their family.

Discussion should be held within a paediatric leukaemia MDM to offer the family referral to palliative care services where there is a likely need to escalate care to manage symptoms and distress in high-risk curative regimens such as HSCT, as well as support when cure is no longer the intent of the MDT.

Scenarios that should prompt the discussion of early referral by the MDT to palliative care include:

- infant leukaemia, particularly associated with mixed-lineage leukaemia and hypodiploidy
- allogeneic HSCT, particularly in high-risk leukaemia
- AML expressing high-risk criteria
- high-risk leukaemia where induction treatment has failed the patient.

STEP 7: End-of-life care

Step 7 is concerned with maintaining the child or adolescent's quality of life and addressing their health and supportive care needs, as well as the needs of the family, at the end-of-life.

Discussion should be held within a paediatric leukaemia MDM to determine patients for whom no further disease-modifying therapy is warranted, to identify those approaching end-of-life, ensuring palliative care services are in place.

- Referral to palliative care service should occur at this time, if not already engaged.

Interventions and responsibilities at the end-of-life are discussed in the 'fundamentals of care' section.

Issues at the end-of-life that are specific to children and adolescents with leukaemia include the following:

- Blood products.** Children with advanced leukaemia often experience pancytopenia and require frequent transfusions. However, transfusion of blood products can have associated burdens, including travel time and inpatient time, as well as the risks of fluid overload and transfusion reactions. The provision of ongoing transfusions should be based on a case-by-case assessment of the child and their experience, rather than just the blood count
- Antibiotic use.** Children with advanced leukaemia are often profoundly neutropenic and at risk of severe infection. As a child's functional status deteriorates, some families prefer to avoid the burden of prolonged inpatient admissions for infection by limiting antibiotic intervention to those able to be administered in the home, or to simply reduce the symptoms of infection. Discussing the different options for infection intervention, and the likely impact on the child, is crucial in supporting patient and family preferences.

Ongoing commitment to continuous improvement in the treatment of acute leukaemia

Due to its prevalence in childhood cancer (despite excellent overall survival), leukaemia remains one of the largest causes of cancer deaths in children.⁹² Key strategies for paediatric health services to prioritise include:

- continued work in establishing the cause of childhood leukaemia
- improving risk stratification through establishing biologically-defined subgroups
- improving technologies in measuring minimal residual disease and other high-risk subgroup
- reducing the incidence of long-term toxicities from therapy
- improved development of molecularly-targeted therapies
- improved technologies in cellular therapies in treating leukaemia
- improving compliance to therapy, particularly adherence to maintenance therapy
- identifying best-evidence practices for minimising physical and psychosocial suffering and optimising quality of life for children with leukaemia in both curative and palliative treatment phases.

SECTION 3:

PAEDIATRIC ONCOLOGY CARE PATHWAY — CENTRAL NERVOUS SYSTEM (CNS) TUMOURS

This oncology care pathway outlines seven critical steps for children diagnosed with CNS tumours. While these steps are portrayed in a linear time model, in practice, patient care is rarely straightforward and predictable. The critical steps will require realignment and adjustment to best meet the needs of patients, their families and care providers, without undermining the effectiveness of the treatment and supportive care program. The pathway describes the optimal cancer care that should be provided at each step.

The key principles and fundamentals of paediatric oncology practice outlined in the 'fundamentals of care' (section 1) underpin the oncology care pathway for CNS tumours.

Scope

This oncology care pathway is intended as a resource in managing children and adolescents diagnosed with CNS tumours.


Critical time points

As mentioned at the beginning of this document the blue clock symbol  is used to highlight a critical time point that has a specific timeframe attached to it.

A red clock symbol  indicates the time point is part of an **urgent pathway**.

Classification of CNS tumours seen in children and adolescents ^{93,94}

Figure 4: CNS tumours classification, WHO 2016



Based on the understanding of the molecular and genetic basis of cancer, the World Health Organization (WHO) introduced changes in the 2016 classification of CNS tumours. The aim of these changes was to provide a combined phenotypic and genotypic diagnosis that more accurately defines real biological entities.⁹⁴ It is important for health professionals to be aware of these changes to the nomenclature to guide patient management, steer enrolment in clinical trials, provide reproducibility and support prognosis.⁹⁴


All new diagnoses of CNS tumours in children and adolescents should be classified according to the most recent WHO classification.

Many health services and government cancer registries do not keep complete data on non-malignant CNS tumours in children and adolescents. However, international data shows us that many of these children also use oncology and rehabilitative services.⁹⁵ As resource allocation is often based on population figures, it is important that health services and cancer registries work together to incorporate all CNS tumours within the cancer registry.

Distribution of CNS tumours seen in children and adolescents

CNS tumours in children and adolescents are a heterogeneous group of malignancies, creating a challenge for clinicians. Figure 5 (based on 2007 WHO data, superseded in 2016) provides an outline of the distribution of CNS tumours in children and adolescents according to histology.⁹⁶

Figure 5: CNS tumours distribution 0-19 years, n = 16,653 (WHO 2007 histology)



Summary

Figure 6: Paediatric oncology care pathway summary – CNS tumours

Assess supportive and/or palliative care at every step of the pathway and refer to the appropriate health professional	STEP 1 Prevention and early detection	<p>RISK FACTORS. Risk factors. There is no clear cause for most CNS tumours in children and adolescents. Some cancer predisposition syndromes may increase the risk of developing CNS tumours. Ionising radiation to the brain and spine (such as previous radiotherapy) is an established risk factor.</p>	<p>There are no efficient screening programs for early detection of <i>de novo</i> CNS tumours in the general population of children and adolescents. There is no evidence that lifestyle plays a role in the development of CNS tumours in children and adolescents.</p>
	STEP 2 Presentation, initial investigations and referral	<p>SIGNS AND SYMPTOMS. The clinical features of CNS tumours are diverse and are dependent on the site of the tumour, the child's age, developmental level and tumour type. The possibility of a CNS tumour as a differential diagnosis should be considered in all patients with new seizures and/or focal neurological deficits. Escalation for further investigations should be considered for those patients presenting with non-localising symptoms that fail to settle or progress rapidly.</p> <p>Non-localising signs and symptoms may include nausea, vomiting, headaches, drowsiness, lethargy, irritability, confusion, growth and endocrine disorders, altered gait, poor coordination, rapid visual changes, behavioural changes and increased head circumference. Primary care and emergency departments should have access to current evidence-based information to guide investigation and referral in the suspicion of a CNS tumour in a child or adolescent.</p>	<p>PARENTAL CONCERN. Escalation for further investigations is also warranted if there have been repeated GP visits or a high level of parental anxiety.</p> <p>REFERRAL. Paediatric tertiary referral centres should provide clear routes of rapid access for GPs and community paediatricians to specialist evaluation.</p>
	STEP 3 Diagnostic work-up, staging and treatment planning	<p>DIAGNOSIS. MRI with contrast of the entire craniospinal axis is the preferred imaging technique for diagnosis. All imaging results should be interpreted by a radiologist with experience in CNS imaging in children. In most cases, a definitive diagnosis will be made via examination of a tissue sample. Access to molecular profiling of tumour samples should also be used when available.</p> <p>TREATMENT PLANNING. Optimal treatment planning includes presentation of all patients with CNS tumours at a state-wide paediatric neuro-oncology MDM.</p>	<p>STAGING. Level five and six paediatric cancer services should use standardised grading systems tailored to specific CNS tumours and, when available, these tumours should also be risk-stratified according to molecular profiling.</p> <p>COMMUNICATION. The lead clinician should discuss the outcomes of the MDM with the patient and family, including the diagnosis, risk assignment, treatment plan and, where appropriate, access to clinical trials. The plan should be communicated with the original referring clinician, the GP and paediatrician if applicable.</p>
	STEP 4 Treatment	<p>TREATMENT. Treatment protocols must aim to offer the best curative approach while reducing morbidity.</p> <p>Neurosurgical interventions should be organised within a state-wide paediatric neuro-oncology MDT structure.</p> <p>CLINICAL TRIALS. When available, clinical trials should be offered to all children and adolescents with CNS tumours. For patients who do not meet trial eligibility criteria, the most recent, evidence-based and published study protocol offering the best outcomes should be used.</p> <p>Chemotherapy is often prescribed within validated treatment protocols.</p>	<p>Targeted therapies are also increasingly being utilised in CNS tumours. Consideration of Radiotherapy, often a key component of treatment, will be discussed within the state-wide paediatric neuro-oncology MDM. Rehabilitative care packages with multidisciplinary support should be available to patients diagnosed with CNS tumours.</p> <p>COMMUNICATION. The lead clinician should discuss the treatment protocol, including intent, risks, benefits and supportive care measures, with the patient and family. The care plan should be communicated with the GP and paediatrician if applicable.</p>

Assess supportive and/or palliative care at every step of the pathway and refer to the appropriate health professional	STEP 5 Care after completing therapy and survivorship	<p>COMING OFF TREATMENT. All patients should have an end-of-treatment consultation with their primary oncologist and, if applicable, their neurosurgeon and clinical trials coordinator, and be provided with a surveillance roadmap.</p> <p>SURVIVORSHIP. All patients completing treatment for CNS tumours will be referred to a survivorship program within three months to formulate a shared care plan between the acute and survivorship services. Minimum documentation should include a treatment summary and a tailored survivorship roadmap for future tests and investigations.</p>	<p>TRANSITION OF CARE. In most cases, transition of adult survivors of a childhood CNS tumour should be to their GP. Transition of patients with actual or a high-risk of possible late effects that require speciality care should be referred to adult speciality facilities. All CNS tumour survivors with ventriculoperitoneal (VP) shunts in situ should have annual reviews by an adult neurosurgeon beyond transition.</p>
	STEP 6 Managing refractory disease or relapse	<p>DETECTION. Most instances of relapse or recurrence are identified through routine clinical examination or medical imaging.</p> <p>TREATMENT PLANNING. Optimal treatment planning requires presentation to a state-wide paediatric neuro-oncology MDM. Early integration to palliative care services (and advance care planning) should also be considered.</p> <p>TREATMENT. Children may be eligible for enrolment in clinical trials. Treatment may involve further surgery, radiotherapy or chemotherapy.</p>	<p>COMMUNICATION. The lead clinician should discuss the outcomes of the state-wide paediatric neuro-oncology MDM with the patient and family, including treatment options, the nature and intent of any treatment, potential clinical trial enrolment, prognosis and risks and benefits of treatment. The plan should be communicated with the GP and/or paediatrician.</p>
	STEP 7 End-of-life care	<p>PLANNING. An advance care plan specific to end-of-life care should be documented early in this stage. Elements of end-of-life care should be guided by evidence and/or expert consensus.</p>	<p>COMMUNICATION. The advance care plan should be communicated in the patient file and shared with the GP and/or paediatrician.</p>

Step 1: Prevention and early detection

Step 1 outlines recommendations for the prevention and early detection of CNS tumours.

1.1 Prevention

Although risk factors have been identified, there is no clear cause for most CNS tumours. There are no proven or recommended preventative strategies. There is no evidence that lifestyle plays a role in the development of CNS tumours in children and adolescents. It is important to ensure the patient and their family are aware of this to avoid feeling responsible for the diagnosis.

1.2 Risk factors

Genetic predisposition and host factors

Some cancer predisposition syndromes can increase the risk of developing a CNS tumour in childhood.⁹⁷ These include, but are not limited to, neurofibromatosis types 1 and 2, tuberous sclerosis, Li-Fraumeni syndrome and hereditary retinoblastoma.⁹⁸ When treated for cancer, some patients who carry genetic predisposition may also have an increased risk of secondary cancers within the field of radiation of the primary tumour.⁹⁹ See the 'fundamentals of care' section for more information regarding genetic predisposition.

Environmental factors

Moderate to high-dose ionising radiation is an established risk factor for developing CNS tumours.¹⁰⁰ In nearly all cases, this is a result of radiotherapy administered to treat cancer.¹⁰¹ There has also been previous history of CNS tumours from craniospinal radiotherapy in the treatment of childhood leukaemia.⁹⁹ Currently, there are no other identifiable environmental factors (including mobile phone technology and powerlines) that have a significant association with the development of childhood CNS tumours.

1.3 Screening and early detection

Children and adolescents with a high predisposition to develop CNS tumours should have medical consultations, according to the most recent published guidance, with a medical expert specialising in these conditions. For the general population without an underlying predisposition, there is no efficient screening program for detecting *de novo* CNS tumours.

Step 2: Presentation, initial investigations and referral

Tumours of the CNS in children and adolescents are rare. This represents a major diagnostic challenge for emergency departments and GPs.

Step 2 outlines the process for establishing a provisional diagnosis and appropriate referral for a child or adolescent suspected of having a CNS tumour.

2.1 Presenting signs and symptoms

The clinical features of CNS tumours are diverse, often non-specific and dependent on the site of the tumour, the child's age, developmental level and tumour type. There is no single clinical finding that is characteristic for all CNS tumours in children and adolescents,⁹⁹ and the predictive power of isolated non-localising signs and symptoms is weak.¹⁰² Furthermore, signs and symptoms are often subtle and mimic more common childhood conditions.¹⁰³ Despite this, health professionals in primary practice and emergency settings should develop an awareness of CNS tumours in children and adolescents in order to make appropriate and timely referrals.⁵⁸

Delays in diagnosis may be associated with inferior outcomes and/or increased morbidity. Although tumour biology and treatment response are the strongest indicators of outcome, when considered across all CNS tumour types, children who experience a long diagnostic time interval are more likely to present with significant neurological deficits at diagnosis,¹⁰⁴ resulting in greater long-term complications such as visual loss and endocrinopathies.^{104,105} A delay in diagnosis can also have major psychological impacts on patients and their families, and their subsequent health-seeking behaviour.

Although non-localising signs and symptoms in isolation do not have high predictive power for diagnosis, their rising frequency and severity is consistent in all CNS tumours,¹⁰² and should influence a decision to seek further investigations. It is important to also recognise parental concern; escalation for investigations should be warranted after repeated visits or high levels of parental anxiety.⁶⁰

The possibility of a CNS tumour as a differential diagnosis should be considered in all patients who present with new seizures or focal neurological deficits.

For patients who present with non-localising signs and symptoms that fail to settle, or progress rapidly, further investigations should be considered, rather than relying on the presence or absence of specific signs or symptoms.¹⁰²

Non-localising signs and symptoms may include, but are not limited to, nausea, vomiting, headaches, papilloedema, drowsiness, lethargy, irritability, confusion, growth and endocrine disorders, declining school performance, altered gait, poor coordination, rapid visual change, behavioural changes and increased head circumference. Presence of two or more symptoms should escalate concern.

Work has been undertaken in the United Kingdom (UK) and North America in raising awareness of early clinical features of CNS tumours in children and adolescents.^{106,107} This pathway supports initiatives aimed at increasing this understanding. A framework such as the UK HeadSmart^{108,109} guidance for health professionals and consumers should be adapted and implemented. Level five and six paediatric cancer services should adopt and actively promote such information and educational resources among the primary healthcare network, local emergency departments and general paediatricians.

Primary care and emergency departments should have access to current evidence-based information to guide investigation and referral in the suspicion of a CNS tumour in a child or adolescent. This guidance should be adapted for local needs and promoted by the level five or six paediatric cancer service.

Paediatric cancer services should monitor key indicators such as time to diagnosis and aim to achieve time intervals that are at least comparable or better than best practice international published data.

2.2 Referral

The following recommendations encourage the use of a decision-support tool such as the UK HeadSmart initiative¹⁰⁹ for supporting (or eliminating) the diagnosis of a CNS tumour in children and adolescents.

- Ⓛ All children and adolescents seen in primary or emergency care with a high suspicion of a possible CNS tumour should be discussed on the same day with a paediatric tertiary health professional. A high suspicion may include new seizures, focal neurological signs or non-localising signs that have increased in frequency and intensity.
- Ⓛ The paediatric tertiary referral centre should be able to offer rapid, same day access for telephone consultation for primary and secondary care health professionals managing a child with a high suspicion of a CNS tumour.

The GP or paediatrician should have a clear process for rapid paediatric tertiary referral and transfer, in both emergency and outpatient based-presentations.

The minimum documentation for referral should include:

- a referral letter, including the patient's demographics, relevant medical history, medications and allergies
- results of any clinical investigations (including imaging and pathology reports)
- the need for interpreter services and other recognised significant psychosocial issues.

The GP or paediatrician should aim to provide electronic or printed confirmation of tests and investigations, but availability should not delay the referral.

2.3 Initial investigations

Medical imaging is the primary modality for the initial diagnosis of CNS tumours.⁹⁹ Health services should be able to demonstrate rapid access to medical imaging, including services that can deliver sedation or general anaesthesia to infants and young children. If general anaesthesia services for medical imaging cannot be delivered in a timely manner, the patient must be referred to a centre with this capability. MRI of the entire craniospinal axis is the preferred modality for all children and adolescents with a suspected CNS tumour.¹⁰⁴ The preference of MRI over CT scanning in children and adolescents with CNS tumours includes the ability to provide superior resolution of the images with

improved anatomical detail without exposure to ionising radiation.⁹⁹ The use of CT scans should be minimised in situations outside of the emergency setting and, if used, should utilise contrast enhancement. All imaging results should be reported by a radiologist with experience in CNS MRI and CT scans in children,¹⁰⁸ and be available to report results in real time for urgent imaging.

MRI should be the imaging technique of choice in all children and adolescents with existing or suspected CNS tumours.

Health services should be able to provide prompt access to MRI, including imaging under general anaesthesia.

CT scanning may be necessary in emergency situations because it can be performed rapidly without the need for general anaesthesia.

All urgent imaging should be reported in real time by a radiologist experienced in paediatric imaging.

- ⌚ All children with a high suspicion of a CNS tumour should have arrangements made for urgent CNS imaging (preferably MRI) within 24 hours.
- ⌚ Telephone consultation with a level five or six paediatric cancer service should be encouraged when planning imaging to exclude the differential diagnosis of a CNS tumour (a low suspicion of a CNS tumour). Imaging required to exclude a differential diagnosis should be performed as soon as practical (optimally within two weeks). Consideration of other differential diagnoses should not cease.

Step 3: Diagnostic work-up, staging and treatment planning

Step 3 outlines the process for confirming the diagnosis and planning subsequent treatment. The guiding principle is that interaction between appropriate multidisciplinary team members should be responsible for determining the treatment plan. The definitive diagnosis of a CNS tumour nearly always requires surgical biopsy.

It is a requirement that diagnostic work-up, staging and treatment planning of children and adolescents with CNS tumours should be undertaken within a level five or six paediatric cancer service.

3.1 Diagnostic work-up and pre-treatment investigations

Physical examination, assessment and history

A physical examination and assessment should be undertaken and documented as a baseline on presentation to a level five or six paediatric cancer service. This should incorporate a comprehensive, developmentally appropriate neurological examination. A baseline examination provides for ongoing comparison during treatment and surveillance. Head circumference, particularly in children under four years, should be documented on growth charts and when available, compared with previous measurements. A normal examination does not exclude a CNS tumour in children and adolescents¹⁰⁹ and other modalities are still necessary to aid diagnosis.

A history of comorbidities and all symptoms elicited from the patient and caregiver (including time of onset, frequency and severity) should be obtained. A history of any regression or failure to achieve developmental milestones, academic performance (particularly declining performance), behavioural changes, growth failure and delayed or arrested puberty should also be recorded.

When diagnosis is confirmed, a comprehensive family cancer history extending back three generations can help further identify patients and families with inherited cancer predisposition syndromes.⁵⁴

- ⌚ A detailed history, physical and age-appropriate neurological examination should be undertaken and documented on the day of presentation to the level five or six paediatric cancer service for all children and adolescents with a suspicion of a CNS tumour.

Medical imaging interventions

As previously discussed, medical imaging is the primary modality for the initial diagnosis of CNS tumours.⁹⁹ MRI with contrast of the entire craniospinal axis is the preferred imaging technique prior to surgery. If a CT scan is undertaken as part of the initial workup, an MRI should be performed prior to any definitive diagnosis and treatment planning.

Surgical interventions at diagnosis

In nearly all cases, a definitive diagnosis will require examination of a tissue sample following biopsy or resection.¹¹⁰ The indications and considerations for surgical intervention are further discussed in Step 4. Surgery is also indicated upfront in urgent cases, such as obstructive hydrocephalus, haemorrhage or significant mass effect.

The level five or six paediatric cancer service should be able to demonstrate urgent pathways for emergency management of CNS tumours, including after-hours services. This should incorporate neurosurgery, oncology, medical imaging, anaesthetics, intensive care, radiation oncology, pathology (including biobanking and discussion of clinical trial samples) and other medical specialties as needed.

Diagnostic laboratory investigations

As well as performing tissue biopsy, for many presentations additional diagnostic interventions may need to be undertaken according to the pathology of the tumour and risk of metastatic disease. Understanding the full extent of disease at diagnosis is vital for optimal treatment planning and prognosis.¹¹¹

3.2 Grading, risk stratification and biobanking of CNS tumours

CNS tumours rarely metastasise to organs outside of the craniospinal axis, but they commonly spread within the CNS. Staging, therefore, if used, is generally limited to CNS metastases. Grading of a tumour, from differentiated (low-grade) through to undifferentiated (high-grade) is frequently used, such as grading of gliomas. Stratifying risk according to variables such as age, presence of metastases and residual tumour following resection are applied to CNS tumours.¹¹² Due to the heterogeneity of CNS tumours, no one system for risk assessment can be applied, as the criteria for identifying risk are often tumour-specific. Increasingly, molecular analysis of CNS tumours will play a role.

Molecular profiling of CNS tumours in children and adolescents

Incorporating genomics into the treatment of CNS tumours is progressing at a rapid rate.¹¹³ Health professionals managing children and adolescents with CNS tumours require an understanding of precision medicine in which the diagnosis, classification and treatment of paediatric CNS tumours are informed by their molecular and genomic characteristics.¹¹⁴ Advances in molecular dissection and

analysis of CNS tumours and their subgroups will alter future clinical care by significantly improving the accuracy of diagnosis, prognostication and identification of appropriate therapies.^{113,115} Rapid transition of these new technologies to the clinical setting will demand continued efforts and collaboration across national and multinational groups.¹¹³

Biobanking

To support the application of precision medicine in patients with CNS tumours (where subgroups of rare cancers are increasingly identified and thereby less common), access to biobanks with high-quality, well-described neuro-oncology bio-specimens is critical.¹¹⁶

The level five or six paediatric cancer service should use standardised systems for grading and/or staging CNS tumours and, when available, these tumours should also be risk-stratified according to molecular profiling.

Molecular classifications and CNS nomenclature identified by the health service should be consistent across international study groups to encourage rapid translation of findings for these small and rare patient cohorts.

The level five and six paediatric cancer services should develop sustainable ethical and clinical governance structures for the biobanking of CNS tumours in children and adolescents that also collaborate with external institutions to encourage rapid translational research.

3.3 The multidisciplinary team and treatment planning

Collaborative, multidisciplinary discussion is recognised as an essential tool for managing paediatric cancer.¹¹⁷ Surveys of European practices show that they are utilised in nearly all paediatric oncology services.¹¹⁷ In adult cancer, MDMs have been shown to lead to significant changes in the way cancer patients are assessed and managed.¹¹⁸ The MDM is considered a central part of the cancer pathway and a gold-standard of cancer care globally.¹¹⁹ All paediatric cancers are rare by nature and therefore children benefit from treatment plans discussed and agreed upon in MDMs. Hence, the whole paediatric oncology community may benefit from the introduction of a well-established, state-wide paediatric neuro-oncology MDM that is convened to share knowledge and expertise.

The neuro-oncology multidisciplinary team

Optimal treatment planning includes presentation of all patients with CNS tumours at a state-wide paediatric neuro-oncology MDM.

It is a requirement that the state-wide paediatric neuro-oncology MDM include all the experts required for the diagnosis and treatment planning of childhood CNS tumours including:

- paediatric oncologist with a subspecialty in neuro-oncology*
- pathologist with experience and expertise in paediatric CNS malignancies*
- nurse consultant with experience and expertise in paediatric CNS malignancies*
- neurosurgeon with experience and expertise in paediatric CNS malignancies*
- radiologist with experience and expertise in paediatric CNS malignancies*
- radiation oncologist with a subspecialty in paediatrics*
- paediatric clinical trials coordinator
- paediatric oncology pharmacist
- social worker with experience in paediatric oncology
- paediatric palliative care clinician
- neuropsychologist.

*Core members of the MDT who will be represented in person or remotely at the time of the meeting.

Ideally, all core members within the institution will attend the state-wide paediatric neuro-oncology MDM, regardless of whether they have patients to present. A secondary but important outcome of the state-wide paediatric neuro-oncology MDM are the educational opportunities they provide for all participants.

Administrative support should be available to ensure efficient documentation and dissemination of meeting recommendations and regular audits to monitor the quality of the meetings.

- Ⓛ A referral is made to the oncology team within 24 hours of presentation for all new diagnoses.
- Ⓛ Discussion at the state-wide paediatric neuro-oncology MDM should occur within two weeks of presentation to the level five or six service and be clearly documented in the patient record in real time.

Communication of the state-wide paediatric neuro-oncology MDM recommendations

The lead clinician should discuss the outcomes of the state-wide paediatric neuro-oncology MDM with the patient and family, including the diagnosis, risk assignment, treatment plan and, if appropriate, access to clinical trials. The plan should be communicated with the original referring clinician, the GP and, if applicable, the child's paediatrician. Where possible, further planning discussions with the family should be collaborative and multidisciplinary and incorporate oncology, neurosurgery and radiotherapy, as applicable.

Consultation with external services

CNS tumours in children and adolescents are rare and may benefit from other centralised paediatric cancer services for further opinion. Level five or six paediatric cancer services should be able to demonstrate effective and timely links to and relationships with paediatric cancer services nationally, as well as other international centres of excellence, when further opinion is required. This type of effective collaboration when diagnosing and treating rare cancers should be encouraged by the health service and clearly communicated to the families. It is acknowledged that a definitive diagnosis in some rare cancers may be delayed due to the need to collaborate with other centres.

Reporting the diagnosis

- Ⓛ All new diagnoses are reported to the state cancer registry. Any changes in a child's final diagnosis will be updated in the state cancer registry.

3.4 Supportive care considerations

Supportive care considerations applicable to all children and adolescents with cancer are discussed in the 'fundamentals of care' section. Additional supportive care requirements in the context of children and adolescents with CNS tumours at diagnosis are discussed below. Rehabilitation in the context of CNS tumours is addressed in Step 4. It is important to acknowledge the supportive care needs of children with either malignant or benign/low-grade CNS tumours.

- Ⓛ All children and adolescents with CNS tumours should have an ongoing, universal referral made to social work at the time of diagnosis.

Endocrinology

Children and adolescents with CNS tumours, particularly those that involve the hypothalamus or pituitary gland,

may present with endocrinopathies prior to diagnosis.¹²⁰ These may develop acutely after therapy. Survivors of childhood CNS tumours are at a significant increased risk of endocrine late effects, with studies showing an incidence of up to 40 per cent.¹²¹ Diagnosing and treating both early and late presentations in a timely manner will improve growth, wellbeing and quality of life.

All patients with CNS tumours who have a proven, or are at risk of, endocrinopathy should be referred to a paediatric endocrinologist who has experience working with children and adolescents with cancer. If clinically required, the paediatric endocrinologist should remain part of the MDT for consultation throughout surveillance and survivorship.

Neuropsychology

Children and adolescents with CNS tumours have a markedly higher risk of neurocognitive impairment compared to their healthy peers.¹²² Younger patients and those receiving cranial radiotherapy have the highest risk for such impairment.¹¹¹

- Ⓛ Neuropsychological care for patients with CNS tumours should be managed in line with risk algorithms defined within the PICS document *A compendium of evidence and framework for neuropsychological services in paediatric cancer (2015)*.³⁴ Screening should be completed with standardised measures²³ by a psychologist with experience in CNS tumours in children and adolescents.¹²³

3.5 Educating the patient and family

Lack of access to information has been identified as a cause of stress and conflict for families of children with cancer.⁷¹ The family and patient will be provided with both verbal and written information, as appropriate to the family's health literacy, that should include the following topics:⁷²

- diagnosis, treatment plan, treatment intent and prognosis
- management of fever and neutropenia (if applicable)
- side effects of treatment
- who/how to call their hospital and/or treating team
- access to clinical trials
- managing medications and compliance at home
- central line care (if applicable)
- caring for the child at home
- supportive care

- orientation to the hospital and overview of the healthcare team (key members)
- preventing infection
- blood counts
- follow-up appointments
- fertility optimisation options (if applicable)
- psychosocial issues.

Information for families of children with CNS tumours may include:⁷²

- raised intracranial pressure/hydrocephalus
- seizures
- shunt malfunctions (if applicable)
- vomiting
- steroid side effects
- post-operative wound care
- headaches
- radiotherapy (if applicable)
- physical limitations
- rehabilitation
- cognitive limitations
- bleeding precautions
- nutrition.

- Ⓛ Verbal education to families is paced throughout the initial admission, and time is allowed to process the diagnosis. Education should not be left to the moment of discharge, and families should be aware that education is ongoing and accessible throughout treatment.

- Ⓛ Written and/or audio-visual educational information is provided as part of the discharge plan following diagnosis and should also include information targeted to children and adolescents.

Consideration must be made and strategies put in place for communicating with families with cultural and linguistic diversity, including providing access to interpreter services and translated educational materials.

Age and developmentally appropriate information should be available for children and adolescents.

A discussion about contraception should be considered for all adolescent patients.

Advice at home

The paediatric cancer service should provide a standardised service allowing timely and consistent remote support monitoring via the telephone for patients and their families when at home.

Step 4: Treatment

Step 4 outlines a framework for delivering treatment for CNS tumours in children and adolescents.

Effective strategies to improve overall survival and reduce late effects are identified through international collaborative clinical trials.

4.1 Treatment intent

For most children and adolescents with CNS tumours, the goal of care and treatment intent at diagnosis is cure, or control of disease with preservation of function. Currently, for some patients with certain tumour types there is no effective treatment. Similarly, for patients who experience a recurrence of the CNS tumour, effective treatment options are often limited. Management strategies for patients with such tumour types and those who develop refractory or relapsed disease are discussed in Step 6.

4.2 The role of clinical trials and research in CNS tumours

The landscape in the management of CNS tumour biology and treatment is undergoing a rapid transition as new molecular pathways and genetic changes are discovered.¹²⁴ Clinical trials will require comprehensive molecular classification of these new pathways at diagnosis and, given the rarity of subsequent subgroups, trials will need to be multi-institutional and international.¹²⁵ Advances can be accelerated by making well-annotated biological samples linked to patient outcome data available to researchers.¹²⁶

The level five and six paediatric cancer services will encourage the development of and/or participation in multi-institutional collaborative clinical trials for childhood CNS tumours.

Clinical trial enrolment should be offered to all patients where open trials are available. For those who do not meet eligibility criteria, or where a clinical trial is not open, the patient should be treated according to the most recent, evidence-based and completed study protocol.

The level five and six paediatric cancer services should be able to demonstrate effective collaboration with other centres of excellence to meet standards for trials enrolment and access to novel agents.

4.3 Surgery

Neurosurgery is the initial step of the treatment pathway for most patients with CNS tumours. For many patients, gross total resection of the tumour (when it is safe to do so) correlates with improved survival rates.¹¹¹ However, there are real risks that significant permanent neurological impairment may result from excessive focus on this goal. Therefore, a carefully balanced approach is required to achieve the goal of maximising the extent of resection while minimising the risk of permanent neurological or neuropsychological sequelae.

Outcomes have also been shown to improve with the centralisation of neurosurgical procedures,¹²⁷ with the evidence supporting lower mortality/morbidity rates of CNS tumour patients in high-volume, specialised hospitals.^{128,129} The volume of patients seen will also improve institutional experience and memory¹³⁰ in areas such as the intensive care setting, as well as active participation by neurosurgeons in a state-wide paediatric neuro-oncology MDM. The high-volume effect and outcomes in paediatric neuro-oncology has not been demonstrated in all studies.¹³¹ Institutional volume of patients should be considered alongside services that encourage and support speciality paediatric neuro-oncology teams under a state-wide MDM structure. In such settings, the volume of individual surgeons is also an important consideration for providing an effective service.^{132,133}

Neurosurgical interventions for treating CNS tumours should be organised within a paediatric neuro-oncology MDT structure with a limited number of neurosurgeons (with experience and training in paediatric neurosurgery) to ensure volume effect.

Indications

Indications for surgery, including both the need for biopsy and/or resection and emergency interventions, vary considerably according to tumour type and location. The treatment for many tumour types (as well as the rapid understanding of their molecular characteristics) has evolved over time and will likely continue to evolve, meaning neurosurgical interventions for individual patients are best organised within a neuro-oncology MDT structure.⁹⁹ When surgery is recommended, it should be taken under the consideration that all interventions aim to preserve brain function while maximising tumour resection and minimising morbidity.¹³⁴

Recommended timings

- ⌚ For patients with CNS tumours who present with an altered level of consciousness from mass effect, surgical interventions (based on neurosurgical assessment) should be performed urgently (on the same day). Optimally, this will occur within a paediatric neurosurgical setting.
- ⌚ For patients with CNS tumours who are alert but have a demonstrable mass effect on assessment and imaging, surgery should optimally be performed within 24 hours in a paediatric neurosurgical setting.
- ⌚ For patients with smaller lesions without risk of mass effect, therapy should be guided by the state-wide paediatric neuro-oncology MDM, diagnostic and clinical trial requirements, as well as the level of institutional resources available to provide optimal care.

Communication

- ⌚ Discussions should occur between the neurosurgical and oncology teams prior to any planned neurosurgery.
- ⌚ Optimally, all planned neurosurgery should be first discussed at a state-wide paediatric neuro-oncology MDM, where timing allows. This is of greater importance in complex cases or where the surgical technique is not well delineated.

- ⌚ All neurosurgical procedures for oncology patients should be presented at the state-wide paediatric neuro-oncology MDM within two weeks of surgery.

Anaesthesia

Children with CNS tumours pose added risks when providing general anaesthesia. Such patients may have impaired function (metabolic and physical) such as electrolyte disturbances, dehydration, seizures, cranial nerve palsies and hypothalamic/pituitary hormonal deficiencies, and require experienced paediatric anaesthetic services.¹³⁵ Dedicated anaesthetic support is provided across the pre- and post-operative period, including intensive care. For all planned interventions (and ideally in the emergency situation) the anaesthetist should be able to demonstrate training, clinical expertise and professional development in delivering anaesthesia in paediatric neurosurgery and have regular work responsibilities in this field.¹³⁶

Theatre environment and technologies

All planned neurosurgery should be undertaken in an appropriately equipped operating theatre. In addition to a specialised medical and nursing workforce, intraoperative technologies and techniques for consideration include spinal cord monitoring, neuro-endoscopy, EEG monitoring, cavitating ultrasonic aspirator, evoked potential testing, operating microscope and neuronavigational techniques.^{136,137}

In older children and adolescents, the use of intraoperative neurophysiological mapping under local anaesthesia and sedation can provide real-time feedback during surgery to avoid damage to eloquent brain structures.^{49,137,138} Consideration should be undertaken when clinically relevant.¹³⁴

Post-operative care

Health services will be able to demonstrate access to paediatric intensive care services and inpatient step-down wards (with appropriately trained and experienced staff) during the post-operative period. All patients should be cared for post-operatively by nurses experienced in neurology and neurosurgery.

All paediatric neurosurgical interventions will be carried out within a theatre appropriately equipped (with technologies and workforce) for neurosurgery.

Health services should continually examine novel perioperative approaches and technologies in neurosurgery that augment field of vision, maximise tumour resection and reduce morbidity, under the auspices of ethical and clinical governance and a MDM structure.

For non-urgent cases, the decision to utilise different approaches (which may determine the place of care) should be made at the state-wide paediatric neuro-oncology MDM prior to surgery, when clinically appropriate.

Access to paediatric ICU services and inpatient step-down wards (staffed by health professionals experienced in paediatric neurosurgery) should be available for all planned surgical cases.

Peri-operative nursing care should be provided by staff competent and experienced in the care of paediatric neurosurgical patients.

4.4 Radiotherapy

Considerations

Radiotherapy is an essential pillar of curative and palliative treatment for CNS tumours in children and adolescents,⁹⁹ and with more conformal methods of delivery, image guidance and technologies that spare healthy tissue while offering precise targeting, at this point in time it will continue to remain so.⁵ With greater numbers of survivors following treatment for CNS tumours, the long-term side effects of radiotherapy have become an important concern, and the reduction of radiation fields and dosage, where possible, is a study aim in many current clinical trials.¹³⁹

Service capability framework for paediatric radiotherapy

Due to small numbers, patients receiving radiotherapy are treated outside the level five or six paediatric cancer services in specialist radiotherapy centres. It is important that these patients are managed under the guidance outlined in the *Service capability framework: a guide for Victorian health services providing radiation therapy to children and adolescents with cancer*, which describes the minimum service requirements for providing a coordinated, sustainable and consistent model of care for delivering radiotherapy to children and adolescents with cancer.⁵

Where available, radiotherapy should be undertaken within the context of a clinical trial and, where eligible, enrolment should be offered as standard of practice.

Radiotherapy delivered outside the context of clinical trials should be informed by evidence-based guidelines.

The pathway for delivering radiotherapy to children and adolescents with CNS tumours should follow the guidance outlined in the *Service capability framework: a guide for Victorian health services providing radiation therapy to children and adolescents with cancer*.

All patients with a history of receiving CNS radiotherapy should be formally reviewed within a survivorship service that is tailored for neuro-oncology. Data should be collected in survivorship of the treatments offered and emerging early and late effects.

Communication and collaboration

⌚ Access to radiotherapy should be delivered as prescribed within the treatment protocol and/or clinical trial. Delays to treatment should be recorded and the reasons clarified and investigated.

All prospective treatment planning of patients requiring CNS-directed radiotherapy will be undertaken within the context of the state-wide paediatric neuro-oncology MDM and documented in the patient's medical record. A detailed referral will be sent to the radiotherapy service.

Written consent (and if applicable assent) should be sought for all patients prior to undergoing radiotherapy and documented in the patient file.

All patients, and their families, should be provided with a tailored education program regarding radiotherapy, indications, side effects and self-care, prior to any interventions.

⌚ At the completion of the treatment, the radiotherapy service should provide a written summary for the referring level five or six paediatric cancer service that documents all radiation fields, total radiation dose to each field and the age of the first dose of radiotherapy.

Proton therapy

Proton therapy is a treatment option for CNS tumours in children with equivalent efficacy to traditional photon therapy and reduced risk of secondary cancer in some diagnoses¹⁴⁰ while potentially reducing dosage to healthy tissue and organs.¹³⁹ Proton therapy has also been shown to be more cost-effective for some paediatric CNS tumours.¹⁴¹ However at this stage, high-quality research continues to be sought to measure efficacy in the long-term.^{142,143} Currently no superiority has yet been shown in the clinical data by proton therapy over advanced photon therapy in late effects of treatment.¹⁴⁰ At this point in time, access to proton therapy may be considered in patients with defined CNS tumour subgroups and discussed at the state-wide paediatric neuro-oncology MDM (especially when under the auspices of a clinical trial) but should not delay critical time to treatment in place of current advanced photon therapy techniques with comparable efficacy.

4.5 Chemotherapy

Indications for chemotherapy

There is a defined role for chemotherapy in treating many childhood CNS tumours. It is used as an adjunct to radiotherapy and/or surgery, as a means of reducing the morbidity associated with radiotherapy and where surgical resection is difficult.¹⁴⁴

Targeted therapy

The current landscape of molecularly-classified CNS tumours provides for more personalised medicine. Investigating the success of potential novel targets should be undertaken within the context of multi-institutional, collaborative paediatric clinical trials after consideration at a state-wide paediatric neuro-oncology MDM.^{145,146}

Role of stem cell supported chemotherapy in CNS tumours

High-dose chemotherapy with autologous stem cell return may be used in younger children with CNS tumours to avoid or delay the use of radiotherapy.

Administering chemotherapy.

⌚ A central venous access device should be placed prior to receiving intravenous chemotherapy. This is most important in young patients, the delivery of vesicant chemotherapy protocols and those requiring myelosuppressive or stem cell supported regimens.

⌚ Planning and decision making for all patients receiving chemotherapy (including potential targets based on tumour characteristics) should be undertaken and documented within the state-wide paediatric neuro-oncology MDM.

Chemotherapy should be prescribed with the use of validated protocols within an electronic prescribing system.

A documented procedure that is strictly followed for the prescribing, dispensing, administering and documenting of all chemotherapy must be used within the health service.

Printed materials for families of all chemotherapy agents prescribed should be available.

4.6 Rehabilitation

Despite an increase in survivorship, morbidity from CNS tumours in children remains high.¹⁴⁷ Some patients will need targeted, complex rehabilitation over long periods of time to manage the neurological sequelae of both the tumour and its treatment. Although research and outcomes from neuro-rehabilitation is limited within the paediatric oncology context,^{147,148} long-term outcomes in large survivorship studies show a high level of morbidity is experienced in this population, and warrants early intervention.^{149,150}

Specialist care: neuro-rehabilitation care packages

In line with models of care such as that recommended by the UK National Institute for Health and Care Excellence,⁹ a neuro-rehabilitation care package of support takes into account the impact of disease and treatment of neurological, physical, psychological and academic function.⁹ The MDT should include (but not be limited to):

- speech and language therapy
- physiotherapy
- occupational therapy
- neurology
- clinical and neuro-psychology
- rehabilitative nursing
- teacher/school liaison
- rehabilitative medicine
- social work.

Level five and six paediatric cancer services should ensure that multidisciplinary care packages of support are provided to patients diagnosed with a CNS tumour who require neuro-rehabilitation.

- ⌚ When applicable, referral to a neuro-rehabilitative team should be made via the neuro-oncology MDT and occur at the time of diagnosis. Interventions should occur concurrently with treatment and not be delayed until the child enters surveillance or survivorship.

An interventional program of neuro-rehabilitation should continue as long as there is a demonstrable effect.

4.7 Place of care

Treatment for CNS tumours is managed at a level five or six paediatric cancer service, in line with the *Service capability framework: a guide for Victorian health services providing primary treatment and shared care to children and adolescents with cancer*.⁴ Consideration for supportive care and some aspects of treatment such as administering low-complexity chemotherapy in paediatric centres closer to the child's home should be made within the neuro-oncology MDT. Shared care centres are required to adhere to the standards outlined in the framework. Episodes of chemotherapy in regional shared care centres should be conducted with the use of telehealth between the local health service and the patient's oncologist.

For regional families, a discussion within the MDT should occur and be documented for potential shared care opportunities within the local scope of practice, including chemotherapy, rehabilitation, supportive care and ongoing imaging (with the use of image sharing software). Regional care should be delivered under the supervision of a consultant paediatrician, who has established links to the level five or six paediatric cancer service via telehealth and access to electronic communication.

For metropolitan families, efforts should be made to support localised and home-based care, when it is safe to do so.

4.8 Adherence and compliance to treatment for CNS tumours

Caring for a child or adolescent with a CNS tumour can be very challenging for the healthcare team and the child's family. These patients require multidisciplinary input to manage their disease, side effects of treatment and ongoing comorbidities. Some treatments are prolonged and involve more than one oral chemotherapy agent to be administered in the home. As well as anti-cancer therapy, many of these patients require other regular medications in the home, which may be prescribed from different healthcare teams. These include medicines for supportive care, antiepileptic drugs and hormone replacement therapy, which can have immediate adverse health effects when not administered correctly. Enrolment on clinical trials for novel targeted therapies also requires strict documentation and monitoring for study compliance. Finally, it is also important to maintain compliance with regular timed appointments for physical examination and medical imaging.

The level five or six paediatric cancer service should have in place a mechanism to measure and record compliance with home-based oral medication administration, including how changes to oral chemotherapy and other medicines are communicated to families in both written and verbal forms.

Health services should be able to deliver strategies to ensure families of patients with chronic and complex needs are able to meet the demands of treatment and supportive care. This is particularly applicable to those patients enrolled on early phase trials, families with cultural and linguistic diversity, regional and remote families, those with low socioeconomic status and those with low-level health literacy.

Health services should be able to provide telephone access for advice both during and after hours.

Patients from regional centres should be assigned a local consultant paediatrician and healthcare team to support shared care locally and maintain compliance support.

Step 5: Care after completing therapy and survivorship

5.1 Coming off treatment and surveillance in CNS tumours

- ⌚ All patients should have a dedicated consultation with their primary oncologist at the end-of-treatment. Where applicable, this consultation should also be timed with their neurosurgeon, clinical nurse consultant and clinical trials coordinator.
- ⌚ At the end-of-treatment consultation, all patients will receive a treatment summary, copies of which should be sent to the patient's GP and, where applicable, the paediatrician. The treatment summary should include:
 - the site of the tumour within the CNS and histological diagnosis (as well as any molecular classifications and other relevant testing performed, both tumour and germline)
 - the date and type of any neurosurgical procedures (for example, partial or gross resection) including the patient's age at the time of surgery
 - the date of diagnosis
 - the treatment protocol (if applicable)
 - all treatments delivered, including the commencement and completion dates
 - chemotherapy (as applicable) including agents administered and dosages
 - radiotherapy (as applicable) including all radiation fields, total radiation dose to each field and the patient's age at the first dose of radiation
 - significant morbidities or adverse events experienced during treatment
 - contacts at each relevant specialty service where treatment was undertaken.

Surveillance management in CNS tumours

Determinants for managing the timing and period of surveillance for CNS tumours include the tumour biology, growth, location, treatment and traditional patterns of recurrence. Surveillance following treatment for a CNS tumour includes a complete physical examination and history, neurological examination, visual acuity and imaging. Other tests and investigations will be tailored to the patient, their prior treatment and tumour type. For patients enrolled on clinical trials, surveillance will be also determined by the requirements of the clinical trial protocol.

Following treatment, surveillance requires more than monitoring for tumour recurrence. Children treated for CNS tumours have a high-risk of long-term effects of treatment. Interventions required in recognising and treating the early and late complications of disease and treatment should be incorporated into the surveillance roadmap and not delayed until entry into a survivorship service. This includes interventions in neuropsychology, psychosocial and educational supports, endocrinology and persisting neurological sequelae.¹¹¹

- ⌚ At the end-of-treatment consultation, all patients should be provided with a tailored surveillance roadmap, including timings for clinical reviews, tests and investigations required following completion of treatment. The roadmap should also be sent to the patient's GP and, if applicable, to the paediatrician. The roadmap will also incorporate timings for interventions that are tailored to the individual, to provide early interventions in managing the late effects of treatment.

Surveillance imaging

Optimal time intervals and the length of surveillance imaging for children and adolescents who have completed treatment for CNS tumours are often varied and sometimes lack consensus, particularly in screening for asymptomatic relapse.^{151,153} Routine imaging also comes with a degree of risk, including the use of general anaesthesia in young patients, the negative psychological impact of testing on the patient and family and the overall costs to the health service.¹⁵⁴

The level five and six paediatric cancer services should develop standardised, state-wide medical imaging surveillance protocols for all CNS tumours (clinical trial demands may override or complement these timings). Considerations should include:

- MRI as the standard imaging technique, avoiding the use of CT
- initiatives that reduce the need for general anaesthesia in young children
- scheduling based on tumour biology, risk stratification, growth and patterns of recurrence
- reducing the burden of travel for imaging for regional and remote families

Continued next page

- consistency of MRI sequences (protocols), particularly across shared care sites
- the use of image-sharing software across sites for comparison reporting
- basing timings and length of surveillance imaging on the available evidence
- being consistent with the ALARA (As Low as Reasonably Achievable) principles of medical imaging.

5.2 Survivorship

Childhood survivors of CNS tumours are at high-risk of late effects and experience poorer health-related quality of life than healthy comparators and other childhood cancer survivors.^{155,156} In particular, the impaired neurocognitive consequences of treatment described,^{157,158} as well as increased risk for neurovascular disease, second cancers and endocrinopathies,¹⁵⁹ demand a more tailored approach.

The survivorship program.

The survivorship program should ideally have a neuro-oncology clinical service that includes representation or access to:

- medical oncology with a subspecialty in childhood cancer survivorship
- school education, with experience in childhood cancer
- paediatric oncology nursing with a subspecialty in childhood cancer survivorship
- paediatric endocrinology
- psychology, with a subspecialty in childhood cancer survivorship
- social work, with experience in childhood cancer
- physio, occupational and speech therapy
- reproductive health.

Where rehabilitative services have been introduced during treatment, their work should continue alongside or within the survivorship service while there is still a demonstrable effect of their interventions on the child and family. Consultation with neurosurgery and radiation oncology should be maintained.

- ⌚ All survivors of childhood CNS tumours should be referred to an appropriate survivorship program within three months of completing treatment to formulate a shared care plan between the acute and survivorship services.
- ⌚ All patients should be given an updated treatment summary and roadmap for late effects surveillance on entering the survivorship program. The roadmap should also be sent to the child's GP and, when applicable, the paediatrician.

Patients and their families should also be provided with educational material about survivorship, including adopting a healthy lifestyle and education bridging programs for school.

5.3 Transition from paediatric to adult care

A general discussion for transition is provided in the 'fundamentals of care' section of this document.

From a CNS tumour perspective, treatment protocols continue to aim to reduce morbidity; however, this cohort still remains at high-risk of late effects and the need for supported transition is magnified for child and adolescent survivors of CNS tumours.¹⁶⁰ Some of this care may exceed the abilities and scope of primary care practice. The patient will often move from a paediatric multidisciplinary neuro-oncology environment to a fragmented adult service.¹⁶¹ Transition of patients with high-risk, chronic health needs may benefit from a joint care model, with the first or initial visits including the paediatric and adult service.¹⁶⁰ Both the adult and paediatric health service will need to develop relationships to be able to collect outcome data on adult survivors of CNS tumours,¹⁵⁶ as well as being a resource for adult services for ongoing support.¹⁶²

Transition of adult survivors of childhood CNS tumours with actual or a high-risk of late effects that require services beyond primary care should be referred to adult speciality facilities. This may include, but not be limited to, adult endocrinology, neurology, vascular, rehabilitative and psychology services.

All CNS tumour survivors with VP shunts in situ should be referred either to their primary neurosurgeon or to an adult neurosurgeon at transition for annual review.

Joint care models to transition from paediatric to adult services require effective two-way communication and information sharing and should be developed as a standard of care.

All correspondence and planning should also be sent to the patient's GP.

Step 6: Managing refractory disease or relapse

The risk of relapse/recurrence and refractory disease in childhood CNS tumours is relative to factors such as the tumour site and pathology, extent of resection, age and previous treatment.¹¹⁰ Some tumours such as diffuse midline gliomas still remain refractory to treatment and have a poor prognosis.¹⁶³ For many malignant tumour types, such as ependymoma¹⁶⁴ and medulloblastoma,¹²⁴ outcomes following relapse are poor. For others, such as pilocytic astrocytoma, disease recurrence may be managed effectively with surgery or chemotherapy.¹²⁵ Disease progression or recurrence is usually at the primary site and can often occur years after diagnosis.¹⁶⁵ Tumours of the CNS are associated with the highest incidence of late mortality in childhood cancer survivors, primarily due to recurrence or progression of disease.¹⁶⁶

6.1 Signs and symptoms

Most signs and symptoms of relapse or disease progression will be noted during routine clinical evaluation or medical imaging; these are diverse and relative to the tumour type and location, as well as the patient's age.

6.2 Multidisciplinary team

- ⌚ There should be an immediate referral to a state-wide paediatric neuro-oncology MDM, as well as a psychosocial referral, for the discussion and management of all children with suspected or confirmed relapse and/or disease progression.

6.3 Treatment

There are few curative management options for most children and adolescents with high-grade tumours who experience recurrence, particularly where gross total resection can't be achieved and/or radiotherapy has already been used as the standard of upfront care. However, due to the rapidly changing molecular landscape, there are more targeted therapies and early-phase clinical trials emerging¹¹⁰ and the level five or six paediatric cancer services should be responding to this by supporting the opening of these trials.

- ⌚ A complete evaluation of the extent of relapse should be undertaken upfront. This is dependent on tumour type and may be limited to imaging but may also include surgery, lumbar puncture and bone marrow biopsy.
- ⌚ Consideration should be made for molecular characterisation of tissue biopsy at the time of relapse where the state-wide paediatric neuro-oncology MDM had identified the potential for actionable targeted therapy.¹¹³ Ideally this will be performed on the relapse sample and within the shortest possible timeframe comparable with best practice international criteria.
- ⌚ The exact nature of the relapse/progression and prospective treatment plan should be shared with the family and, where applicable, the child/adolescent following the state-wide paediatric neuro-oncology MDM. Recommendations from the state-wide neuro-oncology MDM should be communicated with the patient's GP and, where appropriate, their paediatrician or local shared care health service.

As treatment for relapse in high-grade CNS tumours is often about prolonging life rather than cure, the nature and intentions of therapy should be clearly defined to support both the patient and family's decision making. This may still include interventions such as chemotherapy and/or radiotherapy. Participation in active interventions should not preclude involving a palliative care service. As many families will seek alternate opinions at this point in time, it is important that the MDT has carefully considered

options, that these options are discussed with the family, that decisions are made in the best interests of the child and that decisions are communicated to the wider treating team and documented.

6.5 Palliative care

Patients with an uncertain prognosis and/or high symptom burden should be able to access palliative care services alongside any therapies. The principles of a palliative care approach need to be documented and shared with the team. The decision should be made in collaboration with the child or adolescent, and their family.

- Ⓛ A palliative care service referral should be undertaken and documented for all patients when there is no longer a curative regimen available, either at the time of diagnosis or at the time of relapse or disease progression.

Consideration for a referral to palliative care service should be made for all other patients at the time of relapse or disease progression.

- Ⓛ Discussions and documentation of advance care planning should begin during this period and be guided by evidence-based policy, guidance and frameworks such as the Victorian Government's *Thinking ahead framework: planning care for children with life-limiting conditions*.¹⁶⁷⁻¹⁶⁹

The advance care plan should be tailored to the patient's disease and location of the tumour to guide the potential side effect profile and management strategies. This should also be accompanied by tailored, anticipatory guidance for the family.

More information around palliative care can be found in the 'fundamentals of care' section.

Step 7: End-of-life care

Step 7 is concerned with maintaining the child or adolescent's quality of life and addressing their health and supportive care needs, as well as the needs of the family, at the end-of-life.

7.1 Symptoms at the end-of-life and advance care planning

The end-of-life period for children and adolescents with CNS tumours can often be associated with a high symptom

burden¹⁷⁰ and can still be a period of active medical care.¹⁷¹ Symptoms are often relative to the location of the tumour and can include paralysis, cognitive deterioration, behavioural changes, dysphagia, dysarthria and dysphasia.^{170,171} These neurological deficits can rapidly intensify at the end-of-life. From a psychosocial viewpoint, the loss or deterioration in communication has been described as a significant turning point for families of children with CNS malignancies.¹⁷²

Elements of end-of-life care should be in line with the Australian Commission on Safety and Quality in Health Care document *National Consensus Statement: essential elements for safe and high-quality paediatric end-of-life care*.⁵¹

- Ⓛ An advance care plan specific to end-of-life care should be documented early in this stage.

There should be 24-hour on-call support, directed by the palliative care team, for families who choose for their child to die at home.

More information around end-of-life care can be found in the 'fundamentals of care' section.

7.2 Cancer research at the end-of-life

At the end-of-life, many resistant tumours, such as diffuse midline gliomas, that have led to death may not have been biopsied.¹¹¹ Autopsy samples allow the researcher to obtain important information from some of the most aggressive types of tumours, from multiple sites and in larger samples^{111,173} Families who have consented to autopsy of their child in the context of CNS tumour research have been shown to achieve a positive feeling of altruism, and do not regret their decision.^{173,174}

The level five and six cancer services should consider collecting autopsy samples of rare and resistant CNS tumours for research that are guided by evidence-based ethical and clinical governance. Timing of discussions for consent should occur well before the child's death, with clear and concise information shared with the parent/caregiver about the autopsy process and use of tissue.

Ongoing commitment to continuous improvement in the treatment of CNS tumours

Other key strategies for health services to consider include:

- continued collaboration with research institutions in discovering key pathways and genetic changes of CNS tumour initiation and maintenance
- improving risk stratification through establishing biologically-defined subgroups
- reducing the incidence of long-term toxicities of treatment
- improving the discovery and development of molecularly-targeted therapies and novel routes of administration
- encouraging multisite collaborative research and discussion of patients, particularly in managing rare subgroups
- emphasising the importance of supportive and rehabilitative care throughout treatment and into survivorship
- incorporating data from standardised neuropsychology assessments into a collaborative national dataset to assist research into evaluation and interventions¹²²
- supporting active surveillance and recording of metastatic and non-malignant brain tumours in children and adolescents in cancer registries to inform the planning of healthcare services and resource allocation for this patient population⁹⁵
- examining the use of intraoperative MRI, which may be of benefit to increase the extent of tumour resection^{137,175,176} (however, at this point in time, the quality of the evidence remains low and further research is required)^{177,178}
- other technologies or techniques that augment the field of vision, improve resection or facilitate delivery of therapy, such as robot-assisted surgery, laser surgery and convection-enhanced delivery of chemotherapy¹³⁷
- being able to gain a greater understanding of the tumour 'in vivo' through exploring new technologies and techniques in medical imaging.⁹⁹ The use of molecular imaging is likely to play a greater role in the era of precision medicine and targeted therapies and should be encouraged as a standard of care into the future when clinically applicable.¹⁷⁹

SECTION 4:

PAEDIATRIC ONCOLOGY CARE PATHWAY – SOLID TUMOURS

This oncology care pathway outlines seven critical steps for children diagnosed with solid tumours. While these steps are portrayed in a linear time model, in practice, patient care is rarely straightforward and predictable. The critical steps will require realignment and adjustment to best meet the needs of patients and their families as well as care providers, without undermining the effectiveness of the treatment and supportive care program. The pathway describes the optimal cancer care that should be provided at each step.

This pathway outlines the oncology care pathway common for all solid tumours in childhood. Disease-specific summaries are provided at the end of this section, presented according to the same linear time model.

The key principles and fundamentals of paediatric oncology practice outlined in the 'fundamentals of care' section (section 1) underpin the oncology care pathway for solid tumours.

- Wilms tumour
- retinoblastoma
- extracranial germ cell tumour
- Langerhans cell histiocytosis.

A section that summarises principles in managing exceptionally rare tumours is included at the end of this pathway.

Within this document, use of the term solid tumours will signify extracranial tumours only. Central nervous system (CNS) tumours have been discussed in section 3.

Scope

This oncology care pathway is intended as a resource in managing children and adolescents diagnosed with solid tumours. Disease-specific pathways are summarised at the end of this section. Due to the number and heterogeneity of solid tumours in this age group, summaries have been provided for malignant tumour types that make up at least two per cent of the solid tumour incidence, according to Australian childhood cancer statistics.¹⁸⁰ Tumour types include:

- osteosarcoma
- Ewing's sarcoma
- rhabdomyosarcoma
- non-Hodgkin's lymphoma
- Hodgkin's lymphoma
- neuroblastoma
- hepatoblastoma

Critical time points

As mentioned at the beginning of this document the blue clock symbol  is used to highlight a critical time point that has a specific timeframe attached to it.

A red clock symbol  indicates the time point is part of an **urgent pathway**.

Reporting of solid tumours seen in children and adolescents

Ideally, all new diagnoses of solid tumours should be classified according to the most recent international coding tool for paediatric cancers to allow meaningful, population-based comparison.¹⁸¹


Although population-based cancer registries provide incidence of solid tumours, information on staging from a paediatric perspective is often lacking.¹⁸² Providing data on

staging of cancer offers the opportunity to better inform quality interventions around diagnosis and survival.¹⁸² Health services and cancer registries should consider adopting guidelines specific to paediatric oncology for reporting staging, such as the *Toronto childhood cancer stage guidelines*.^{182,183}

Classification and current clinical staging for individual diseases is provided in the respective disease-specific summaries at the end of this section.

Distribution of solid tumours seen in children and adolescents

Figure 7: Malignant solid tumours 2013–2017, Victorian hospital patients aged 0–17 years, n = 665 (Victorian Admitted Episodes Dataset, provided by the Department of Health and Human Services, 2018)



Step 1: Prevention and early detection

Step 1 outlines recommendations common to all solid tumours for prevention and early detection.

1.1 Prevention

At this point in time, there are no effective interventions available to prevent the development of the majority of solid tumours in the general paediatric population.

1.2 Risk factors

Risk factors specific to each disease are listed in the corresponding section at the end of this document.

Genetic predisposition and host factors

Germline mutations in cancer predisposing genes have been identified in up to 8.5 per cent of all children and adolescents with cancer.¹⁸⁴ There is a higher incidence of inherited genetic predisposition to solid tumours than other cancer types in childhood. However, the majority of solid tumours in the paediatric age group are sporadic and the genetic basis is confined to somatic mutations.¹⁸⁵ Inherited genetic alterations are discussed within their corresponding disease-specific summary at the end of this section. The 'fundamentals of care' section provides more discussion about and recommendations for the genetic predisposition to cancer.

Environmental factors

A history of exposure to ionising radiation (generally for a previous cancer diagnosis) has been associated with developing some types of solid tumours in children.¹⁸⁶ At this point in time, there are no other clear causal links in the development of solid tumours in children from external environmental sources.¹⁸⁷ High-quality, high-volume studies with accurate exposure assessments are necessary to identify risk from environmental sources. This type of study is particularly difficult with the small number of patients who develop solid tumours and is not currently a feasible option.¹⁸⁷

1.3 Screening and early detection

Recommendations for screening and early detection in solid tumours with associated genetic predisposition or risk groups are outlined at the end of this section.

Step 2: Presentation, initial investigations and referral

Step 2 outlines the process for establishing a provisional diagnosis and appropriate referral for a child or adolescent suspected of having a solid tumour.

2.1 Presenting signs and symptoms

The incidence of solid tumours in children is low, with about 350 diagnoses in Australian children under 15 years of age each year.¹⁸⁸ This represents a major diagnostic challenge for GPs and paediatricians. This is compounded by the heterogeneity of solid tumours in children, where presenting signs and symptoms are often tumour and site specific, and require a tailored program of investigations.

Common signs and symptoms at diagnosis across each disease type are presented in the summaries at the end of this section.

2.2 Referral

The GP or paediatrician should have a clear pathway for rapid referral and transfer to a level five or six paediatric cancer service where there is a concern of a possible solid tumour.

Telephone consultation with a level five or six paediatric cancer service should also be encouraged when planning tests and investigations to confirm or exclude the differential diagnosis of a childhood cancer. It may also be preferable to defer complex imaging involving ionising radiation and/or general anaesthesia until after discussion, to ensure optimal information is obtained.

Step 3: Diagnostics, staging and treatment planning

Step 3 outlines the processes common to children and adolescents with solid tumours for confirming the diagnosis and the planning of subsequent treatment. The overarching principles of care require close and sustained interaction between appropriate multidisciplinary team (MDT) members who are responsible for determining the treatment plan.

Diagnostic work-up, staging and treatment planning of children and adolescents with solid tumours should be undertaken within a level five or six paediatric cancer service.

3.1 Diagnostic work-up and staging of solid tumours

The specific diagnosis and pre-treatment investigations for each solid tumour type are discussed at the end of this section.

Diagnostic tests and investigations should be guided by evidence-based guidelines or as mandated by the relevant clinical trial. Imaging should be reported by a radiologist with experience and expertise in paediatric solid tumours and who participates in the state-wide paediatric solid tumour multidisciplinary team meeting (MDM). Biopsy samples should be interpreted by a pathologist with experience in solid tumours who also participates in the MDM. Ideally, if applicable, consent should also be sought for tumour biobanking for research.

Patients with a confirmed diagnosis should be documented according to ICD-O topography and histopathology coding, as well as the most recent World Health Organization (WHO) classification of tumours of soft tissue and bone, according to morphological, immunohistochemical and genetic features.¹⁸⁹

Stage of disease for most patients plays a crucial role in treatment planning and follow-up. Level five and six paediatric cancer services should adopt guidelines for staging for all solid tumours when reporting new diagnoses to cancer registries.¹⁸³

3.2 The multidisciplinary team and treatment planning

The state-wide paediatric solid tumour MDM

The discussion of paediatric patients with newly diagnosed solid tumours within a dedicated MDM has been shown to add substantially to the quality and accuracy of diagnostic information. It can result in alterations in data interpretation in up to one-third of cases in some diseases and to changes in recommendations to clinical management in two-thirds of those patients.¹⁹⁰ Solid tumours in children are rare and therefore treatment plans discussed, developed and agreed in MDMs are crucial. A state-wide MDM allows the entire paediatric oncology community to have access to and

benefit from discussions in an MDM that is convened to share knowledge and expertise.

Optimal treatment planning includes presentation of *all* solid tumour patients at a state-wide paediatric solid tumour MDM.

It is a requirement that the MDM includes staff who are able to demonstrate current experience and expertise in managing childhood solid tumours including:

- paediatric oncologist*
- pathologist*
- nurse consultant*
- radiologist*
- radiation oncologist*
- paediatric surgeon*
- other surgical specialties according to the type of intervention (see below)
- clinical trials coordinator
- oncology pharmacist
- social worker
- palliative care clinician.

* Core members of the MDT who will be represented in person or remotely at the time of the meeting.

Surgery is commonly a major component of therapy in children and adolescents with solid tumours. Attendance of additional subspecialty surgeons (with experience in paediatric malignancies) will be defined according to disease type and the site of the tumour and may include:

- orthopaedic surgeons (for example, bone sarcomas)
- ophthalmologist (for example, retinoblastoma (RB) or orbital rhabdomyosarcoma)
- urology and gynaecology surgeons (for example, renal or germ cell tumours (GCT), rhabdomyosarcoma)
- neurosurgeon (for example, paraspinal neuroblastoma).

Other subspecialties in surgery may also be required in caring for children with solid tumours, depending on the surgical intervention needed. This may include otolaryngology, plastic surgery, maxillofacial, cardiothoracic and solid organ transplantation.

Core members from the treating institution(s) are expected to attend the state-wide paediatric solid tumour MDM, which supports optimal treatment planning and provides significant educational opportunities for all participants.

Administrative support should be available to ensure efficient documentation and dissemination of meeting recommendations.

- Ⓛ Ideally, all patients should be discussed at a state-wide paediatric solid tumour MDM *within two weeks of presentation*. Diagnosis and staging are based on clinical findings, laboratory investigations and medical imaging results and should be clearly documented in the patient's record in real time.

Communication of the state-wide paediatric solid tumour MDM recommendations

The lead clinician should discuss the outcomes of the state-wide paediatric solid tumour MDM with the patient and family, including the diagnosis, risk assignment, treatment plan and, if appropriate, access to available clinical trials. The plan should be communicated to the original referring source, the GP and, if applicable, the paediatrician. Further planning discussions with the family should be collaborative and incorporate oncology, surgery and radiotherapy disciplines as applicable.

Consultation with external services

The management of children and adolescents with solid tumours may at times benefit from input from other centralised paediatric cancer services for a further opinion. Level five or six paediatric cancer services should demonstrate effective and timely links to, and relationships with, paediatric cancer services nationally, as well as with international centres of excellence, when a further opinion about diagnosis or treatment is required. The health service should encourage this type of effective collaboration when diagnosing and treating rare cancers with the effort and outcome clearly communicated to the families. A definitive diagnosis in some rare cancers may be unavoidably delayed pending the results of investigations or external additional opinions.

Reporting the diagnosis

- Ⓛ All new diagnoses are reported to the state cancer registry. Any changes in the final diagnosis will be updated in the state cancer registry.

3.3 Supportive care considerations

Supportive care needs that are applicable to all children and adolescents with cancer are discussed in the 'fundamentals of care' section. Additional supportive care considerations in the context of children and adolescents with solid tumours are discussed below.

Psychosocial support

- Ⓛ All patients with solid tumours should have a referral made to social work at the time of diagnosis.

Nutritional support

There is evidence that malnutrition is seen more consistently in children with solid tumours than other cancers such as leukaemia,¹⁹¹ particularly in children with tumours such as metastatic neuroblastoma (NB), metastatic Wilms' tumour (WT), osteosarcoma and rhabdomyosarcoma.¹⁹²

- Ⓛ Consideration should be made for all children and adolescents with solid tumours to have a nutritional assessment undertaken at the time of diagnosis to guide future interventions.

Fertility

Treating children and adolescents with solid tumours may involve exposure to one or more high-risk factors for infertility such as radiation, surgery and alkylating agents.¹⁹³

- Ⓛ Fertility discussions should be undertaken in all new solid tumour diagnoses at the time of the MDM to define the risk of infertility and to guide prospective interventions.

Further information regarding fertility can be found in the 'fundamentals of care' section of this document.

3.4 Educating the patient and family

Lack of ready access to information can be a cause of stress and conflict with the healthcare team for families of children with cancer.⁷¹ The family and patient (if appropriate) should be provided with both verbal and written information, as appropriate to the family's health literacy, that should cover the following topics:⁷²

- diagnosis, treatment plan, treatment intent and prognosis
- management of fever and neutropenia (if applicable)
- side effects of treatment

- who/how to call their hospital and/or treating team
- access to clinical trials
- managing medications and compliance at home
- central line care (if applicable)
- caring for the child at home
- supportive care
- orientation to the hospital and overview of the healthcare team (key members)
- preventing infection
- blood counts
- follow-up appointments
- fertility optimisation options (if applicable)
- psychosocial issues.

Information specifically targeted to children with solid tumours immediately following diagnosis may include:⁷²

- post-operative/wound care
- nutrition
- physical limitations
- granulocyte colony stimulating factor (if applicable)
- radiotherapy (if applicable)
- pain management
- rehabilitation (if applicable).

It is important that patients and their families are given the time to process the initial information about the diagnosis before providing education on supportive and essential care.¹⁹⁴

- Ⓛ Verbal education to families is paced throughout the initial admission, and time is allowed to process the diagnosis. Education should not be left to the moment of discharge, and families should be aware that education is ongoing and accessible throughout treatment.
- Ⓛ Written and/or audio-visual educational information is provided as part of the discharge plan following diagnosis and should also include information targeted to children and adolescents.

Consideration must be made and strategies put in place for communicating with families from diverse backgrounds,

including provision of access to interpreter services and translated educational materials.

Age and developmentally appropriate information should be available for children and adolescents.

A discussion about contraception should be considered for all adolescent patients.

Advice at home

The paediatric cancer service should be able to demonstrate a process for providing timely and consistent remote symptom monitoring via the telephone for patients with solid tumours, and their families.

Step 4: Treatment

Step 4 outlines a framework for delivering treatment common to all solid tumours.

4.1 Treatment intent

The goal of care and treatment intent for nearly all patients is cure. For patients who experience relapse, treatment options vary according to the type of disease.

4.2 The role of clinical trials and research in solid tumours

Active participation in international collaborative study groups is vital to promote rapid completion of trials with efficient patient accrual in rare disease subtypes such as childhood solid tumours.¹⁹⁶ As event-free survival rates improve, trials will require increasing numbers of enrolments to demonstrate the effectiveness of interventions.¹⁹⁶ Clinical trials also provide the opportunity to collect well-annotated, ethically obtained and high-quality cancer biospecimens needed to facilitate research into rare tumours.^{197,198}

The level five and six paediatric cancer services should engage in collaborative therapeutic clinical trials in the treatment of childhood solid tumours.

Clinical trial enrolment should be offered to all patients where open trials are available. For those who do not meet eligibility criteria, or where a clinical trial is not open, the patient should follow the most recently completed and published 'standard of care' treatment protocol offering the best possible outcome.

Discussions of biobanking malignant tissue samples should be undertaken at diagnosis to support the development of datasets for research.

The level five and six paediatric cancer services should be able to demonstrate effective collaboration with other centres of excellence to be able to develop standards and participation in clinical trials in solid tumours.

4.3 Surgery

Surgery is a major component of therapy for nearly all childhood solid tumours.¹⁹⁹ It is critical that paediatric surgeons (with expertise and current experience in paediatric cancer) are core members of the MDT and prioritise their attendance at the state-wide MDM.¹⁹⁹ The design and implementation of new surgical techniques and practices continue to evolve alongside the molecular advances in paediatric cancer care.²⁰⁰ It is essential that these technical advances and practices meet the demands of new protocols and trials, and are implemented under clinical and ethical governance.

Indications

Surgical interventions depend on the type and presentation of disease and are discussed in more detail at the end of this section. Indications for surgery include to manage oncological emergencies, tumour biopsy, upfront resection, staging, delayed resection, palliative care and supportive care measures such as central venous access device placement, nutritional support and fertility optimisation. Due to the increased use and emphasis of biologically defined tools in cancer care, the use of surgery in diagnosis and staging is expected to change over time.

Minimally invasive surgery

Optimal care involves maximising surgical outcomes with the least amount of morbidity. In adult oncology and general surgery, minimally invasive surgery has been shown to reduce pain and length of stay while improving outcomes. Although there is some evidence to support the use of minimally invasive surgery in the paediatric oncology environment,^{201,202} the real benefit remains unclear.^{203,204} Minimally invasive surgery in children with cancer should only be performed by surgeons with appropriate experience and expertise and ideally formulated within the context of a clinical trial.²⁰⁵

Volume effect, MDT and treatment planning

Although there is an association with improved outcomes in childhood cancer when care is delivered in larger volume centres, the evidence at this stage is not conclusive for all tumour types.^{128,206–208} The use of an MDT structure for planning is associated with improved outcomes in oncology care^{117–119} and has been cited as a reason for effective surgical outcomes in lower volume centres.²⁰⁹ It is important that planning for surgery is made within this MDT structure, ideally under the auspices of a clinical trial. Unplanned resections of rare tumours such as sarcomas can result in poor local control and demand for supplemental therapies.^{210–212} Multidisciplinary collaboration in planning surgery may also reduce the number of general anaesthetics required. Centralisation within a MDT promotes volume effect of both the surgeon and the institution and offers an opportunity to discuss host factors (such as genetic predisposition) that may influence surgical procedure choice,²¹³ as well as reducing the incidence of surgical protocol violations²¹⁴ (such as pre-operative checklists with the onsite clinical trials team).

All planned surgical interventions in the diagnosis and treatment of paediatric solid tumours should be organised within the state-wide paediatric solid tumour MDT structure in a level five or six paediatric cancer service.

Recommended timings

For patients presenting with oncological emergencies requiring surgical interventions, these should be performed within 24 hours, based on the surgeon's assessment and after discussion with the oncology team.

For all other patients, surgery should be guided by the diagnostic and clinical trial requirements, as well as the level of institutional resources available to provide optimal care.

Communications

Discussions should occur between the surgical and oncology teams before any planned oncology surgery.

All emergency surgical procedures should be presented for review at the next available state-wide paediatric solid tumour MDM following surgery.

Optimally, all planned surgery should be first discussed within a state-wide paediatric solid tumour MDM, where timing allows. This is of greater importance in complex cases, or where a standard surgical technique or intervention has not been established.

Further considerations

Further considerations in providing optimal surgical oncology care are summarised in the relevant disease-specific sections at the end of this section.

4.4 Radiotherapy

Indications

At this point in time, radiotherapy remains an important treatment modality for many children with solid tumours, including those with rhabdomyosarcoma, Ewing's sarcoma, Wilms tumour and neuroblastoma, as well as some risk-adapted lymphoma protocols. Radiotherapy also has a recognised role in the palliation of symptoms caused by the burden of the disease.

Service capability framework for paediatric radiotherapy

Radiotherapy should be undertaken within the context of a clinical trial if available and, where applicable, enrolment should be offered as standard practice.

Radiotherapy delivered outside the context of clinical trials should be guided by evidence-based guidelines.

Delivering radiotherapy to children and adolescents with solid tumours should follow all recommendations within the framework.

All patients with a history of receiving radiotherapy should be formally reviewed within a survivorship service. In survivorship, data should be collected about the treatments offered and emerging early and late effects.

Radiotherapy should be considered for symptomatic lesions in the palliative care setting.

Due to small numbers, patients requiring radiotherapy are treated at centres outside the level five or six paediatric cancer service. These patients should be managed as per the recommendations outlined in the *Service capability framework: a guide for Victorian health services providing radiation therapy to children and adolescents with cancer* (2015).⁵ The framework describes the minimum service requirements for providing a coordinated, sustainable and consistent model of care for delivering radiotherapy to children and adolescents with cancer.

Proton therapy

Despite the potential of proton therapy to deliver effective treatment with reduced radiation doses to normal tissues, there is no data currently available that supports the long-term efficacy and cost-effectiveness of proton therapy in solid tumours of childhood compared with contemporary photon therapy.^{141,215} The indications for and access to proton therapy should be considered in defined subgroups and discussed at the state-wide paediatric solid tumour MDM. Proton therapy, if available, should be delivered whenever possible within the context of a clinical trial. The timing of radiotherapy is a crucial consideration in management plans. At this point in time, proton therapy is not available in Australia, and decisions regarding its role should not interfere with the recommended timings of

radiotherapy. Current advanced photon therapy techniques offer outcomes of comparable efficacy.

Brachytherapy

The use of brachytherapy should be considered for selected children with solid tumours based on tumour type, stage and location. Brachytherapy can achieve local control with reduced long-term sequelae. This modality has shown efficacy^{216,217} but requires local expertise to deliver. It is not considered standard care for most patients.²¹⁸ At this stage, brachytherapy should be centralised to services experienced in this modality in children.

Communication and collaboration

Radiotherapy should be delivered as prescribed according to timings within the treatment protocol and/or clinical trial. Delays to treatment are sometimes necessary, and the justification for these should be recorded and if necessary investigated within the context of the MDM. Written consent (and, if applicable, assent) should be sought for all patients before undergoing radiotherapy and documented in the patient's medical record.

All patients and their families should be provided with a tailored education program regarding radiotherapy, indications, side effects and self-care before any interventions take place.

At the completion of the treatment, the radiotherapy service should provide a written summary for the referring level five or six paediatric cancer service that documents all radiation fields, total radiation dose to at-risk organs and target volumes, and the patient's age at the first dose of radiation.

4.5 Chemotherapy

Indications for chemotherapy

Combination chemotherapy is part of standard treatment for many childhood solid tumours and has proven effectiveness in settings both before and after surgical interventions.²¹⁹

Targeted therapy

Precision medicine increasingly allows tailoring of cancer care for children with solid tumours. To take maximum advantage of this technology requires the development and use of workflows for molecular analysis of tumours to help identify potential targeted therapies.²²⁰ Level five and six

paediatric cancer services need to promote the assessment and use of targeted therapies through clinical trials, which requires identifying the appropriate subpopulations for enrolment. This is currently most valuable in the context of children with relapsed, progressive or poor-prognostic tumours.

Immunotherapy

The field of immunotherapy provides improved outcomes in selected cancers in both adults and children, and its application to improve survival in patients with solid tumours is increasing.²²¹ The monoclonal antibodies rituximab (lymphoma) and dinutuximab (NB) have become standard therapies.²²² Immunotherapy and other personalised medicine approaches should be actively encouraged and undertaken within the context of collaborative multi-institutional clinical trials.

Role of stem cell supported chemotherapy

High-dose chemotherapy with autologous stem cell return is a component of therapy for certain patients with high-risk and relapsed disease such as metastatic neuroblastoma and relapsed Ewing's sarcoma.

Administering chemotherapy.

A central venous access device should be placed in all patients receiving intravenous chemotherapy.

Planning and decision making for all patients receiving chemotherapy or immunotherapy should be undertaken and documented within the state-wide paediatric solid tumour MDM. This includes a discussion and rationale for using targeted therapy.

Chemotherapy should be prescribed according to validated protocols within an electronic prescribing system.

A documented procedure that is strictly followed for prescribing, dispensing, administering and documenting all chemotherapy must be used within the health service. This should include all new agents, as well as traditional therapies.

Printed materials for families of all chemotherapy agents prescribed should be available.

4.6 Rehabilitation

Physical disability in children treated for solid tumours is not uncommon.²²³ A diagnosis of cancer and subsequent treatment can result in impairments that interfere with mobility, vision, hearing, coordination and cardiac and pulmonary function.²²³ This risk may be present at diagnosis or begin during treatment, and early intervention to restore or maximise function is essential.²²⁴ All children with solid tumours who demonstrate a risk of limitations to physical performance should be referred to rehabilitative services.

When applicable, a referral to rehabilitation should be made and occur before surgery. Interventions should occur concurrently with treatment and not be delayed.

An interventional program of rehabilitation should continue as long as there is a demonstrable effect, including transition of care to adult services.

4.7 Place of care

For regional families, a discussion within the MDT should occur and be documented for potential shared care opportunities within the local scope of practice, including chemotherapy, rehabilitation, supportive care and ongoing imaging (with the use of image-sharing software). Regional care should be delivered under the supervision of a consultant paediatrician who has established and robust links to a level five or six paediatric cancer service via telehealth, and access to electronic communication.

For metropolitan families, efforts should be made to support localised and home-based care when it is safe to do so.

4.8 Adherence and compliance to treatment for solid tumours

Level five and six paediatric cancer services should have in place a mechanism to measure and record compliance with home-based oral medication administration, including how changes to oral chemotherapy and other medicines are communicated to families in both written and verbal forms.

Health services should be able to deliver strategies to ensure families of patients with chronic and complex needs are able to meet the demands of treatment and supportive care. This is particularly applicable to those patients enrolled in early-phase trials, families with cultural and linguistic diversity and those with low socioeconomic status.

Health services should be able to demonstrate telephone access for advice both during and after hours.

Patients from regional centres should be assigned a local consultant paediatrician and healthcare team to support shared care locally, to maintain adherence to treatment and continuity of care.

Step 5: Care after completing therapy and survivorship

5.1 Coming off treatment and surveillance

Ⓛ All patients should have a dedicated consultation with their primary oncologist at the end of treatment. Where applicable, this consultation should also be timed with their respective surgeon, rehabilitation team, clinical nurse coordinator and clinical trials coordinator.

Ⓛ At the end-of-treatment consultation, all patients/families should receive a treatment summary. Copies should be sent to the child's GP and, where applicable, the paediatrician.

The treatment summary should include:

- the type and site of the tumour, histology, staging and risk stratification

- date and type of any surgery, including the child's age at the time of surgery
- the date of diagnosis
- the treatment protocol (if applicable)
- all treatments delivered, including the start and end dates
- chemotherapy (as applicable) including the agents administered and cumulative dosages
- radiotherapy (as applicable) including all radiation fields, total radiation dose to at-risk organs and target volumes, as well as the child's age at the first dose of radiation
- significant morbidities or adverse events experienced during treatment
- fertility optimisation measures (if applicable)
- contacts at each relevant specialty service where treatment was undertaken.

Surveillance management in solid tumours

Ⓛ At the end-of-treatment consultation, all patients should be provided with a tailored surveillance roadmap that includes timings for clinical reviews, tests and investigations required after treatment. The roadmap should also be sent to the child's GP and, if applicable, to the paediatrician so that managing the late effects of treatment can be addressed early.

Surveillance imaging

Where applicable, the level five or six paediatric cancer service should follow standardised, state-wide medical imaging surveillance protocols for solid tumours (clinical trial demands may override or complement these timings). Considerations should include:

- initiatives that reduce the need for general anaesthesia in young children
- scheduling based on tumour biology, risk stratification, growth and patterns of recurrence
- reducing the burden of travel for imaging for regional and remote families
- consistency of imaging sequences (protocols), particularly across shared care sites
- the use of image-sharing software across sites for comparison reporting
- basing timings and the length of surveillance imaging on the available evidence

- consistency with the ALARA (as low as reasonably achievable) principles of medical imaging.

Other tests and investigations in surveillance due to the late effects of therapy (generally determined by the clinical trial protocol) should also be followed.

5.2 Survivorship

Long-term survivors of solid tumour malignancies are at risk of the late effects of treatment. Combination chemotherapy with medications such as anthracyclines/alkylating agents, radiotherapy (particularly in the young) and surgery, such as amputation, limb-sparing procedures, nephrectomy and enucleation, contribute to a high-risk of late complications and impairment to quality of life.²²⁵

The survivorship program

All childhood survivors of solid tumours should be referred to a survivorship program where interventions are risk-adapted according to their disease, treatment and patient-specific factors.

Where rehabilitative services have been introduced during treatment, rehabilitation should continue alongside or within the survivorship service while there is still a demonstrable effect of their interventions on the child and family. Consultation with other disciplines such as surgery and radiation oncology should be maintained as required.

- Ⓛ All patients should be referred to a survivorship program within three years of completing treatment.
- Ⓛ All patients should be given an updated treatment summary and roadmap for late effects surveillance on entering the survivorship program. The roadmap should also be sent to the child's GP and, if applicable, to the paediatrician.

Patients and their families should also be provided with educational material about survivorship including adopting a healthy lifestyle and education bridging programs for school.

5.3 Transition

A general discussion for transition is provided in the 'fundamentals of care' section of this document.

Step 6: Managing refractory disease or relapse

6.1 Signs and symptoms

Common signs and symptoms at the time of relapse are addressed for each disease at the end of this section.

6.2 Multidisciplinary team

Ⓛ There should be prompt referral to the state-wide paediatric solid tumour MDM, as well as psychosocial referral, to discuss and manage all children with suspected or confirmed relapse or disease progression.

6.3 Treatment

Treatments (and outcomes) for relapsed disease vary across disease groups and are presented at the end of this section.

6.4 Palliative care

Patients with an uncertain prognosis or a high symptom burden should have access to palliative care support alongside any therapies. The principles of a palliative care approach need to be documented and shared with the team. The decision should be made in collaboration with the child or adolescent and their family.

- Ⓛ A palliative care referral should be made and documented for all patients when there is no longer a curative regimen available, either at the time of diagnosis or at the time of relapse or disease progression.
- Ⓛ Consideration for a referral to palliative care should be made for all other patients at the time of relapse or disease progression, or for those with a high symptom burden.

6.5 Research in refractory disease or relapse

Relapse or refractory disease is associated with a poor prognosis in many children with solid tumours. Further research in developing new approaches or therapies is required in these small groups. Due to their rarity there are few opportunities to evaluate experimental agents in childhood cancer.²²⁶ Processes that govern enrolment into collaborative early-phase trials in refractory or relapsed solid tumours should be well delineated within the level five or six paediatric cancer service. A discussion regarding

enrolment should occur within the context of the state-wide paediatric solid tumour MDM.

Step 7: End-of-life care

Step 7 is concerned with maintaining the child or adolescent's quality of life and addressing their health and supportive care needs, as well as the needs of their family, at the end of life.

7.1 Symptoms at the end of life and advance care planning

Children and adolescents with solid tumours at the end of life may exhibit a significant symptom burden but can benefit from interventions directed from a palliative care service.²²⁷

Elements of end-of-life care should be in line with the Australian Commission on Safety and Quality in Health Care document *National consensus statement: essential elements for safe and high-quality paediatric end-of-life care*.⁵¹

 An advance care plan specific to end-of-life care should be documented early in this stage.

End-of-life care should be tailored to the patient's disease and to the location of the tumour to guide the potential side-effect profile and management strategies. This should also be accompanied by tailored, anticipatory guidance for the family. There should be 24-hour on-call telephone support, directed by the palliative care team, for families who choose for their child to die at home.

More information about palliative and end-of-life care can be found in the 'fundamentals of care' section.

Disease-specific considerations: sarcomas

Sarcomas are a heterogeneous group of cancers that account for approximately 15 per cent of all solid tumours diagnosed in Victorian children and adolescents. They are generally divided into soft tissue and bone tumours. Soft tissue sarcomas are further divided into rhabdomyosarcoma (RMS), which mainly affects young children, and non-rhabdomyosarcomas, a diverse range of tumours more common in adolescents, though may also present in infants.²²⁸ The most common bone sarcomas are osteosarcoma and Ewing's sarcoma. Treatment for sarcomas in children and adolescents is generally staged and multimodal, though some low-risk patients may have surgery alone.²²⁸ The three most common sarcomas seen in children and adolescents are described below.

Bone sarcomas

Step 1: Prevention and early detection

Exposure to ionising radiation and inherited mutations of the TP53 or RB1 genes are known risk factors in osteosarcoma.^{229,230} Currently, apart from ionising radiation, there are no other known environmental causes of this disease. Germline mutations in children and adolescents with osteosarcoma do occur, and it is one of the more closely related tumours to hereditary cancer predisposition mutations in childhood.²³¹

Currently, there are no known causes of Ewing's sarcoma. In very rare situations it may appear as a secondary malignancy, predominantly from therapy for a primary haematological cancer²³² or carcinoma²³³

 Patients with a new diagnosis of osteosarcoma should be considered for referral to genetics. A family history of childhood, adolescent or young adult cancer should trigger a mandatory referral.

Step 2: Presentation, initial investigations and referral

Signs and symptoms in bone sarcomas are often non-specific.²³⁴ The most common presenting symptom in bone

sarcomas is intermittent localised pain that generally increases over time,¹⁸⁶ particularly occurring at night.^{229,235} There may also be presence of a palpable mass and localised swelling, but it is not consistent in all presentations.^{236,237} Fever, weight loss and fatigue may also be present and is more common in Ewing's sarcoma.²³⁸ Delays in diagnoses are not uncommon but do not appear to have a strong association with risk of metastasis or poorer outcome.²³⁷

A two-plane x-ray of the affected site will help guide decision making at presentation.²²⁹ Abnormalities on initial imaging such as bone destruction, new bone formation and periosteal or soft tissue swelling should be discussed with the paediatric tertiary orthopaedic service for consideration of referral.²²⁹ A normal x-ray does not rule out a bone sarcoma; further investigations should continue in the context of persistent pain.²²⁹ Once the possibility of a malignant bone tumour is raised, discussion with a paediatric tertiary referral centre is essential. Referral before further investigations, particularly biopsy, is essential; further pre-referral investigations can significantly increase the diagnostic interval²³⁹ and compromise future treatment.²²⁹

 Patients with abnormalities on plain film imaging suggestive of bone sarcomas should aim to be discussed with the orthopaedic service of a paediatric tertiary referral centre within 48 hours.

Step 3: Diagnosis, staging and treatment planning

Diagnosis is made via an intervention-guided core needle biopsy following the completion of all other medical imaging. MRI of the whole affected bone is required to delineate the disease process, define the extent of involvement and help plan the surgical biopsy so as not to compromise the surgical resection and reconstruction. Surgical biopsy should be performed by a practitioner who is experienced in the diagnosis and surgical management of bone sarcomas and who participates in the state-wide paediatric solid tumour MDM.¹⁸⁶ Biopsy should be performed by, or in consultation with, the surgical team that will perform the primary tumour resection.²²⁹ Histopathological examination should be by a pathologist with experience in bone sarcomas and who participates in the MDM.²²⁹ In Ewing's sarcoma, bone marrow biopsy should be undertaken due to the risk of marrow metastases²²⁹ however, future screening by fluorodeoxyglucose (FDG)

PET-CT may be able to replace this investigation.^{240,241} At this point in time, optimal medical imaging interventions for evaluating metastatic disease include chest CT and whole-body functional CT.^{186,230} MDM discussion has been shown to improve outcomes in this cohort, particularly in those patients with metastatic disease.²⁴²

Step 4: Treatment

Treatment is multimodal and, as such, should be developed and ratified within the state-wide paediatric solid tumour MDM.

Surgery

Decisions about managing local control in bone sarcomas are complex, influenced by multiple factors and should be discussed at a state-wide paediatric solid tumour MDM. Failure to deliver appropriate local therapy may significantly influence outcomes.²⁴³ Patients should undergo resection by a surgeon who is a core member of the MDM and who has tumour site-specific skills and experience. Discussion of the optimal surgical procedure, tailored to the needs of the patient, include an open discussion of the risks and benefits of available options and expected functional outcomes, and will be undertaken at the MDM and documented. Planning for post-operative care, such as prosthetics and referral to rehabilitation, should be documented and begin at the time of the MDM. Following surgery, all patients should be prescribed and participate in a musculoskeletal health program, with weight-bearing and activity status clearly communicated.

 Referral to rehabilitation and prosthetics (if indicated) should be made once the prospective treatment plan is decided within the MDM.

Radiotherapy

Radiotherapy is not indicated in most cases of osteosarcoma due to the higher therapeutic doses required and subsequent unacceptable side-effect profile.¹⁸⁶ However, it does have a role for local control (including consideration of particle therapy) in cases where complete resection is not achievable, in selected patients for whole lung irradiation after resection of metastases and in palliation.^{229,244,245} The use of SABR (stereotactic ablative body radiotherapy) may be considered for oligometastatic disease,²⁴⁶ in particular, lung lesions where surgery may result in an unacceptable risk of morbidity.²⁴⁷

Conversely, because Ewing's sarcoma is a radiosensitive tumour, radiotherapy has a role to play in managing some

patients. Indications for using radiotherapy may include cases where local control via surgical resection is associated with an unacceptable level of morbidity or risk due to anatomical location, the presence of positive surgical margins, poor histological response to treatment or symptom control in palliation.²²⁹

All decisions about radiotherapy will be discussed and ratified via the state-wide paediatric solid tumour MDM.

Chemotherapy

Systemic chemotherapy is standard treatment for bone sarcomas, both neoadjuvant and adjuvant cycles,²²⁹ preferably under the auspices of a clinical trial. Due to toxicities of therapy, fertility optimisation strategies should be discussed before beginning treatment.

Adjuvant chemotherapy should be resumed as soon as possible; delays to starting adjuvant chemotherapy, particularly in non-metastatic osteosarcoma, have been associated with poorer outcomes.²⁴⁸ Consideration of high-dose, stem cell supported therapy may be an option for those with metastatic Ewing's sarcoma.

- Ⓛ Adjuvant chemotherapy in the treatment of bone sarcomas should not be delayed.

Metastatic disease management

Although some patients may present with distant bony metastases, the most common site of metastases is pulmonary. Open thoracotomy is currently recommended for most patients for resection of pulmonary metastases in curative treatment plans.²²⁹

Response to therapy

Response to neoadjuvant chemotherapy is currently one of the most sensitive prognostic indicators in bone sarcomas.²⁴⁹⁻²⁵¹ Patients should therefore be discussed at the state-wide paediatric solid tumour MDM for initial treatment response assessment.

- Ⓛ All patients with bone sarcomas should be discussed at a state-wide paediatric solid tumour MDM following primary surgical resection.

Step 5: Care after completing therapy and survivorship

Surveillance should include regular, timed physical exams and imaging of the chest and surgical site as performed during the initial work-up.²³⁸ Timings should be defined by

the clinical trial and be standardised for all patients within the level five or six paediatric cancer service.

Overall prolonged post-recurrence survival has been observed in patients with Ewing's sarcoma who undergo strict follow-up imaging compared with those identified by clinical symptomatic relapse.²⁵² Studies show that the risk for late mortality and secondary cancers in Ewing's sarcoma does not plateau with extended follow-up, while treatment-related conditions can develop years after therapy, highlighting the need for ongoing follow-up.²⁵³

Survivors of childhood osteosarcoma are at a greater risk than the general population of secondary cancers,²⁵⁴ as well as experiencing higher risk of chronic medical conditions and adverse health status,²⁵⁵ and also warrant lifelong follow-up with clinical review with their GP after leaving the paediatric service.

Step 6: Managing refractory disease or relapse

At this point in time, survival for patients with relapsed or refractory bone sarcomas is poor.²⁵⁶ There is currently no standardised second-line chemotherapy regimen.

Primary curative treatment for disease recurrence in osteosarcoma, whenever possible, is complete surgical resection.²²⁹

In Ewing's sarcoma, most patients will generally receive some form of salvage treatment.²⁵⁷ At this point in time, survival advantage using intensive regimens such as high-dose chemotherapy and stem cell transplant for patients with relapsed Ewing's sarcoma are used, but their long-term effectiveness remains inconclusive.^{257,258}

All treatment planning in this context (including for radiotherapy) should occur after presentation within a state-wide paediatric solid tumour MDM. Due to poorer outcomes, all patients in this context should have a referral to palliative care initiated. Radiotherapy should be considered for symptomatic lesions.

Rhabdomyosarcoma

Step 1: Prevention and early detection

Currently, there are no formal screening measures for the early detection of RMS, and most cases are sporadic,

although it has been associated with a number of genetic syndromes including Li-Fraumeni syndrome, neurofibromatosis type-1, Beckwith-Wiedemann syndrome and hereditary RB.^{259,260}

- Ⓛ Patients with a new diagnosis of RMS should be considered for referral to genetics. Greater emphasis to refer should be considered for those patients of younger age at the time of diagnosis and those whose tumours have anaplastic features.²⁶¹

Step 2: Presentation, initial investigations and referral

Clinically evident signs and symptoms of RMS are produced in two ways at presentation: the appearance of a mass lesion without a history of trauma and/or the disturbance of a normal bodily function due to mass effect.²⁶² RMS can occur anywhere within the body.

- Ⓛ Access to ultrasound should be arranged within 48 hours to assess any unexplained lump or mass, particularly if it is increasing in size.²⁶³
- Ⓛ Discussion with a level five or six paediatric cancer service should occur within 48 hours for any imaging findings suggestive of a malignancy such as RMS or uncertain findings on ultrasound that do not exclude a malignancy while clinical concerns persist.²⁶³

Step 3: Diagnosis, staging and treatment planning

Medical imaging requirements include an initial MRI of the primary tumour. Functional CT is more effective for metastatic disease imaging and staging of RMS compared with other modalities^{264,265} and may eliminate the need for bone scans.²⁶⁶ A biopsy for histology and molecular testing is required for diagnosis.²⁶⁷ Core needle biopsies, when undertaken, should be performed by an interventional radiologist with experience and expertise in paediatric solid tumours. Other testing for staging may include bone marrow biopsy and, if indicated, lymph node sampling and lumbar puncture.

Step 4: Treatment

Treatment is multimodal and incorporates chemotherapy and, in most cases, radiotherapy and/or surgery, all according to location and risk stratification.²⁶⁸ All treatment should be directed under the auspices of a state-wide

paediatric solid tumour MDM, preferably within the context of a clinical trial.

Surgery

Generally, surgical resection should only be attempted when negative margins are anticipated without significant morbidity for the patient.²⁶⁰ Clear communication with radiation oncology, medical oncology, pathology and radiology is essential for pre-operative planning, including reimaging for delayed primary excision.²⁶⁰

Radiotherapy

Radiotherapy has a critical role for local control in many cases of RMS;²⁶⁹ however, significant late effects often result despite advances in radiotherapy technologies.²⁷⁰ In cases where local control is excessively complex or difficult, or close to vital structures, further discussion on the best radiotherapy plan is warranted and may include consideration of proton therapy or brachytherapy,²⁶¹ the latter showing promise in some types of RMS.^{216,217}

Chemotherapy

Currently, due to the use of alkylating agents and radiotherapy in RMS, fertility optimisation strategies should also be discussed and implemented before beginning treatment.²⁵⁹

Response to therapy

Clinical and radiological (ideally functional imaging^{265,266}) response to treatment should be measured using the same procedures at diagnosis, at time points that are ideally defined by a clinical trial. Early response assessment in RMS (in terms of total reduction in tumour size after initial therapy) is not currently of prognostic significance,²⁷¹ and changes in the treatment plan in the early response assessment should be limited to those with progressive disease.

Step 5: Care after completing therapy and survivorship

Surveillance should include regular, timed physical exams and imaging of the chest and primary site. Enhanced imaging techniques at the end of treatment may be considered in high-risk patients.²⁶¹ Timings should be defined by the clinical trial and be standardised for all RMS patients.

Complications of treatment for RMS are related to the site of the tumour and the residual effects of surgery, radiotherapy

and chemotherapy,²⁶² some of which can persist and affect quality of life, particularly in areas such as the head, neck,²⁷⁰ bladder and prostate.²⁶² There is an increased risk of secondary malignancies, partly due to therapy, and for some patients an underlying genetic predisposition. Late effects monitoring should be tailored to the individual.

Step 6: Managing refractory disease or relapse

Relapsed RMS is generally detected earlier through surveillance imaging than presenting signs and symptoms, but earlier detection does not appear to influence outcomes.²⁷² Overall survival in relapsed RMS is driven by the disease biology and the type of recurrence.²⁷³ A biopsy of tissue is required to confirm relapse and to help develop an appropriate treatment strategy.²⁷⁴ Outcomes in patients with relapsed RMS are generally poor, and at this point in time there is no standardised relapsed protocol. Chemotherapy followed by local control (either radiotherapy, surgery or a combination of both) has shown some favourable outcomes.^{273,275} Enrolment in a clinical trial for patients with relapsed RMS is preferable.²⁶¹

Disease-specific considerations: lymphomas

Lymphoma is the third most common paediatric cancer group and accounts for approximately 25 per cent of all solid tumours seen in Victorian children and adolescents. There are two clinicopathological types, non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL), each with their own distinct subtypes and respective treatment modalities.²⁷⁶ In some health services, NHL is managed under a haematological tumour stream because some presentations and treatments are more aligned with acute leukaemia. Each is discussed below.

Non-Hodgkin's lymphoma

Step 1: Prevention and early detection

The cause of NHL remains largely unknown. There is an increased risk in first-degree relatives with a history of leukaemia or lymphoma, as well as a strong risk factor for children with congenital or acquired immunodeficiency.^{277,278} There is an association with Burkitt's lymphoma and Epstein-Barr virus.²⁷⁶ Solid organ transplant patients are also at high risk of developing post-transplant lymphoproliferative disease, usually due to the effects of chronic immunosuppressive medication.²⁷⁹

There are no recommended preventative measures or early detection screening for de novo NHL in children. Patients with underlying immunodeficiency or who have had a haematopoietic stem cell transplant (HSCT) should have regular medical consultations.

Step 2: Presentation, initial investigations and referral

Children with NHL usually present with high-grade aggressive disease and will need prompt referral to a specialty centre.²⁷⁷ An urgent referral is required in the presence of respiratory distress, abdominal masses, splenomegaly or unexplained lymphadenopathy.²⁶³

⌚ Referral to a level five or six paediatric cancer service should be made within 48 hours for patients with splenomegaly or unexplained lymphadenopathy.

⌚ Urgent, same day referral (including via telephone) should be made for patients with cardiorespiratory symptoms.

Step 3: Diagnosis, staging and treatment planning

Definitive diagnosis requires initial tissue biopsy upfront (if clinically feasible). Staging should include cross-sectional anatomic imaging, functional CT and an examination of the bone marrow and cerebrospinal fluid.²⁷⁷ Staging should strictly follow a current and internationally recognised tool that allows reproducibility across sites and has relevance for prognosis and treatment stratification.²⁸⁰ Tumour subtyping should also follow an international classification tool to incorporate the most up-to-date and relevant data.²⁸¹

Oncology emergencies from tumour burden and mass effect should always be anticipated in children who present with NHL,²⁸² including acute cardiorespiratory insufficiency, spinal cord compression, abdominal complications, neurological compromise and metabolic derangement. The most life-threatening situations arise from the presence of a mediastinal mass²⁸³ or tumour lysis syndrome.²⁸² The level five or six paediatric cancer service should have documented clinical governance, responsibilities, training and strategies in place to manage these scenarios. In cases of oncology emergencies, the least invasive procedure (for example, marrow, pleural tap or image-guide core biopsy) should be used to obtain a tissue biopsy for diagnosis.

⌚ For patients who present with oncology emergencies, supportive interventions and emergency cytoreduction treatment (chemotherapy and/or radiotherapy) should be initiated as soon as possible. Biopsy will be carefully undertaken after clinical consultation with the MDT for the best approach.

Step 4: Treatment

The treatment plan is determined via the state-wide paediatric solid tumour MDM and ideally under the auspices of a clinical trial.

Chemotherapy

Currently, standard of care is risk-adapted, multi-agent chemotherapy and in some cases, with CNS prophylaxis.²⁷⁶

Treatment for lymphoblastic lymphoma is quite distinct and follows acute leukaemia protocol.²⁷⁶ Refer to section two of this document for more information regarding leukaemia treatment. The timing of therapy between cycles in NHL (particularly Burkitt's and diffuse large B-cell) is very important; delays in administering chemotherapy may have adverse prognostic significance.²⁸⁴ Immunotherapy has been shown to improve outcomes in children with high-risk B-cell NHL and is likely to have an important future role in other lymphomas.²⁸⁵

Radiotherapy

Radiotherapy may also be used upfront for emergency cytoreduction.²⁷⁶ The level five or six paediatric cancer service should have documented clinical guidelines for coordinating and administering emergency radiotherapy (delivered offsite) in patients who present with life-threatening complications. Radiotherapy may also be used in some patients with CNS disease and those requiring conditioning for HSCT.

Surgery

Surgery currently has a limited role in the primary resection of some tumour subtypes in children with NHL,²⁷⁶ such as those who present with localised disease.²⁷⁷

Response to therapy

The objective assessment of treatment response for most cases of NHL through the use of functional imaging is important in stratifying risk-tailored therapy.²⁸⁶

⌚ Timing of therapy between cycles should be strictly followed in NHL and any delays recorded and investigated.

⌚ All patients should have interim PET scanning undertaken following initial therapy to measure response to treatment. There should be an agreed timing for imaging to be undertaken and subsequent presentation at the state-wide paediatric solid tumour MDM.

Step 5: Care after completing therapy and survivorship

Type and frequency of interventions following treatment for NHL should be determined by enrolment in a clinical trial. Surveillance in lymphoblastic lymphoma follows similar protocols to acute lymphoblastic leukaemia. Surveillance in other types of NHL shows that regular, timed physical

examination and careful review of history are the most effective interventions in detecting relapse. Current medical imaging techniques are not considered effective in surveillance, with only a low yield of asymptomatic recurrences.²⁸⁷⁻²⁸⁹ The use of PET scanning in surveillance as standard of care remains unclear at this point in time.²⁸² The choice and timing of medical imaging following treatment for NHL should be defined by risk and tumour subgroup and be clearly documented.

Late effects of treatment include risk of infertility, cardiotoxicity and secondary cancers, generally from the effects of chemotherapy.²⁷⁷ The risk of late effects is greater in patients who received high-dose chemotherapy with HSCT. Current adult survivors of NHL have a significant burden of chronic health conditions.²⁹⁰

Step 6: Managing refractory disease or relapse

Currently, the outcome for children with relapsed NHL remains poor.²⁹¹ The use of HSCT in relapsed patients following second complete remission with high-dose chemotherapy results in long-term cures in some patients,^{291,292} though enrolment in clinical trials and new strategies should be sought, particularly for those with high-risk features.²⁹²

Hodgkin's lymphoma

Step 1: Prevention and early detection

The cause of HL is not well understood. There is a strong association with Epstein-Barr virus in patients with HL.²⁹³ A family history of early-onset cancer or HL in a first-degree relative are also risk factors.²⁹⁴

There are no preventative measures or recommended effective population screening for HL in children.

Step 2: Presentation, initial investigations and referral

Most patients present with lymphadenopathy, but its absence does not rule out a diagnosis of HL.²⁷⁶ Patients with lymph nodes that are fixed, firm, non-tender and persistent, particularly in the supraclavicular region, should be evaluated for potential malignancy.²⁹⁵ Constitutional (B symptoms) of night sweats, weight loss of more than 10 per cent within the preceding six months and a persistent fever

are strongly associated with HL.²⁹⁵ Any signs of airway compression or respiratory distress may signify a mediastinal mass and in this context demands an urgent referral.

Ⓛ Referral to a level five or six paediatric cancer service should be made within 48 hours for patients with unexplained lymphadenopathy, particularly with associated B symptoms.

Ⓛ Urgent, same day referral should be made for patients who exhibit symptoms of respiratory distress.

Step 3: Diagnosis, staging and treatment planning

A biopsy is required to establish a diagnosis, with an excisional lymph node biopsy the preferred procedure to avoid incorrect diagnosis.²⁹⁶ Classification²⁸¹ and staging²⁹⁷ should follow internationally recognised tools. Imaging modalities in staging should incorporate PET imaging at diagnosis for all patients.^{298,299} Central review of tests and investigations at diagnosis (within the context of a clinical trial) has been shown to improve the accuracy of treatment planning³⁰⁰ and progression-free survival.³⁰¹ Patients with HL may present with a mediastinal mass and associated cardiorespiratory compromise, which can be life-threatening.²⁸³ The level five or six paediatric cancer service should have documented clinical governance, responsibilities, training and strategies in place to manage this risk.

Ⓛ For patients who present with life-threatening oncological complications, supportive interventions and emergency cytoreduction treatment (chemotherapy and/or radiotherapy) should be initiated as soon as possible.

Step 4: Treatment

The treatment plan is determined via the state-wide paediatric solid tumour MDM and ideally under the auspices of a clinical trial. Treatment can be multimodal, is risk stratified and consists of systemic multi-agent chemotherapy with the consideration of involved field radiotherapy in patients whose disease responds slowly.²⁷⁶ Surgery has a limited role in managing HL.

Response to treatment

Because HL is highly curable, it is important that an accurate response to initial treatment is measured to determine subsequent intensity and design of therapy. At this point in

time, the best modality for measuring treatment response is via PET imaging.³⁰²⁻³⁰⁴

Ⓛ All patients should have interim PET scanning undertaken following initial therapy to measure their response to treatment. There should be an agreed timing for imaging to be undertaken and subsequent presentation at the state-wide paediatric solid tumour MDM.

Step 5: Care after completing therapy and survivorship

Following treatment, a careful history and physical examination at regular time points (over three to four years) are the most important tools to detect relapse in most patients.³⁰⁵ Imaging may incorporate ultrasound, CT and PET. However, the yield for detecting relapse by imaging alone is very low in HL,³⁰⁶⁻³⁰⁸ and although still recommended, priority should be given to those patients at high-risk of relapse.²⁷⁶

In survivorship, patients can experience a high degree of late effects, though new risk-adapted approaches to treatment have reduced these risks.²⁷⁶ Late effects include infertility, ovarian failure in females and cardiovascular, pulmonary and musculoskeletal complications.³⁰⁹ There is also a risk of secondary cancers such as thyroid and breast cancer, particularly in those who received radiotherapy.³⁰⁹

Step 6: Managing refractory disease or relapse

Participation in a clinical trial should be considered for all patients with relapsed or refractory HL. At this stage, treatment for relapsed HL is risk-based and generally involves immunotherapy and high-dose chemotherapy, usually with autologous stem cell transplant.³¹⁰

Disease-specific considerations: embryonal tumours

Embryonal tumours are a heterogeneous group of cancers that are composed of undifferentiated cells similar to those of the developing embryo and, as such, occur almost exclusively in children or adolescents.³¹¹ Embryonal tumours are some of the most common paediatric cancers accounting for at least 20 per cent of all the solid tumours seen in Victorian children and adolescents. This section describes the most common extracranial embryonal tumours; CNS embryonal tumours are discussed in section 3.

Neuroblastoma

Step 1: Prevention and early detection

As is the case with the majority of childhood cancers, the cause of NB is still largely not known.³¹² About two per cent of patients with NB have an underlying genetic predisposition, including germline mutations in the ALK and PHOX2B genes or certain genetic predisposition syndromes such as Li-Fraumeni, Costello or Beckwith-Wiedemann syndrome.³¹³ The overwhelming majority of cases occur sporadically.³¹⁴ Recommendations have been published in the literature for screening patients who have a risk of hereditary NB.³¹³

Ⓛ Patients at risk of hereditary NB should be considered for surveillance with regular, timed consultations and investigations according to the most recent peer-reviewed consensus recommendations.^{313,315}

Step 2: Presentation, initial investigations and referral

Presenting signs and symptoms are widespread and diverse³¹⁶ and are directly linked to the patient's age at the time of presentation, location of the primary tumour and extent of disease.³¹⁷ Metastatic disease is present in more than 50 per cent of patients at diagnosis.³¹⁶ As such, a high index of suspicion is required due to the wide spectrum of clinical presentations. Signs and symptoms may include, but are not limited to, breathing difficulties, failure to thrive,

abdominal pain, palpable mass (abdomen/neck), ocular symptoms, subcutaneous nodules, fever, malaise, bone pain, pallor and irritability.^{318,319} Although there is a poor predictive power for isolated symptoms,⁵⁸ abnormal physical examination, increasing frequency, number and intensity of symptoms and escalating parental concern, should warrant further consultation for suspicion of malignancy. Neurological motor deficits may be due to spinal cord compression associated with an underlying paraspinal NB at diagnosis (particularly in the young), and this warrants a rapid referral for prompt assessment and intervention to minimise complications.³²⁰ Patients who present with an unexplained abdominal mass or enlarged abdominal organs may warrant discussion with a level five or six paediatric cancer service.³²¹ A diagnosis of opsoclonus myoclonus syndrome (OMS) will always warrant a work-up for NB.³²² NB is present in 50–80 per cent of young patients with OMS, and OMS occurs in two to three per cent of all cases of NB.³¹⁷

- ⌚ Access to ultrasound should be arranged within 48 hours for patients with palpable abdominal masses or unexplained enlarged abdominal organs.
- ⌚ Discussion with a level five or six paediatric cancer service should occur within 24 hours for any ultrasound findings suggestive of a malignancy or uncertain findings on ultrasound that do not exclude a malignancy while clinical concerns persist.
- ⌚ Patients with neurological motor deficits or respiratory distress should be discussed on the same day with a level five or six paediatric cancer service.

Step 3: Diagnosis, staging and treatment planning

Imaging should be of clinically relevant sites plus examination of further extension.³¹⁸ A baseline ultrasound of the primary site at diagnosis will confirm the presence of a mass and provide guidance for further interventions.³¹⁸ At this point in time, the combined use of PET-CT and i-MIBG have demonstrated the greatest sensitivity^{323–325} and specificity^{325,326} in the medical imaging of NB at diagnosis. Clinicians working in a level five or six paediatric cancer service with experience in managing NB should report on all internal and external diagnostic imaging. A complete urinary catecholamine metabolite panel will increase sensitivity for a diagnosis of NB.³²⁷

Biopsy of the primary tumour can be undertaken with image-guided core biopsy, biopsy of metastases (such as marrow) or, in rarer instances, via open biopsy.^{328,329} Essential tests of the biopsy sample include histopathology and molecular testing to aid diagnosis and prognosis.³¹⁸ Bilateral bone marrow aspirate and trephine biopsies are usually required to support evidence of metastatic disease.³³⁰

Clinical heterogeneity of signs and symptoms is a hallmark of NB.³³¹ Pre-treatment staging and classification should be according to the most recent international consensus (such as the INRGSS) to homogenise subgroups of NB according to risk, which facilitates comparisons of treatment as well as the conduct of collaborative clinical trials.^{332,333} Further staging, conducted in parallel, may still be required for clinical trial requirements, such as post-surgical staging.

Step 4: Treatment

Treatment is based on an accurate risk assessment and staging. Curative treatment can range from observation only in low-risk NB to intensive chemotherapy, radiotherapy, surgical resection, myeloablative autologous HSCT and combined immunotherapy in high-risk disease.³³⁴ All treatment should be developed and ratified through a state-wide paediatric solid tumour MDM, preferably within the context of a clinical trial.

Surgery

Gross total resection in low-risk NB in children is considered standard of care.³³⁵ In intermediate- and high-risk NB the value of gross total resection is uncertain and does not appear to be associated with improvement in overall survival.^{336–338} The role of surgery as optimal care in high-risk NB remains challenging and requires long-term, large-scale prospective studies.³³⁸ Clear communication and pre-operative planning is required for all surgical resections in NB, particularly in high-risk groups.

Paraspinal NB

Paraspinal NB, and the subsequent risk of spinal cord compression, is a medical emergency.³³⁰ There is no demonstrated advantage of surgery over chemotherapy in symptomatic patients³³⁹ however, the late effects burden in both is high.³²⁰ The severity of neurological motor deficit before intervention is the most sensitive predictor of permanent functional disability. This clinical emergency requires prompt initiation of therapy to decompress the spinal cord before complete and permanent loss of

function.³²⁰ Neurosurgery should be limited only to those patients with rapid neurological deterioration. It is important to be vigilant about neurological function and to maintain a high level of suspicion for all neurological symptoms as symptoms of intraspinal extension.³²⁰ Radiotherapy should be considered where surgery is contraindicated.

- ⌚ All patients with neurological motor deficits from paraspinal NB should have immediate discussions between medical imaging, oncology and surgery to address and manage spinal cord compression *at the time of presentation*.

Radiotherapy

The use of radiotherapy is an effective part of multimodal treatment of high-risk NB for local control^{340–342} and should be ideally undertaken within the context of a clinical trial. The use of i-MIBG therapy as active treatment currently has a role in the relapsed/refractory setting.³⁴³ Its role in newly diagnosed patients at this stage is still under investigation.³⁴⁴ Active i-MIBG therapy has significant patient, family and work safety implications and requires extensive preparation of facilities, staff and clinical governance³⁴⁵ as it creates a real risk of exposure of ionising radiation to staff.³⁴⁶ Although safe practices have been demonstrated in sites without dedicated facilities,³⁴⁷ i-MIBG is best achieved through centralisation within a small number of services in Australia.

Chemotherapy

Chemotherapy, together with surgery, is standard care for patients with intermediate and high-risk NB.³³⁰ The introduction of targeted immunotherapy, together with differentiation therapy, has shown significant and sustained overall survival,³⁴⁸ while the use of myeloablative HSCT in high-risk NB is an important treatment modality to improve event-free survival.^{349,350} Chemotherapy for high-risk NB is intensive and requires stringent supportive care demands from the level five or six paediatric cancer service. Prospective treatment planning should be undertaken within the context of the state-wide paediatric solid tumour MDM and ideally within the context of a clinical trial to ensure access to therapies and best practice.

Step 5: Care after completing therapy and survivorship

After completing treatment, all patients require regular, timed follow-up with physical examination, urinary

catecholamine metabolite screening and medical imaging. The surveillance timing and interventions are determined by the NB location, stage and risk.³⁵¹ I-MIBG scanning is recommended in follow-up if the patient has persistent bone disease.³²³ Reduction of CT scanning and radiation exposure should also be considered,³⁵² particularly in non-thoracic tumours.³⁵³

In survivorship, childhood survivors of high-risk NB have an 18-fold increased risk of developing a secondary malignancy compared with their peers³⁵⁴ and are hospitalised twice as often for new somatic conditions than the general population.³⁵⁵ Growth and endocrine late effects are a serious issue for those who undergo HSCT.^{356,357} The incidence of late effects may be underestimated because of recent improvements in survival, as therapies have become more intensive.³⁵⁵ Childhood survivors of paraspinal NB also have a high burden of late complications of therapy.³²⁰

Step 6: Managing refractory disease or relapse

At this point in time, overall long-term survival in high-risk NB is only 50 per cent.³⁵⁸ A recent meta-analysis of relapsed trials showed median overall survival in relapsed high-risk NB of 11 months and 27 months in refractory NB.³⁵⁹ As such, early integration into palliative care should be encouraged for patients with high-risk NB and implemented for all relapsed patients. Considerations in treatment planning for children with relapsed/refractory NB include re-biopsy of the relapsed tumour with molecular analysis, a genuine balance of the burden of therapy with the likelihood of benefit and exploring clinical trials for all patients.³⁵⁸

Hepatoblastoma

Step 1: Prevention and early detection

Hepatoblastoma (HB) is associated with cancer predisposition conditions such as with Beckwith-Wiedemann syndrome and familial adenomatous polyposis,³⁶⁰ with reported incidence in the literature of 1.7 per cent³⁶¹ and 2.5 per cent³⁶² respectively. A history of very low birthweight is a significant risk factor associated with developing HB³⁶³ that may be associated with the neonatal intensive care unit environment.³⁶⁴ There are no effective

screening methods for early diagnosis of HB in the healthy population.

- Children with a cancer predisposition for developing HB should have regular surveillance in line with recent consensus recommendations,³⁶⁰ which at this point in time includes serum alpha-fetoprotein (AFP) monitoring and abdominal ultrasound for the first four years of life. Patients with familial inherited syndromes associated with HB should have genetic counselling.³⁶⁵

Step 2: Presentation, initial investigations and referral

The most common presenting sign in HB is an asymptomatic abdominal mass³⁶⁶ that is often discovered by a caregiver.³⁶⁷ Non-specific symptoms are varied but may include gastrointestinal disturbance, weight loss, irritability, fever and pallor.^{367,368} Initial imaging in suspected HB from an unexplained abdominal mass or distension should be via an abdominal ultrasound.³⁶⁷

- Access to an ultrasound should be arranged within 48 hours to assess patients suspected of having an abdominal mass or distension.
- Discussion with a level five or six paediatric cancer service should occur within 24 hours for any ultrasound findings suggestive of a malignancy or uncertain findings on ultrasound that do not exclude a malignancy while clinical concerns persist.

Step 3: Diagnosis, staging and treatment planning

All diagnosis, staging and treatment planning should be centralised for optimal care in HB. Staging and treatment for HB depends heavily on medical imaging.³⁶⁹ An abdominal ultrasound is required to identify the organ of origin of an abdominal mass, which helps guide the subsequent cross-sectional imaging modality.³⁷⁰ Currently, MRI is the recommended imaging technique.^{370,371} A chest CT is required for identifying presence of lung metastasis.³⁷⁰ A biopsy is mandated for all cases, optimally as an image-guided core needle biopsy undertaken by an interventional radiologist with experience in paediatric oncology.³⁷² Serum levels of the tumour biomarker AFP should be undertaken in all patients.³⁶⁷ A risk-stratified staging system that incorporates a variety of prognostic factors such as PRETEXT group, AFP level, age and the presence of metastases should be utilised.^{367,370,373,374} Such a system is

currently being recommended under the Children's Hepatic tumours International Collaboration HB staging.³⁷⁴

Step 4: Treatment

Treatment should ideally be conducted under the auspices of a clinical trial. Enrolment should be through an international collaborative clinical trial.³⁷⁵

Surgery

Complete resection is necessary for cure. Patients with unresectable tumours are candidates for liver transplantation.³⁶⁷ Surgery in HB is highly complex and should be centralised under a dedicated HB multidisciplinary surgical team, with synergy between oncology surgeons and (if required) liver transplantation surgeons.³⁷⁶

Chemotherapy

Optimal treatment is with risk-stratified chemotherapy (neoadjuvant and/or adjuvant) combined with surgical resection of the tumour.³⁶⁷ Timing between the last neoadjuvant chemotherapy and transplantation (when required) should be as short as possible to reduce excessive toxicity from prolonged cycles of chemotherapy.^{377,378}

Radiotherapy

There is no indication for radiotherapy in upfront treatment, and its use in recurrent or unresectable HB remains to be determined.³⁷⁹

- Strategies should be in place to ensure accurate timing between neoadjuvant chemotherapy and surgery as determined by the clinical trial.
- When required, referral to transplantation should be made as soon as the diagnosis and prospective treatment plan is made.³⁷⁷

Step 5: Care after completing therapy and survivorship

Surveillance monitoring should be determined by the clinical trial. For patients with AFP-positive HB, serum AFP monitoring is the most sensitive test during surveillance.³⁸⁰ Imaging during surveillance should be undertaken in the immediate period after treatment and prioritised for patients with high-risk disease and/or AFP non-secretory HB.³⁸¹ Follow-up should be multidisciplinary and include oncology, surgery and, if applicable, transplant services.

Late effects of current treatment include ototoxicity, nephrotoxicity and cardiotoxicity, primarily from the chemotherapy treatment plan,³⁸² and patients should be reviewed regularly following treatment.

Step 6: Managing refractory disease or relapse

Relapses in HB are rare events,³⁸⁰ and there is limited data concerning outcomes in patients with relapsed HB,³⁸³ though at this time, treatment with combined chemotherapy and surgery can provide cure in some patients.^{380,383}

Wilms tumour

Step 1: Prevention and early detection

WT (also known as nephroblastoma) may occur in association with cancer predisposition syndromes such as Beckwith-Wiedemann, Denys-Drash and WAGR³⁸⁴ and with clinical malformations such as hemihypertrophy and genitourinary malformations.³⁸⁵ WT is associated with genetic abnormalities such as the WT1, DICER1 and BRCA2 gene mutation or deletion.^{386,387} Families with more than one individual with WT occur in one to two per cent of cases.³⁸⁵ No firm environmental links have been identified to developing WT,³⁸⁸ and no current population-based screening program exists for individuals without known risk factors. Clinical screening via regular, timed physical examination and abdominal ultrasounds have been recommended for high-risk groups that have a greater than one to two per cent risk of developing WT during infancy and childhood.^{360,389}

- Children with a high risk of developing WT should have regular surveillance, including physical examination and abdominal ultrasound.

Step 2: Presentation, initial investigations and referral

Most patients with WT present with an abdominal mass (generally firm and non-tender on physical exam) that is often first noticed by a caregiver.²⁹⁵ Constipation, vomiting, fever, malaise, hypertension and, importantly, haematuria (with exclusion of other causes) are also presenting signs and symptoms.^{319,390}

- An ultrasound should be performed within 48 hours for a suspicion of WT in a patient with a palpable abdominal mass, unexplained enlarged abdomen or unexplained haematuria.²⁶³

- Discussion with a level five or six paediatric cancer service should occur within 24 hours for any ultrasound findings suggestive of a malignancy or uncertain findings on ultrasound that do not exclude a malignancy while clinical concerns persist.

Step 3: Diagnosis, staging and treatment planning

Currently, the standard imaging requirements include abdominal ultrasound for diagnosing a renal mass³⁸⁶ followed by MRI/CT of the abdomen and pelvis.³⁹⁰ A CT of the chest is required to establish the presence of lung metastases.³⁹¹ Core needle biopsy of the tumour may also be obtained, depending on the protocol. Staging should follow an internationally recognised tool for paediatric renal tumours. Currently, there are two staging tools used for WT, and the survival rates for both strategies are similar.³⁹² Treatment is based on tumour stage, histology and, in the case of the Société Internationale d'Oncologie Pédiatrique group, assessment of chemotherapy sensitivity.³⁹³ Interpretation of all images, laboratory results, histopathology and any surgical or invasive diagnostic interventions should be performed by personnel experienced in managing WT within a level five or six paediatric cancer service.

- If the protocol requires neoadjuvant chemotherapy, then a second discussion within the MDM will be required to discuss histological evaluation and staging following surgery.

Step 4: Treatment

The primary goal for all children diagnosed with WT is cure. Treatment is multimodal, ideally directed under the auspices of a clinical trial and requiring a multidisciplinary approach from a team of personnel experienced in managing WT.

Surgery

Surgery (currently involving nephrectomy and lymph node sampling for unilateral tumours) is the cornerstone of treatment for WT.³⁹² Patients with bilateral WT require an individualised approach focused on nephron-sparing

surgery. Optimally, surgery should be undertaken by a limited number of experienced personnel (in a level five or six paediatric cancer service).^{390,393}

Chemotherapy

Neoadjuvant and adjuvant chemotherapy is used in most circumstances and needs to be carefully timed around surgery³⁹⁴ through discussion and planning at the state-wide paediatric solid tumour MDM.

Radiotherapy

Whole-lung irradiation and radiotherapy to other metastatic sites is still indicated in some settings, though in new clinical trials the use of radiotherapy is reducing.³⁹³

Step 5: Care after completing therapy and survivorship

Following treatment, surveillance should be defined by the clinical trial and generally consists of regular, timed imaging and physical examinations every few months for the first few years off treatment.³⁹⁵ More than 80 per cent of relapse cases occur in the first two years (with the lungs the most common site) and the majority are found through medical imaging alone, highlighting the need for more frequent reviews with medical imaging in this period.³⁹⁵ Imaging interventions should, at a minimum, include abdominal ultrasound and chest x-ray. The practice of reducing radiation dosing through reduction in the use of CT scanning in surveillance for WT, as well as reducing the frequency of imaging after two years off treatment should be considered.³⁹⁶⁻³⁹⁸ Despite this, frequency and length of surveillance may need to be considered in patients at higher risk of relapse.

Long-term effects in WT include impairment in renal, cardiac and pulmonary function,^{395,399} as well as an increased risk of secondary malignancies,⁴⁰⁰ traditionally from radiotherapy and anthracyclines.³⁸⁶ Although WT survivors still experience a higher level of chronic illness than controls,³⁸⁶ the reduction in treatment intensity has seen a subsequent reduction in late effects.⁴⁰¹

Step 6: Managing refractory disease or relapse

Currently, up to 15 per cent of patients with WT will relapse,³⁹⁵ but many of these are still cured of their disease.³⁸⁶ Treatment is intensive chemotherapy, including the use at times of stem cell supported chemotherapy.³⁸⁶ Radiation to oligometastatic sites may be indicated in some

situations. Overall survival for relapsed WT varies according to risk features, with treatment stratified according to risk.⁴⁰² Radiotherapy should also be considered in the palliative setting for symptomatic lesions.

Retinoblastoma

Step 1: Prevention and early detection

RB results from mutations in both alleles of the RB1 gene. Germline mutations occur in about 40 per cent of cases.³¹³ Carrying the RB1 germline mutation also predisposes patients to a risk of second primary malignancies later in life.⁴⁰³ For patients with hereditary RB, screening programs (including ophthalmic screening, genetic counselling and testing) can facilitate early detection for optimising outcomes of visual potential and long-term survival.⁴⁰³

L Patients with a family history of RB should be part of a risk-stratified screening strategy, including genetic testing and fundus examination by an ophthalmologist experienced in managing RB. Patients who carry a germline RB1 mutation should continue to have regular examinations throughout life due to the increased risk of second malignancies.

Step 2: Presentation, initial investigations and referral

In developed countries such as Australia most cases of RB present with intraocular disease following the observation of leukocoria or strabismus by a caregiver.⁴⁰⁴ Presenting with strabismus has been associated with an increased likelihood of patient survival and globe salvage.⁴⁰⁵ The presence of strabismus should prompt a red reflex test of the eye. Rarely, patients present late with proptosis from extraocular tumour invasion.⁴⁰⁶ A delay in diagnosis and treatment may result in difficult-to-treat large tumours, blindness, extraocular disease and increased mortality.⁴⁰⁷ An absent red reflex warrants urgent consultation with a paediatric ophthalmologist.⁴⁰⁴ No further tests or investigations are required in primary care beyond the referral.

L Consultation with a paediatric ophthalmologist should be made within 48 hours in any infant or child with an absent red reflex. Any infant or child over four months of age presenting with a history of constant or

intermittent strabismus should be tested for red reflex and their fundus examined.

Step 3: Diagnosis, staging and treatment planning

The diagnosis and prospective treatment planning for all infants and children with RB should be directed from within a level five or six paediatric cancer service within a dedicated RB MDT that is participating in the state-wide paediatric solid tumour MDM. This team should include (but not be limited to) a paediatric ophthalmologist with experience in managing RB, a nurse coordinator whose direct responsibilities include the care of infants and children with RB, a medical imaging practitioner, a paediatric oncologist with experience in RB, a radiation oncologist (with a subspeciality in paediatrics) and a clinical geneticist.⁴⁰⁸ A bilateral dilated ocular fundus examination (performed by a paediatric ophthalmologist⁴⁰⁴) is generally sufficient for diagnosis.⁴⁰⁹ Histological confirmation through biopsy of the tumour is not required and increases the risk of metastasis.⁴¹⁰ Ocular ultrasound helps to identify diagnostic calcification, and an MRI should be used to assess any invasion of the optic nerve and presence of intracranial tumours (generally associated with a germline RB1 mutation).⁴⁰⁹ CT scans should be avoided, particularly in those with cancer predisposition. Extraocular tumours will require further work-up for metastatic disease, such as bone marrow aspiration and trephine biopsy, lumbar puncture and craniospinal imaging.⁴⁰⁹

Staging of RB should follow an internationally recognised tool to promote collaboration in clinical trials such as the International Intraocular Retinoblastoma Classification⁴¹¹ or the TNM classification of RB that takes into account recent innovations in local therapy.⁴¹²

Step 4: Treatment

The primary goals of treatment for RB are preserving life and minimising the likelihood of metastatic disease.⁴¹³ Further decisions on the choice of therapy are based on eye salvage, ultimate visual potential and possible short- and long-term complications.⁴⁰⁹ Treatment may include enucleation, focal therapy (such as with a diode laser or cryotherapy) or intra-arterial or intravitreal chemotherapy.⁴⁰⁹

Place of care

Due to the unique demands of surgery and surgical techniques⁴¹³ and rarity of disease, all delivered to an infant

or very young child, treatment is centralised and administered at a level five or six paediatric cancer service under the RB MDT.

Radiotherapy

The use of external beam radiotherapy in infants and young children with RB should be avoided due to the risk of local complications and secondary cancers in the field of radiation, particularly patients with a germline RB1 mutation.⁴¹⁴ Radiotherapy may be indicated in the setting of positive surgical margins (for example, optic nerve) at enucleation. In the setting of an intact eye, radiotherapy should only be considered if there is a strong likelihood of preserving vision and all other local therapies beyond enucleation have failed.

Step 5: Care after completing therapy and survivorship

Ideally surveillance following RB will be determined by the treatment and RB1 mutation status. Following treatment, all patients should continue regular, timed ophthalmic surveillance until at least nine years of age.⁴⁰⁷ Patients with a germline RB1 mutation and all those who received treatment beyond unilateral primary enucleation should also have oncology surveillance.⁴⁰⁷ Visual rehabilitation should also be ongoing during surveillance.

Although outcomes for intraocular RB are excellent, almost half of adult survivors have reported restrictions in activities of daily living,⁴¹⁵ and quality of life in paediatric patients is also less than their peers.⁴¹⁶ Late effects include visual deficits, long-term toxicities of chemotherapy and a risk of endocrine dysfunction in those requiring radiation.⁴⁰⁷ Patients with a germline RB1 mutation have a lifetime risk of secondary cancers,⁴¹⁷ which is heightened when radiotherapy is delivered.³¹³ Furthermore, the implications of genetics on RB phenotype and risk are not widely understood by survivors and their families.⁴¹⁸

Patients with a germline RB1 mutation should also have regular physical examinations with a high index of suspicion for secondary cancers.⁴⁰⁷ All patients with a germline RB1 mutation (and their immediate families) should have genetic counselling and be provided with appropriate resources.

Step 6: Managing refractory disease or relapse

All patients who relapse with RB should be offered entry into a clinical trial. Metastatic disease or relapse may be

treated with high-dose chemotherapy that may include HSCT rescue.⁴⁰⁷ Patients with RB who also have intracranial tumours (trilateral RB) with leptomeningeal and cerebrospinal fluid disease are very difficult to cure,⁴⁰⁶ and at this point in time the prognosis is poor.⁴⁰⁴

- All patients with refractory or relapsed disease should be discussed within a state-wide paediatric solid tumour MDM with RB team participation. Patients diagnosed with trilateral RB should also have early referral to palliative care.

Disease-specific considerations: germ cell tumours

GCTs are a diverse group of both benign and malignant cancers of primordial germ cells, represented by a variety of histological diagnoses and tumour locations.⁴¹⁹ Although they only represent five per cent of all paediatric solid tumours in Victoria, they make up almost 15 per cent of all cancers diagnosed in 15–19 year olds.⁴²⁰ Although GCTs can arise in the CNS, this section only relates to extracranial GCTs.

Extracranial germ cell tumours

Step 1: Prevention and early detection

Currently, the cause of GCTs in children is unknown, though patients with germline DICER1 mutations have an increased risk of developing some types of GCTs.³⁸⁷ There is no clear association with the environment.⁴²¹ There is association with testicular GCT and a history of cryptorchidism⁴²² (predominantly when treated in post-pubertal boys)⁴²³ as well as some evidence of family aggregation of GCT,⁴²⁴ but no targeted early screening recommendations exist at this point in time.

Step 2: Presentation, initial investigations and referral

Most ovarian GCTs present with abdominal pain with or without a palpable mass⁴²⁵ and may be associated with other localised signs such as constipation, vaginal bleeding and amenorrhoea.⁴²⁶

Testicular GCTs usually present with a non-tender palpable mass in the scrotum⁴²⁵ and, less frequently, the presence of a hydrocele in younger patients.⁴²⁶ Older adolescent males experience more delays to diagnosis due to psychological and emotional issues.^{427,428} Enlarged testes may be ignored, allowing the disease to spread until symptoms are more severe, such as back and abdominal pain.⁴²⁶ Health services should encourage health-seeking behaviours in all adolescents to promote early interventions.^{429,430}

The presentation of extragonadal GCTs varies according to location. Mediastinal GCTs most often present with respiratory distress or recurrent airway infections⁴³¹ and should be considered as a differential diagnosis with any midline tumours.⁴³² Sacrococcygeal tumours are generally visible exophytic masses that are frequently detected antenatally.⁴³² Internal masses may present with constipation, bladder dysfunction or buttock pain with refusal to sit.⁴²⁶

- Access to ultrasound should be arranged within 48 hours to assess any unexplained mass in a stable patient.
- Discussion with a level five or six paediatric cancer service should occur within 24 hours for any ultrasound findings suggestive of a malignancy or uncertain findings on ultrasound that do not exclude a malignancy while clinical concerns persist.
- Any unexplained mass associated with respiratory distress or acute pain should be referred on the same day to a paediatric tertiary referral service.

Step 3: Diagnosis, staging and treatment planning

An ultrasound that confirms the presence of a suspected tumour is generally followed by cross-sectional imaging such as CT or MRI for most patients with a GCT.⁴³² Serum tumour markers AFP and B-hCG should be sought and may aid in diagnosis,⁴³² but elevated levels are not present in all GCTs,⁴²⁶ nor are they specific predictors of outcome.⁴³³ Histology of the primary tumour (either via upfront resection or biopsy) provides a definitive diagnosis.⁴³² Further diagnostic work-up should be defined by the clinical trial or strictly following the most recently completed and published clinical trial.

GCTs are rare and occur at any age, from prenatal diagnoses through to adulthood. There are many staging systems, but most follow a risk-adapted methodology.⁴²¹ An internationally recognised staging and risk classification tool that has been developed from the most recent evidence should be used.⁴³⁴

Central pathology and surgical review in GCTs within the context of a clinical trial has been shown to optimise care by improving complete data collection and assignment of correct staging, allowing for prompt initiation of therapy, and should be encouraged.⁴³⁵

Step 4: Treatment

Treatment is often multimodal and should ideally be conducted under the auspices of an international clinical trial, stratified according to risk criteria.

Surgery

Surgery is a mainstay of treatment for most GCTs,⁴³⁶ though aggressive resections in GCT should be avoided by using neoadjuvant chemotherapy.⁴³² The role for surgery at diagnosis for extragonadal GCT is age- and site-dependent and must be individualised.⁴²⁶ All non-urgent surgical interventions should be first presented at the state-wide paediatric solid tumour MDM to facilitate the timing of surgery, the optimal approach and likely histopathology requirements, as well as potential clinical trial demands.⁴²⁶

Chemotherapy

Currently, systemic chemotherapy is indicated for many patients, either before and/or after surgery,⁴²⁶ though current treatments are still associated with a substantial burden of acute and late toxicity.⁴³⁷ New clinical trials will aim to reduce the burden of late effects by removing chemotherapy agents with a high risk of toxicity while maintaining the high levels of cure.⁴³⁸

Radiotherapy

Radiation may have a place in some advanced or recurrent GCTs⁴³⁹ but is not routinely advocated.⁴³⁶

- All patients with a GCT should be discussed at a state-wide paediatric solid tumour MDM before and after surgical resection with representation from the appropriate paediatric surgical subspecialty.

- All patients requiring urgent resection should have discussions between medical imaging, pathology, oncology and surgery before interventions.

Step 5: Care after completing therapy and survivorship

For patients with secretory tumour markers at diagnosis, serum measurement of these markers is a sensitive measure in surveillance⁴³² but may not be sufficient to remove the need for imaging.⁴⁴⁰ All imaging should follow ALARA principles.

The most common late effects in GCTs are from side effects of chemotherapy, including ototoxicity, nephrotoxicity, cardiovascular risk and secondary malignancies.⁴³² Gonadal

tumours, and their respective treatments, including surgery and radiotherapy, also place added risk to fertility.¹⁹³ Level five or six paediatric cancer services should undertake informed decisions by applying the evidence to strategies and treatments that reduce the toxicities of therapy for GCTs,⁴⁴¹ ideally though enrolment in clinical trials.

Step 6: Managing refractory disease or relapse

Recurrent or refractory GCTs are rare, and reports on salvage therapies are limited⁴⁴² but are associated with a poor prognosis.⁴⁴³ Treatment is multimodal and has been shown to demonstrate response,⁴⁴² although complete surgical excision appears to be critical in achieving overall survivorship.⁴⁴³

Disease-specific considerations: histiocytic disorders

Histiocytic disorders encompass a diverse group of proliferative diseases characterised by the accumulation and infiltration of white cells in the affected tissues. The most common of these, Langerhans cell histiocytosis (LCH), is discussed below. LCH occurs in approximately four per cent of all solid tumours seen in Victorian children and adolescents. There has been debate over whether LCH is an immune disorder or a cancer; however, since the identification of activating BRAF mutations in LCH cells,⁴⁴⁴ consensus is moving towards its recognition as a neoplastic disease.⁴⁴⁵

Langerhans cell histiocytosis

Step 1: Prevention and early detection

The exact cause of LCH remains unknown⁴⁴⁶ and, at this point in time, there are no environmental factors or infectious agents associated with the disease.^{447,448}

Step 2: Presentation, initial investigations and referral

LCH is an extremely heterogeneous disease where almost every organ and system can be affected, making diagnosis challenging.⁴⁴⁹ This is compounded by the fact that many initial signs and symptoms mimic more common childhood illnesses, further delaying time to diagnosis.⁴⁵⁰ Presentations are widely variable, ranging from a self-limiting skin rash to severe, life-threatening systemic disease.⁴⁵¹

The most common presentations are bone pain, rash and endocrinopathies.⁴⁵² Lytic bone lesions occur more commonly in the axial skeleton.⁴⁴⁶ Skin rashes can take different forms with varying degrees of severity, with crusted or scaly papules and/or papulovesicles the most common seen.⁴⁵² Some children may also present with endocrinopathy such as polyuria from diabetes insipidus.⁴⁴⁷

 A differential diagnosis of LCH should be made in the setting of persistent, refractory skin conditions, central endocrinopathies or persistent bone pain in children. A

child who presents with a high suspicion of LCH should be referred to a paediatric tertiary referral centre within 48 hours. Children who present with life-threatening complications should have a same day discussion and referral.

Step 3: Diagnosis, staging and treatment planning

A definitive diagnosis of LCH is made on histological and immunophenotypical examination of lesional tissue.⁴⁵³ The sample should be from a core needle or open biopsy of the most easily resectable yet representative lesion.⁴⁵³ Where the risk of biopsy outweighs the need for a definitive diagnosis (for example, isolated vertebral lesions without an adjacent soft tissue component), the diagnostic plan should be discussed within a state-wide paediatric solid tumour MDM. Strategies for further evaluation and staging for LCH will be driven by specific clinical features, as well as potential clinical trial demands.

A thorough physical examination of the skin and mucosa, a neurological exam, a lung exam and the presence of hepatosplenomegaly should be undertaken.⁴⁵⁴ Pathology testing should include liver function for possible hepatic involvement as well as a full blood examination for potential marrow disease (+/- bone marrow biopsy in infants or those with resultant cytopaenia).⁴⁵⁴ Radiological work-up should include a skeletal survey or PET scan for potential bone involvement, as well as an MRI of the brain if there is suspicion of CNS disease.⁴⁵⁴

As somatic mutations have been described in the majority of cases of LCH (and with potential new targeted therapies becoming available),⁴⁵⁴ an LCH-cell genotype assessment should also be considered for all new diagnoses.

At this point in time, staging and classification of LCH is via three main subgroups: single system single site, single system multi-site and multisystem.^{452,455} Presence of LCH in high-risk organs (bone marrow, liver and spleen) will also determine the risk profile. Ideally, all staging will follow guidance under the auspices of a collaborative clinical trial.

Step 4: Treatment

Despite lacking full consensus as a neoplastic disease, the 'cancer model' of treating children within prospective, collaborative clinical trials with correlative biology is critical to improve overall outcomes in LCH.⁴⁵⁴

Treatment is defined by staging and can vary from no treatment in cases of spontaneous regression to multimodal therapy. All treatment should be directed under the auspices of a state-wide paediatric solid tumour MDM, preferably within the context of a clinical trial. The patient's response to frontline therapy, ideally with the use of functional imaging in multisite LCH,⁴⁵² is also a critical determinant of outcomes.⁴⁵⁴

Surgery

Small, isolated skin lesions may at times be surgically resected, while bone lesions may be treated with curettage and local steroid therapy.⁴⁵⁴ Radical excision of LCH lesions is not recommended.⁴⁵³ Ideally, all surgical interventions in treating LCH should be undertaken within the context of an MDT in a level five or six paediatric cancer service.

Chemotherapy

Empirically derived chemotherapy remains the standard of frontline treatment for multisite LCH.⁴⁵¹ At this point in time, despite reported successes in achieving remission in multisite LCH,^{456,457} the use of targeted therapy such as MAPK-pathway inhibitors is not a standard of care in frontline treatment.⁴⁵² However, it may be considered in future clinical trials and presently in the context of refractory or relapsed disease.

Radiotherapy

Radiotherapy may be effective in older children and adolescents with refractory, progressive lesions that are dangerous to surgically resect; however, the benefits of radiotherapy rarely outweigh the risks.⁴⁴⁷ There is now a reduced role for radiotherapy in most children with LCH due to the risk of long-term sequelae.^{453,458}

Step 5: Care after completing therapy and survivorship

Up to 50 per cent of patients with multisite LCH are either refractory to frontline therapy or will relapse, generally within the first two years following treatment. This calls for frequent, tailored surveillance monitoring.⁴⁵⁰ Long-term sequelae of LCH are also common, with permanent late effects occurring in more than half of all survivors.⁴⁵⁹ The highest risk groups to experience late effects appear to be those with multisite LCH, relapsed disease, CNS involvement and those who received radiotherapy.⁴⁶⁰ Neurological sequelae can be particularly devastating, requiring vigilant long-term follow-up. Neurodegenerative CNS LCH is a syndrome characterised by relentless progression of central

neurodegeneration that can occur more than 10 years after resolution of active LCH.⁴⁵²

Ⓛ All patients should have regular, tailored consultations following treatment and in survivorship. Of particular importance are assessments of growth and development (including any issues of pituitary dysfunction), learning difficulties and signs of neuropathy.

All child and adolescent survivors of LCH who develop new neurological signs and symptoms in survivorship should be referred back to the level five or six paediatric cancer service for neuropsychological evaluation and CNS imaging. Adult services managing childhood survivors of LCH should have a consultation with the level five or six paediatric cancer service where new neurological signs and symptoms are noted.

Step 6: Managing refractory disease or relapse

A paucity of data exists to help guide therapy when frontline treatment fails a patient with LCH,⁴⁵¹ which, as already discussed, occurs in almost half of all patients with multisite disease.⁴⁵⁰ Salvage treatment using more intense chemotherapy regimens, as well as the use of HSCT, may be curative for some patients.⁴⁶¹ The use of mutation-specific targeted therapy should also be considered in this setting.⁴⁵⁴ Optimal treatment for relapsed and refractory disease at this point in time remains uncertain,⁴⁵⁴ and all cases should be discussed within a state-wide paediatric solid tumour MDM and preferably under the auspices of a clinical trial.

Disease-specific considerations: rare paediatric solid tumours

When compared with national population data, a diagnosis of childhood cancer is a rare event, representing less than one per cent of the total number of cancers seen in Australia each year.¹⁸⁰ Therefore, those that occur infrequently within the childhood cancer population are considered 'exceptionally rare' events, and to date, many have not benefited from the successes of other more common childhood cancers such as leukaemia and lymphoma.⁴⁶²

Rare tumours are difficult to classify, though they can be defined by several observations. Aside from their low incidence, generally there are few or no published reports on clinical experiences, it is difficult to establish shared treatment guidelines, there are generally no evidence-based therapeutic recommendations available and few or no cooperative groups have dedicated projects or financial support to manage them.⁴⁶³ This is complicated by the fact that many of these diseases may be inappropriately classified and coded, leading to inadequate treatment.⁴⁶³ Consequently, children and adolescents with a rare tumour histology represent a vulnerable population⁴⁶⁴ where low numbers of heterogeneous diseases may seriously limit translational research.⁴⁶⁵ Furthermore, this trend may continue to grow as more molecularly defined subgroups in more common childhood cancers are discovered, requiring different treatments.⁴⁶²

This creates a real challenge for the paediatric oncology community, all the more so as this large variety of rare but biologically distinct tumours actually make up five to 10 per cent of the total number of diagnoses. It is therefore important to draw on the experiences gained in recent decades of international collaboration in diseases such as childhood leukaemia to determine the correct course in addressing rare solid tumours in children.

To meet these challenges, the level five and six paediatric cancer services need to participate in, or advocate for, several approaches:

1. For adult-type cancers that are rare in childhood, greater collaboration and partnership with adult centres is needed to promote access to clinical trials and expertise.
2. For paediatric-type cancers that are 'exceptionally rare' events:
 - (a) Advocate for the development of internationally recognised classification and staging of rare cancers to promote and harmonise further collaboration.
 - (b) Encourage participation or enrolment in international cooperatives and agreements in rare tumours such as the European cooperative study group for Pediatric Rare Tumors (EXPeRT) in Europe and the Children's Oncology Group rare tumours committee in North America.⁴⁶²
 - (c) Provide the mechanisms to register all children and adolescents with rare diseases into a national or international dataset, including biobanking tumour samples.
 - (d) Advocate for the development of epidemiological and biological studies of rare tumours.
 - (e) Encourage the development of a single tumour board for rare tumours, at the national level, to provide volume effect and centralised pathology and imaging review.
 - (f) Consider participating in 'virtual' tumour boards with international cooperatives.⁴⁶³
 - (g) Encourage the development of new partnerships with pharmaceutical industries, regulatory authorities and international funding bodies.⁴⁶³

Ongoing commitment to continuous improvement in the treatment of solid tumours

Health services must continue to pursue and commit to key strategies in the management of solid tumours in children, to ensure outcomes improve, while reducing the late effects of disease and treatment.

Genetic predisposition

Consideration should be made for standardised surveillance protocols for children with high-risk genetic predisposition to solid tumours,⁴⁶⁶ as well as ongoing support for genetic counselling for patients and their families. Initiatives should also be developed that facilitate the transition of adolescent patients with cancer predisposition into appropriate adult facilities.

Genomics and precision medicine

Health services should continue to advocate and support the use of clinical genomics in solid tumours to facilitate the development of a more complete catalogue of the various somatic and germline mutations. Personalised profiling of solid tumours has the potential to increase diagnostic accuracy, develop risk stratification and staging, and exploit more effective, less harmful therapy.⁴⁶⁷ This will increase the understanding of the genetics underpinning the disease and potential 'druggable' mutations.⁴⁶⁸ Supporting the development of precision medicine to augment conventional therapy is a priority in many solid tumours,^{391,437,469–476} particularly in high-risk disease and relapse. To support this, health services should also encourage the consent of additional tissue to be collected (both at diagnosis and relapse) so banking of cell lines and in vivo tumour grafts can be generated within associated research facilities.

Immunotherapy

As well as the advances in molecular pathways to targeted therapy, immunotherapy is also demonstrating unprecedented activity in childhood cancers,²²¹ including some solid tumours.^{285,318} Health services should encourage enquiry into and participation in the use of immunotherapy for solid tumours, particularly in the setting of refractory or relapsed disease.²²²

Clinical trials

It is important (and usually necessary) in supporting an ongoing commitment to improving the care of children and adolescents diagnosed with solid tumours, that health services actively promote and seek clinical trial enrolment for all patients, both at diagnosis and at relapse.

Glossary

Advance care planning

A process of discussing future medical treatment and care based on an individual's preferences, goals, beliefs and values, which can guide future decisions should the person become unable to communicate.

Child/adolescent

The Children, Youth and Families Act 2005 defines childhood (including adolescence) as the period from 0 to 17 years. The World Health Organization defines adolescents as individuals aged 10–19 years. The paediatric oncology care pathway is intended as a resource in managing children and adolescents diagnosed with cancer from birth to 18 years of age.

Consumer

A term that can refer to people affected by cancer, patients and potential patients, carers, organisations representing cancer consumer interests, members of the public who are targets of cancer promotion programs and groups affected in a specific way as a result of cancer policy, treatment or services.

Cultural and linguistic diversity

Refers to the range of different cultures and language groups represented in the population who identify as having particular cultural or linguistic affiliations by virtue of their place of birth, ancestry or ethnic origin, religion, preferred language or language spoken at home.

End-of-life care

A distinct phase of palliative care, appropriate when a patient's symptoms are increasing and functional status is declining despite anti-cancer therapy.

Family

The patient, their carers and relatives. Family may include parents, siblings, other relatives, guardians and friends.

Level five paediatric cancer service

A level five service provides state-wide, national and international leadership in paediatric oncology, including research, clinical guidance, education and policy development. A level five service will also assess and manage risk in new therapies and supportive care interventions, providing leadership and planning for other service levels. A level five service is recognised as a primary treatment centre and will provide diagnostic services and/or management of at least 30 new cancer patients per year. A level five service will provide comprehensive care for the majority of paediatric oncology presentations within its catchment area, with direct links to a level six service.

Level six paediatric cancer service

As per level five, as well as being as a state-wide referral centre for paediatric oncology, a level six service will provide diagnostic services and/or management of at least 100 diagnoses per year from the local catchment as well as referrals from other geographical regions.

Multidisciplinary meeting (MDM)

A regularly scheduled meeting of core and invited team members of the health service for the purpose of prospective treatment and care planning of newly diagnosed cancer patients as well as those requiring a review of their treatment plan or palliative care.⁹⁴

Multidisciplinary team (MDT)

Comprises the core disciplines integral to providing good care. The team is flexible in approach, reflects the patient's clinical and psychosocial needs and has processes to facilitate good communication.

Oncology care pathway

The key principles and practices required at each stage of the care pathway to guide the delivery of consistent, safe, high-quality and evidence-based care.

Advance care planning

A process of discussing future medical treatment and care based on an individual's preferences, goals, beliefs and values, which can guide future decisions should the person become unable to communicate.

Child/adolescent

The Children, Youth and Families Act 2005 defines childhood (including adolescence) as the period from 0 to 17 years. The World Health Organization defines adolescents as individuals aged 10–19 years. The paediatric oncology care pathway is intended as a resource in managing children and adolescents diagnosed with cancer from birth to 18 years of age.

Consumer

A term that can refer to people affected by cancer, patients and potential patients, carers, organisations representing cancer consumer interests, members of the public who are targets of cancer promotion programs and groups affected in a specific way as a result of cancer policy, treatment or services.

Cultural and linguistic diversity

Refers to the range of different cultures and language groups represented in the population who identify as having particular cultural or linguistic affiliations by virtue of their place of birth, ancestry or ethnic origin, religion, preferred language or language spoken at home.

End-of-life care

A distinct phase of palliative care, appropriate when a patient's symptoms are increasing and functional status is declining despite anti-cancer therapy.

Family

The patient, their carers and relatives. Family may include parents, siblings, other relatives, guardians and friends.

Level five paediatric cancer service

A level five service provides state-wide, national and international leadership in paediatric oncology, including

research, clinical guidance, education and policy development. A level five service will also assess and manage risk in new therapies and supportive care interventions, providing leadership and planning for other service levels. A level five service is recognised as a primary treatment centre and will provide diagnostic services and/or management of at least 30 new cancer patients per year. A level five service will provide comprehensive care for the majority of paediatric oncology presentations within its catchment area, with direct links to a level six service.

Level six paediatric cancer service

As per level five, as well as being as a state-wide referral centre for paediatric oncology, a level six service will provide diagnostic services and/or management of at least 100 diagnoses per year from the local catchment as well as referrals from other geographical regions.

Multidisciplinary meeting (MDM)

A regularly scheduled meeting of core and invited team members of the health service for the purpose of prospective treatment and care planning of newly diagnosed cancer patients as well as those requiring a review of their treatment plan or palliative care.⁹⁴

Multidisciplinary team (MDT)

Comprises the core disciplines integral to providing good care. The team is flexible in approach, reflects the patient's clinical and psychosocial needs and has processes to facilitate good communication.

Oncology care pathway

The key principles and practices required at each stage of the care pathway to guide the delivery of consistent, safe, high-quality and evidence-based care.

Palliative care

Any form of medical care or treatment that concentrates on reducing the severity of disease symptoms.

Primary oncologist

The clinician who has lead responsibility for managing the patient's cancer care. The lead clinician may change over time depending on the stage of the care pathway and where care is being provided.

Rehabilitation

Comprises multidisciplinary efforts to allow the patient to achieve optimal physical, social, physiological and vocational functioning within the limits imposed by the disease and its treatment.

Shared care

The establishment of pathways through which clients and health professionals in hospital and community settings can collaborate in developing a therapeutic plan that meets the clinical and functional needs of the client.

Surveillance

Period of time the healthcare team is looking for signs of relapse and monitoring side effects of treatment for cancer.

Survivorship

Period beyond surveillance where the healthcare team is looking at the potential late effects of treatment for cancer.

Telehealth

Healthcare delivery or related activities (such as education) when some of the participants are separated by distance and information and communications technologies are used to overcome that distance.

Acknowledgements

Fundamentals of care and acute leukaemia

Primary author

Chris Williams, Nurse Consultant (Paediatric Oncology), Paediatric Integrated Cancer Service

Steering committee

We are grateful for the leadership, expertise and commitment of the steering committee, members as follows:

Dr Luciano Dalla-Pozza, Head, Cancer Centre for Children, The Children's Hospital at Westmead

Dr Peter Downie, Director, Children's Cancer Centre, Monash Children's Hospital

Professor Yves Heloury, Medical Director, Paediatric Integrated Cancer Service

Dr Françoise Mechinaud, Director, Children's Cancer Centre, The Royal Children's Hospital, Melbourne

Emma Sayers, Project Lead, Paediatric Integrated Cancer Service

Jane Williamson, Program Manager, Paediatric Integrated Cancer Service

Chris Williams, Nurse Consultant (Paediatric Oncology), Paediatric Integrated Cancer Service

We are also grateful to the range of multidisciplinary professionals and parent representatives who generously contributed their expertise and experience to the content and review of the document.

Representatives from the following groups participated in expert review

Albury Wodonga Health

Cancer Strategy and Development, Department of Health and Human Services

Children's Cancer Centre, Monash Children's Hospital

Cancer Centre for Children, The Children's Hospital at Westmead

Children's Cancer Centre, The Royal Children's Hospital, Melbourne

Fertility Preservation Taskforce, The Royal Children's Hospital, Melbourne

ONTrac at Peter Mac Victorian Adolescent and Young Adult Cancer Service

Oncology Service, Lady Cilento Children's Hospital Brisbane

Parent Advisory Group, The Royal Children's Hospital, Melbourne, Children's Cancer Centre

Radiation Oncology, Peter MacCallum Cancer Centre

Paediatrics, Royal Hobart Hospital

Victorian Paediatric Integrated Cancer Service

Victorian Paediatric Palliative Care Program

Central nervous system tumours

Primary author

Chris Williams, Nurse Consultant (Paediatric Oncology), Paediatric Integrated Cancer Service

Steering committee

We are grateful for the leadership, expertise and commitment of the local reference group, members as follows:

Dr Luciano Dalla-Pozza, Head, Cancer Centre for Children, The Children's Hospital at Westmead

Dr Peter Downie, Director, Children's Cancer Centre, Monash Children's Hospital

Dr Françoise Mechinaud, Director, Children's Cancer Centre, The Royal Children's Hospital, Melbourne

Professor Yves Heloury, Medical Director, Paediatric Integrated Cancer Service

Dr Jordan Hansford, Children's Cancer Centre, The Royal Children's Hospital, Melbourne

Dr Paul Wood, Children's Cancer Centre, Monash Children's Hospital

Kerina Princi, Project Lead, Paediatric Integrated Cancer Service

Jane Williamson, Program Manager, Paediatric Integrated Cancer Service

Chris Williams, Nurse Consultant (Paediatric Oncology), Paediatric Integrated Cancer Service

We are also grateful to the range of multidisciplinary professionals and parent representatives who generously contributed their expertise and experience to the content and review of the document.

Representatives from the following groups participated in the expert review:

Albury Wodonga Health

Cancer Strategy and Development, Department of Health and Human Services

Children's Cancer Centre, Monash Children's Hospital

Cancer Centre for Children, The Children's Hospital at Westmead

Children's Cancer Centre, The Royal Children's Hospital, Melbourne

Fertility Preservation Taskforce, The Royal Children's Hospital, Melbourne

Medical Imaging, The Royal Children's Hospital, Melbourne

Neurosurgery, The Royal Children's Hospital, Melbourne

Neurosurgery, Monash Children's Hospital

Paediatric Oncology Haematology, Princess Margaret Hospital for Children

Parent Advisory Group, The Royal Children's Hospital, Melbourne, Children's Cancer Centre

Victorian Paediatric Rehabilitation Service

Radiation Oncology, Peter MacCallum Cancer Centre

Victorian Paediatric Integrated Cancer Service

Victorian Paediatric Palliative Care Program

Solid Tumours Pathway Acknowledgements

Primary author

Chris Williams, Nurse Consultant (Paediatric Oncology), Paediatric Integrated Cancer Service

Steering committee

We are grateful for the leadership, expertise and commitment of the steering committee members as follows:

Dr Luciano Dalla-Pozza, Head, Cancer Centre for Children, The Children's Hospital at Westmead

Dr Paul Wood, Acting Director, Children's Cancer Centre, Monash Children's Hospital

Dr Marty Campbell, Senior Clinical Specialist, Children's Cancer Centre, The Royal Children's Hospital

Professor Yves Heloury, Medical Director, Paediatric Integrated Cancer Service

Professor Michael Sullivan Paediatric Oncologist, Children's Cancer Centre, The Royal Children's Hospital

Kerina Princi, Project Lead, Paediatric Integrated Cancer Service

Amy Shelly, Acting Program Manager, Paediatric Integrated Cancer Service

Belinda Zambello, Assistant Program Manager, Paediatric Integrated Cancer Service

Chris Williams, Nurse Consultant (Paediatric Oncology), Paediatric Integrated Cancer Service

Jane Williamson, Program Manager, Paediatric Integrated Cancer Service

We are also grateful to the range of multidisciplinary professionals and parent representatives who generously contributed their expertise and experience to the content and review of the document.

Representatives from the following services participated in the expert review:

Cancer Centre for Children, The Children's Hospital at Westmead

Cancer Strategy and Development, Department of Health and Human Services

Children's Cancer Centre, Monash Children's Hospital

Children's Cancer Centre, The Royal Children's Hospital

Consumer Representative, Children's Cancer Centre, Monash Children's Hospital

Department of Clinical Oncology/Haematology, Women's and Children's Hospital, Adelaide

Department of Ophthalmology, The Royal Children's Hospital

Department of Orthopaedics, The Royal Children's Hospital

Division of Surgery, The Royal Children's Hospital

Parent Advisory Group, Children's Cancer Centre, The Royal Children's Hospital

Pathology Services, The Royal Children's Hospital

Radiation Oncology, Peter MacCallum Cancer Centre

Victorian Paediatric Integrated Cancer Service

References

1. Victorian Department of Health and Human Services, Optimal cancer care pathway for people with Hodgkin and diffuse large B-cell lymphomas. Cancer Council Australia: **2016**.
2. Viner, A. H.; Williams-Spence, J. M.; Whitfield, K.; Thomas, R. J. S., Optimal cancer care pathways: developing best practice guides to improve patient outcomes and identify variations in care. *Australian Journal of Cancer Nursing* **2016**, *17* (2), 21-25.
3. Victorian Department of Health and Human Services, Better, safer care: delivering a world-class healthcare system. Victorian Government.: Melbourne, Victoria, **2016**.
4. Paediatric Integrated Cancer Service, *Service Capability Framework: A guide for Victorian health services providing primary treatment and shared care to children and adolescents with cancer* PICS: Melbourne, **2014**.
5. Paediatric Integrated Cancer Service, *Service Capability Framework: A guide for Victorian health services providing radiation therapy to children and adolescents with cancer* PICS: Melbourne, **2015**.
6. Royal Australasian College of Physicians, Policy on the co-location of adults with children and adolescents in healthcare settings. RACP: Sydney, **2009**.
7. Australian College of Children and Young People's Nurses, Position Statement: minimum standard for nurses caring for children and young people. ACCYPN: Canberra, **2009**.
8. Harrison, T. M., Family-centered pediatric nursing care: state of the science. *J Pediatr Nurs* **2010**, *25* (5), 335-43.
9. National Institute for Health and Care Excellence *Children and Young People with Cancer*; NICE: **2015**.
10. The Royal College of Radiologists Society and College of Radiographers Children's Cancer and Leukaemia Group, Good practice guide for paediatric radiotherapy. Royal College of Radiologists: London, **2012**.
11. Children's Oncology Group, Policy Statement: Personnel and service requirements for member institutions. Children's Oncology Group: **2012**.
12. Stevens, W. B.; van Krieken, J. H.; Mus, R. D.; Arens, A. I.; Mattijssen, V.; Oosterveld, M.; de Kruijff, E. J.; de Vries, F.; Koster, A.; van der Maazen, R.; Raemaekers, J., Centralised multidisciplinary re-evaluation of diagnostic procedures in patients with newly diagnosed Hodgkin lymphoma. *Ann Oncol* **2012**, *23* (10), 2676-81.
13. Howard, S.; Pedrosa, M.; Lins, M.; Pedrosa, A.; Pui, C.; Ribiero, R.; Pedrosa, F., Establishment of a pediatric oncology program and outcomes of childhood leukaemia in a resource-poor area. *Journal of the American Medical Association* **2004**, *291* (20).
14. Bröckelmann, P. J.; Goergen, H.; Fuchs, M.; Kriz, J.; Semrau, R.; Baues, C.; Kobe, C.; Behringer, K.; Eichenauer, D. A.; von Tresckow, B.; Klimm, B.; Halbsguth, T.; Wongso, D.; Plütschow, A.; Haverkamp, H.; Dietlein, M.; Eich, H. T.; Stein, H.; Diehl, V.; Borchmann, P.; Engert, A., Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group. *British Journal of Haematology* **2015**, *171* (4), 547-556.
15. Knops, R. R.; Hulscher, M. E.; Hermens, R. P.; Hilbink-Smolters, M.; Loeffen, J. L.; Kollen, W. J.; Kaspers, G. J.; Caron, H. N.; Kremer, L. C., High-quality care for all children with cancer. *Ann Oncol* **2012**, *23* (7), 1906-11.
16. Baggot, C.; Fochtman, D.; Foley, G. V.; Kelly, K. P., *Nursing care of children and adolescents with cancer and blood disorders*. 4 ed.; Association of Pediatric Hematology/Oncology Nurses: Glenview, **2011**.
17. Cancer Council Australia. Optimal cancer care pathway for people with acute myeloid leukaemia *Optimal cancer care pathway for people with acute myeloid leukaemia* [Online], **2016**. www.cancer.org.au/ocp.
18. Phillips, S. M.; Padgett, L. S.; Leisenring, W. M.; Stratton, K. K.; Bishop, K.; Krull, K. R.; Alfano, C. M.; Gibson, T. M.; de Moor, J. S.; Hartigan, D. B.; Armstrong, G. T.; Robison, L. L.; Rowland, J. H.; Oeffinger, K. C.; Mariotto, A. B., Survivors of childhood cancer in the United States: prevalence and burden of morbidity. *Cancer Epidemiol Biomarkers Prev* **2015**, *24* (4), 653-63.
19. Kinahan, K. E.; Sanford, S.; Sadak, K. T.; Salsman, J. M.; Danner-Koptik, K.; Didwania, A., Models of cancer survivorship care for adolescents and young adults. *Seminars in Oncology Nursing* **2015**, *31* (3), 251-259 9p.
20. McNally, W.; Cruickshank, S., Transition from child to adult services for young people with cancer. *Nursing Children & Young People* **2013**, *25* (1), 14-18.
21. Sung, L.; Zaoutis, T.; Ullrich, N. J.; Johnston, D.; Dupuis, L.; Ladas, E.; Children's Oncology Group Cancer, C.; Supportive Care, C., Children's Oncology Group's 2013 blueprint for research: cancer control and supportive care. *Pediatr Blood Cancer* **2013**, *60* (6), 1027-30.
22. Armenian, S. H.; Landier, W.; Hudson, M. M.; Robison, L. L.; Bhatia, S.; Survivorship, C. O. G.; Outcomes, C., Children's Oncology Group's 2013 blueprint for research: survivorship and outcomes. *Pediatr Blood Cancer* **2013**, *60* (6), 1063-8.
23. Noll, R. B.; Patel, S. K.; Embry, L.; Hardy, K. K.; Pelletier, W.; Annett, R. D.; Patenaude, A.; Lown, E. A.; Sands, S. A.; Barakat, L. P.; Committee, C. O. G. B. S., Children's Oncology Group's 2013 blueprint for research: behavioral science. *Pediatr Blood Cancer* **2013**, *60* (6), 1048-54.
24. Landier, W.; Leonard, M.; Ruccione, K. S., Children's Oncology Group's 2013 blueprint for research: nursing discipline. *Pediatr Blood Cancer* **2013**, *60* (6), 1031-6.
25. Gibbins, J.; Steinhardt, K.; Beinart, H., A systematic review of qualitative studies exploring the experience of parents whose child is diagnosed and treated for cancer. *J Pediatr Oncol Nurs* **2012**, *29* (5), 253-71.
26. Alderfer, M. A.; Long, K. A.; Lown, E. A.; Marsland, A. L.; Ostrowski, N. L.; Hock, J. M.; Ewing, L. J., Psychosocial adjustment of siblings of children with cancer: a systematic review. *Psychooncology* **2010**, *19* (8), 789-805.
27. McCarthy, M. C.; Clarke, N. E.; Vance, A.; Ashley, D. M.; Heath, J. A.; Anderson, V. A., Measuring psychosocial risk in families caring for a child with cancer: the Psychosocial Assessment Tool (PAT2.0). *Pediatr Blood Cancer* **2009**, *53* (1), 78-83.
28. Baggott, C.; Baird, J.; Hinds, P.; Ruland, C. M.; Miaskowski, C., Evaluation of Sisom: A computer-based animated tool to elicit symptoms and psychosocial concerns from children with cancer. *European journal of oncology nursing : the official journal of European Oncology Nursing Society* **2015**, *19* (4), 359-69.
29. Children's Oncology Group. Long-term Follow-up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers **2018**.
30. Jacobs, S.; Baggott, C.; Agarwal, R.; Hesser, T.; Schechter, T.; Judd, P.; Tomlinson, D.; Beyene, J.; Sung, L., Validation of the Children's International Mucositis Evaluation Scale (CHIMES) in paediatric cancer and SCT. *Br J Cancer* **2013**, *109* (10), 2515-22.
31. Murphy, A. J.; White, M.; Viani, K.; Mosby, T. T., Evaluation of the nutrition screening tool for childhood cancer (SCAN). *Clin Nutr* **2016**, *35* (1), 219-24.

32. The Royal Australasian College of Physicians, Routine Adolescent Psychosocial Health Assessment- Position Statement. RACP: Sydney, Australia, **2008**.
33. Loeffen, E. A. H.; Kremer, L. C. M.; Mulder, R. L.; Font-Gonzalez, A.; Dupuis, L. L.; Sung, L.; Robinson, P. D.; van de Wetering, M. D.; Tissing, W. J. E., The importance of evidence-based supportive care practice guidelines in childhood cancer—a plea for their development and implementation. *Supportive Care in Cancer* **2017**, *25* (4), 1121-1125.
34. Paediatric Integrated Cancer Service, *A compendium of evidence and framework for neuropsychological services in paediatric cancer*. Paediatric Integrated Cancer Service: Parkville, Victoria, **2015**.
35. Wiener, L.; Kazak, A. E.; Noll, R. B.; Patenaude, A. F.; Kupst, M. J., Standards for the Psychosocial Care of Children With Cancer and Their Families: An Introduction to the Special Issue. *Pediatr Blood Cancer* **2015**, *62* Suppl 5, S419-24.
36. Brinksma, A.; Huizinga, G.; Sulkers, E.; Kamps, W.; Roodbol, P.; Tissing, W., Malnutrition in childhood cancer patients: a review on its prevalence and possible causes. *Crit Rev Oncol Hematol* **2012**, *83* (2), 249-75.
37. Zhang, F. F.; Parsons, S. K., Obesity in Childhood Cancer Survivors: Call for Early Weight Management. *Adv Nutr* **2015**, *6* (5), 611-9.
38. Green, D. M.; Kawashima, T.; Stovall, M.; Leisenring, W.; Sklar, C. A.; Mertens, A. C.; Donaldson, S. S.; Byrne, J.; Robison, L. L., Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. *J Clin Oncol* **2010**, *28* (2), 332-9.
39. Barton, S. E.; Najita, J. S.; Ginsburg, E. S.; Leisenring, W. M.; Stovall, M.; Weathers, R. E.; Sklar, C. A.; Robison, L. L.; Diller, L., Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. *The Lancet. Oncology* **2013**, *14* (9), 873-81.
40. Sklar, C. A.; Mertens, A. C.; Mitby, P.; Whitton, J.; Stovall, M.; Kasper, C.; Mulder, J.; Green, D.; Nicholson, H. S.; Yasui, Y.; Robison, L. L., Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. *Journal of the National Cancer Institute* **2006**, *98* (13), 890-6.
41. Clinical Oncology Society of Australia, Fertility preservation for AYA's diagnosed with cancer: guidance for health professionals. Cancer Council Australia: Sydney, **2014**.
42. Black, L., Clarke, T., Barnes, P., Stussman, B., Nahin, R., Use of complementary health approaches among children aged 4-17 years in the United States: national health interview survey 2007-2012. US Department of Health and Human Services, Ed. Hyattsville, MD, **2015**; Vol. no. 78.
43. Bishop, F. L.; Prescott, P.; Chan, Y. K.; Saville, J.; von Elm, E.; Lewith, G. T., Prevalence of complementary medicine use in pediatric cancer: a systematic review. *Pediatrics* **2010**, *125* (4), 768-76.
44. Cancer Council Australia Position statement — complementary and alternative therapies. www.cancer.org.au
45. Spector, L. G.; Pankratz, N.; Marcotte, E. L., Genetic and nongenetic risk factors for childhood cancer. *Pediatr Clin North Am* **2015**, *62* (1), 11-25.
46. Saletta, F.; Dalla Pozza, L.; Byrne, J. A., Genetic causes of cancer predisposition in children and adolescents. *Translational Pediatrics; Vol 4, No 2 (April 2015): Translational Pediatrics (Studies on Genetic Diseases for better therapies in Pediatrics)* **2015**.
47. Rahman, N., Realizing the promise of cancer predisposition genes. *Nature* **2014**, *505* (7483), 302-8.
48. Hopman, S. M.; Merks, J. H.; de Borgie, C. A.; Aalfs, C. M.; Biesecker, L. G.; Cole, T.; Eng, C.; Legius, E.; Maher, E. R.; van Noesel, M. M.; Verloes, A.; Viskochil, D. H.; Wagner, A.; Weksberg, R.; Caron, H. N.; Hennekam, R. C., The development of a clinical screening instrument for tumour predisposition syndromes in childhood cancer patients. *Eur J Cancer* **2013**, *49* (15), 3247-54.
49. Hobbie, W. L.; Ogle, S. K.; Reilly, M.; Ginsberg, J. P.; Rourke, M.; Ratcliffe, S.; Deatrick, J. A., Identifying the educational needs of parents at the completion of their child's cancer therapy. *J Pediatr Oncol Nurs* **2010**, *27* (4), 190-195.
50. Hudson, M. M.; Ness, K. K.; Gurney, J. G.; et al., CLinical ascertainment of health outcomes among adults treated for childhood cancer. *Jama* **2013**, *309* (22), 2371-2381.
51. Australian Commission on Safety and Quality in Health Care, National consensus statement: essential elements for safe and high-quality paediatric end-of-life care. ACSQHC: Sydney, **2016**.
52. Victorian Department of Health and Human Services, Thinking ahead framework: Planning care for children with life-limiting conditions. Services, D. o. H. a. H., Ed. Victorian Government: Melbourne, **2016**.
53. Eden, T., Aetiology of childhood leukaemia. *Cancer Treat Rev* **2010**, *36* (4), 286-97.
54. D'Orazio, J. A., Inherited cancer syndromes in children and young adults. *J Pediatr Hematol Oncol* **2010**, *32* (3), 195-228.
55. Pearce, M. S.; Salotti, J. A.; Little, M. P.; McHugh, K.; Lee, C.; Kim, K. P.; Howe, N. L.; Ronckers, C. M.; Rajaraman, P.; Craft, A. W.; Parker, L.; Berrington de González, A., Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. *The Lancet* **2012**, *380* (9840), 499-505.
56. Puumala, S. E.; Ross, J. A.; Aplenc, R.; Spector, L. G., Epidemiology of childhood acute myeloid leukemia. *Pediatr Blood Cancer* **2013**, *60* (5), 728-33.
57. Mathews, J. D.; Forsythe, A. V.; Brady, Z.; Butler, M. W.; Goergen, S. K.; Byrnes, G. B.; Giles, G. G.; Wallace, A. B.; Anderson, P. R.; Guiver, T. A.; McGale, P.; Cain, T. M.; Dowty, J. G.; Bickerstaffe, A. C.; Darby, S. C., Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. *BMJ* **2013**, *346*, f2360.
58. Dommert, R. M.; Redaniel, M. T.; Stevens, M. C.; Hamilton, W.; Martin, R. M., Features of childhood cancer in primary care: a population-based nested case-control study. *Br J Cancer* **2012**, *106* (5), 982-7.
59. Cooper, T., Hasle, H., Smith, F., Acute myeloid leukemia, myeloproliferative and myelodysplastic disorders. In *Principles and Practice of Pediatric Oncology*, 6th ed.; Pizzo, P., Poplack, D., Ed. Lipponcott Williams & Wilkins: Boston, **2011**.
60. Feltbower, R. G.; Lewis, I. J.; Picton, S.; Richards, M.; Glaser, A. W.; Kinsey, S. E.; McKinney, P. A., Diagnosing childhood cancer in primary care—a realistic expectation? *Br J Cancer* **2004**, *90* (10), 1882-4.
61. European Network for Cancer Research in Children and Adolescents, Common guidelines for diagnostic approaches to leukaemias. ENCCA: Kiel, Germany, **2011**.
62. Conter, V.; Bartram, C. R.; Valsecchi, M. G.; Schrauder, A.; Panzer-Grumayer, R.; Moricke, A.; Arico, M.; Zimmermann, M.; Mann, G.; De Rossi, G.; Stanulla, M.; Locatelli, F.; Basso, G.; Niggli, F.; Barisone, E.; Henze, G.; Ludwig, W. D.; Haas, O. A.; Cazzaniga, G.; Koehler, R.; Silvestri, D.; Bradtke, J.; Parasole, R.; Beier, R.; van Dongen, J. J.; Biondi, A.; Schrappe, M., Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. *Blood* **2010**, *115* (16), 3206-14.
63. O'Connor, D.; Moorman, A. V.; Wade, R.; Hancock, J.; Tan, R. M. R.; Bartram, J.; Moppett, J.; Schwab, C.; Patrick, K.; Harrison, C. J.; Hough, R.; Goulden, N.; Vora, A.; Samarasinghe, S., Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology* **2017**, *0* (0), JCO.2016.69.6278.
64. Athale, U. H.; Gibson, P. J.; Bradley, N. M.; Malkin, D. M.; Hitzler, J., Minimal Residual Disease and Childhood Leukemia: Standard of Care Recommendations From the Pediatric Oncology Group of Ontario MRD Working Group. *Pediatr Blood Cancer* **2016**.
65. Lo Nigro, L., Biology of childhood acute lymphoblastic leukemia. *J Pediatr Hematol Oncol* **2013**, *35* (4), 245-52.
66. Eckert, C.; von Stackelberg, A.; Seeger, K.; Groeneveld, T. W.; Peters, C.; Klingebiel, T.; Borkhardt, A.; Schrappe, M.; Escherich, G.; Henze, G., Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia — long-term results of trial ALL-REZ BFM P95/96. *Eur J Cancer* **2013**, *49* (6), 1346-55.
67. Foresto, S. A.; Youlden, D. R.; Baade, P. D.; Hallahan, A. R.; Aitken, J. F.; Moore, A. S., The outcomes and treatment burden of childhood acute myeloid leukaemia in Australia, 1997-2008: A report from the Australian Paediatric Cancer Registry. *Pediatr Blood Cancer* **2015**, *62* (9), 1664-6.
68. Radhi, M.; Meshinchi, S.; Gamis, A., Prognostic factors in pediatric acute myeloid leukemia. *Curr Hematol Malig Rep* **2010**, *5* (4), 200-6.
69. Vrooman, L. M.; Silverman, L. B., Childhood acute lymphoblastic leukemia: update on prognostic factors. *Curr Opin Pediatr* **2009**, *21* (1), 1-8.
70. Hunger, S. P.; Loh, M. L.; Whitlock, J. A.; Winick, N. J.; Carroll, W. L.; Devidas, M.; Raetz, E. A.; Committee, C. O. G. A. L. L., Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. *Pediatr Blood Cancer* **2013**, *60* (6), 957-63.
71. Moore, J. B.; Kordick, M. F., Sources of conflict between families and health care professionals. *J Pediatr Oncol Nurs* **2006**, *23* (2), 82-91.
72. Haugen, M. S.; Landier, W.; Mandrell, B. N.; Sullivan, J.; Schwartz, C.; Skeens, M. A.; Hockenberry, M., Educating Families of Children Newly Diagnosed With Cancer: Insights of a Delphi Panel of Expert Clinicians From the Children's Oncology Group. *J Pediatr Oncol Nurs* **2016**.
73. Goodman, E. K.; Reilly, A. F.; Fisher, B. T.; et al., Association of weekend admission with hospital length of stay, time to chemotherapy, and risk for respiratory failure in pediatric patients with newly diagnosed leukemia at freestanding us children's hospitals. *JAMA pediatrics* **2014**, *168* (10), 925-931.
74. Gamis, A. S.; Alonso, T. A.; Perentesis, J. P.; Meshinchi, S.; Committee, C. O. G. A. M. L., Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemia. *Pediatr Blood Cancer* **2013**, *60* (6), 964-71.
75. Smith, M. A.; Seibel, N. L.; Altekruse, S. F.; Ries, L. A.; Melbert, D. L.; O'Leary, M.; Smith, F. O.; Reaman, G. H., Outcomes for children and adolescents with cancer: challenges for the twenty-first century. *J Clin Oncol* **2010**, *28* (15), 2625-34.
76. Kotecha, R. S.; Gottardo, N. G.; Kees, U. R.; Cole, C. H., The evolution of clinical trials for infant acute lymphoblastic leukemia. *Blood Cancer J* **2014**, *4*, e200.
77. Carroll, W. L.; Hunger, S. P., Therapies on the horizon for childhood acute lymphoblastic leukemia. *Current Opinion in Pediatrics* **2016**, *28* (1), 12-8.
78. Pui, C.-H. M. D.; Campana, D. M. D. P.; Pei, D. M. S.; Bowman, W. P. M. D.; Sandlund, J. T. M. D.; Kaste, S. C. D. O.; Ribeiro, R. C. M. D.; Rubnitz, J. E. M. D. P.; Raimondi, S. C. P.; Onciu, M. M. D.; Coustan-Smith, E. M. S.; Kun, L. E. M. D.; Jeha, S. M. D.; Cheng, C. P.; Howard, S. C. M. D.; Simmons, V. R. N.; Bayles, A. C.; Metzger, M. L. M. D.; Boyett, J. M. P.; Leung, W. M. D. P.; Handgretinger, R. M. D.; Downing, J. R. M. D.; Evans, W. E. P.; Relling, M. V. P., Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation. *The New England Journal of Medicine* **2009**, *360* (26), 2730-41.
79. Vora, A.; Andreano, A.; Pui, C. H.; Hunger, S. P.; Schrappe, M.; Moericke, A.; Biondi, A.; Escherich, G.; Silverman, L. B.; Goulden, N.; Taskinen, M.; Pieters, R.; Horibe, K.; Devidas, M.; Locatelli, F.; Valsecchi, M. G., Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy. *Journal of Clinical Oncology* **2016**, *34* (9), 919-26.
80. Fletcher, M.; Hodgkiss, H.; Zhang, S.; Browning, R.; Hadden, C.; Hoffman, T.; Winick, N.; McCavit, T. L., Prompt administration of antibiotics is associated with improved outcomes in febrile neutropenia in children with cancer. *Pediatr Blood Cancer* **2013**, *60* (8), 1299-306.
81. Salstrom, J. L.; Coughlin, R. L.; Pool, K.; Bojan, M.; Mediavilla, C.; Schwent, W.; Rannie, M.; Law, D.; Finnerty, M.; Hilden, J., Pediatric patients who receive antibiotics for fever and neutropenia in less than 60 min have decreased intensive care needs. *Pediatr Blood Cancer* **2015**, *62* (5), 807-15.
82. Whitlock, J. A., Down syndrome and acute lymphoblastic leukaemia. *British Journal of Haematology* **2006**, *135* (5), 595-602.
83. Inaba, H.; Greaves, M.; Mullighan, C. G., Acute lymphoblastic leukaemia. *The Lancet* **2013**, *381* (9881), 1943-1955.
84. Walsh, K. E.; Dodd, K. S.; Seetharaman, K.; Roblin, D. W.; Herrinton, L. J.; Von Worley, A.; Naheed Usmani, G.; Baer, D.; Gurwitz, J. H., Medication errors among adults and children with cancer in the outpatient setting. *Journal of Clinical Oncology* **2009**, *27* (6), 891-896.
85. Walsh, K. E.; Roblin, D. W.; Weingart, S. N.; Houlihan, K. E.; Degar, B.; Billett, A.; Keuker, C.; Biggins, C.; Li, J.; Wasilewski, K.; Mazor, K. M., Medication errors in the home: a multisite study of children with cancer. *Pediatrics* **2013**, *131* (5), e1405-14.
86. Landier, W.; Hageman, L.; Chen, Y.; Kornegay, N.; Evans, W. E.; Bostrom, B. C.; Casillas, J.; Dickens, D. S.; Angiolillo, A. L.; Lew, G.; Maloney, K. W.; Mascarenhas, L.; Ritchey, A. K.; Termuhlen, A. M.; Carroll, W. L.; Relling, M. V.; Wong, F. L.; Bhatia, S., Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1. *Journal of Clinical Oncology* **2017**.
87. Essig, S.; Li, Q.; Chen, Y.; Hitzler, J.; Leisenring, W.; Greenberg, M.; Sklar, C.; Hudson, M. M.; Armstrong, G. T.; Krull, K. R.; Neglia, J. P.; Oeffinger, K. C.; Robison, L. L.; Kuehni, C. E.; Yasui, Y.; Nathan, P. C., Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort. *The Lancet Oncology* **2014**, *15* (8), 841-851.
88. Locatelli, F.; Moretta, F.; Rutella, S., Management of relapsed acute lymphoblastic leukemia in childhood with conventional and innovative approaches. *Curr Opin Oncol* **2013**, *25* (6), 707-15.

89. Reismuller, B.; Peters, C.; Dworzak, M. N.; Potschger, U.; Urban, C.; Meister, B.; Schmitt, K.; Dieckmann, K.; Gadner, H.; Attarbaschi, A.; Mann, G.; Austrian, A. L. L. B. F. M. S. G., Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Munster) study group. *J Pediatr Hematol Oncol* **2013**, *35* (5), e200-4.
90. de Rooij, J. D.; Zwaan, C. M.; van den Heuvel-Eibrink, M., Pediatric AML: From Biology to Clinical Management. *J Clin Med* **2015**, *4* (1), 127-49.
91. Maude, S. L.; Frey, N.; Shaw, P. A.; Aplenc, R.; Barrett, D. M.; Bunin, N. J.; Chew, A.; Gonzalez, V. E.; Zheng, Z.; Lacey, S. F.; Mahnke, Y. D.; Melenhorst, J. J.; Rheingold, S. R.; Shen, A.; Teachey, D. T.; Levine, B. L.; June, C. H.; Porter, D. L.; Grupp, S. A., Chimeric antigen receptor T cells for sustained remissions in leukemia. *N Engl J Med* **2014**, *371* (16), 1507-17.
92. Smith, M. A.; Reaman, G. H., Remaining challenges in childhood cancer and newer targeted therapeutics. *Pediatr Clin North Am* **2015**, *62* (1), 301-12.
93. Louis, D. N.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, W. K.; Ohgaki, H.; Wiestler, O. D.; Kleihues, P.; Ellison, D. W., The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta neuropathologica* **2016**, *131* (6), 803-820.
94. Chhabda, S.; Carney, O.; D'Arco, F.; Jacques, T. S.; Mankad, K., The 2016 World Health Organization Classification of tumours of the Central Nervous System: what the paediatric neuroradiologist needs to know. *Quantitative imaging in medicine and surgery* **2016**, *6* (5), 486-489.
95. Chan, V.; Pole, J. D.; Mann, R. E.; Colantonio, A., A population based perspective on children and youth with brain tumours. *BMC Cancer* **2015**, *15*, 1-9.
96. Ostrom, Q. T.; Gittleman, H.; Xu, J.; Kromer, C.; Wolinsky, Y.; Kruchko, C.; Barnholtz-Sloan, J. S., CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013. *Neuro-Oncology* **2016**, *18* (suppl_5), v1-v75.
97. Postema, F. A. M.; Hopman, S. M. J.; Hennekam, R. C.; Merks, J. H. M., Consequences of diagnosing a tumor predisposition syndrome in children with cancer: A literature review. *Pediatr Blood Cancer* **2018**, *65* (1), e26718-n/a.
98. Johnson, K. J.; Cullen, J.; Barnholtz-Sloan, J. S.; Ostrom, Q. T.; Langer, C. E.; Turner, M. C.; McKean-Cowdin, R.; Fisher, J. L.; Lupo, P. J.; Partap, S.; Schwartzbaum, J. A.; Scheurer, M. E., Childhood Brain Tumor Epidemiology: A Brain Tumor Epidemiology Consortium Review. *Cancer Epidemiology Biomarkers and Prevention* **2014**, *23* (12), 2716-2736.
99. Parsons, W. D.; Ploak, I. F.; Hass-Kogan, D. A.; Poussaint, T. Y.; Adensina, A. M. & Chintagumpala, M. M., Gliomas, ependymomas and other nonembryonal tumors of the central nervous system. In *Principles and Practice of Pediatric Oncology*, 7 ed., Pizzo, P. A.; Poplack, D. G., Eds. Wolters Kluwer: Philadelphia, Pa., **2016**.
100. Braganza, M. Z.; Kitahara, C. M.; Berrington de Gonzalez, A.; Inskip, P. D.; Johnson, K. J.; Rajaraman, P., Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. *Neuro-Oncology* **2012**, *14* (11), 1316-24.
101. American Cancer Society About brain and spinal cord tumours in children. <https://www.cancer.org/cancer/brain-spinal-cord-tumors-children.html> (accessed 24.03.2017).
102. Chu, T. P.; Shah, A.; Walker, D.; Coleman, M. P., Pattern of symptoms and signs of primary intracranial tumours in children and young adults: a record linkage study. *Arch Dis Child* **2015**, *100* (12), 1115-22.
103. Rogers, E. K.; Cannon, A.; Zaborowski, K.; Paul, S. P., Early recognition and management of brain tumours in children. *Nursing standard (Royal College of Nursing (Great Britain) : 1987)* **2016**, *31* (1), 42-9.
104. Wilne, S.; Koller, K.; Collier, J.; Kennedy, C.; Grundy, R.; Walker, D., The diagnosis of brain tumours in children: a guideline to assist healthcare professionals in the assessment of children who may have a brain tumour. *Archives of Disease in Childhood* **2010**, *95* (7), 534-539 6p.
105. Fukuoka, K.; Yanagisawa, T.; Suzuki, T.; Shirahata, M.; Adachi, J.; Mishima, K.; Fujimaki, T.; Matsutani, M.; Nishikawa, R., Duration between onset and diagnosis in central nervous system tumors: impact on prognosis and functional outcome. *Pediatrics international : official journal of the Japan Pediatric Society* **2014**, *56* (6), 829-33.
106. Walker, D., A new clinical guideline from the Royal College of Paediatrics and Child Health with a national awareness campaign accelerates brain tumor diagnosis in UK children--"HeadSmart: Be Brain Tumour Aware". *Neuro-Oncology* **2016**, *18* (3), 445-454.
107. Arnautovic, A.; Billups, C.; Broniscer, A.; Gajjar, A.; Boop, F.; Qaddoumi, I., Delayed diagnosis of childhood low-grade glioma: causes, consequences, and potential solutions. *Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery* **2015**, *31* (7), 1067-77.
108. Children's Brain Tumour Research Centre, The brain pathways guideline: a guideline to assist healthcare professionals in the assessment of children who may have a brain tumour. Childrens Brain Tumour Research Centre: **2016**.
109. Brain Tumour Charity Headsmart: early diagnosis of brain tumours. www.headsmart.org.uk (accessed 23.06.2017).
110. Crawford, J., Childhood brain tumors. *Pediatrics in review* **2013**, *34* (2), 63-78.
111. Fischer, C.; Petriccione, M.; Donzelli, M.; Pottenger, E., Improving Care in Pediatric Neuro-oncology Patients: An Overview of the Unique Needs of Children With Brain Tumors. *J Child Neurol* **2016**, *31* (4), 488-505.
112. Pollack, I. F.; Jakacki, R. I., Childhood brain tumors: epidemiology, current management and future directions. *Nature reviews. Neurology* **2011**, *7* (9), 495-506.
113. Mack, S. C., Northcott, P. A., Genomic Analysis of Childhood Brain Tumors: Methods for Genome-Wide Discovery and Precision Medicine Become Mainstream. *Journal of Clinical Oncology* **2017**, *35*, 1-10.
114. Bavle, A. A.; Lin, F. Y.; Parsons, D. W., Applications of Genomic Sequencing in Pediatric CNS Tumors. *Oncology (Williston Park, N.Y.)* **2016**, *30* (5), 411-23.
115. Kline, C. N.; Joseph, N. M.; Grenert, J. P.; van Ziffle, J.; Talevich, E.; Onodera, C.; Aboian, M.; Cha, S.; Raleigh, D. R.; Braunstein, S.; Torkildson, J.; Samuel, D.; Bloomer, M.; Campomanes, A. G.; Banerjee, A.; Butowski, N.; Raffel, C.; Tihan, T.; Bollen, A. W.; Phillips, J. J.; Korn, W. M.; Yeh, I.; Bastian, B. C.; Gupta, N.; Mueller, S.; Perry, A.; Nicolaidis, T.; Solomon, D. A., Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. *Neuro Oncology* **2016**, *14*, 14.
116. Ostrom, Q., Devine, K., Fulop, J., Wolinsky, Y., Liao, P., Stetson, L., Couce, M., Sloan, A. & Barnholtz-Sloan, J., Brain tumor biobanking in the precision medicine era: building a high-quality resource for translational research in neuro-oncology. *Neurooncology Practice* **2016**.
117. Juan Ribelles, A.; Berlanga, P.; Schreier, G.; Nitzlader, M.; Brunmair, B.; Castel, V.; Essiaf, S.; Canete, A.; Ladenstein, R., Survey on paediatric tumour boards in Europe: current situation and results from the ExPo-r-Net project. *Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico* **2018**.
118. Pillay, B.; Wooten, A. C.; Crowe, H.; Corcoran, N.; Tran, B.; Bowden, P.; Crowe, J.; Costello, A. J., The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. *Cancer Treat Rev* **2016**, *42*, 56-72.
119. Soukup, T.; Lamb, B. W.; Arora, S.; Darzi, A.; Sevdalis, N.; Green, J. S., Successful strategies in implementing a multidisciplinary team working in the care of patients with cancer: an overview and synthesis of the available literature. *J Multidiscip Healthc* **2018**, *11*, 49-61.
120. Aslan, I. R.; Cheung, C. C., Early and late endocrine effects in pediatric central nervous system diseases. *Journal of pediatric rehabilitation medicine* **2014**, *7* (4), 281-94.
121. Gurney, J. G.; Kadan-Lottick, N. S.; Packer, R. J.; Neglia, J. P.; Sklar, C. A.; Punyko, J. A.; Stovall, M.; Yasui, Y.; Nicholson, H. S.; Wolden, S.; McNeil, D. E.; Mertens, A. C.; Robison, L. L., Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors. *Cancer* **2003**, *97* (3), 663-673.
122. Tonning Olsson, I.; Perrin, S.; Lundgren, J.; Hjorth, L.; Johanson, A., Long-term cognitive sequelae after pediatric brain tumor related to medical risk factors, age, and sex. *Pediatric neurology* **2014**, *51* (4), 515-21.
123. Annett, R. D.; Patel, S. K.; Phipps, S., Monitoring and Assessment of Neuropsychological Outcomes as a Standard of Care in Pediatric Oncology. *Pediatr Blood Cancer* **2015**, *62* Suppl 5, S460-513.
124. Gajjar, A.; Packer, R. J.; Foreman, N. K.; Cohen, K.; Haas-Kogan, D.; Merchant, T. E., Children's Oncology Group's 2013 blueprint for research: central nervous system tumors. *Pediatr Blood Cancer* **2013**, *60* (6), 1022-6.
125. Sturm, D.; Pfister, S. M.; Jones, D. T. W., Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management. *Journal of Clinical Oncology* **2017**, *35* (21), JCO.2017.73.0242.
126. Pappo, A.; Furman, W.; Schultz, K.; Ferrari, A.; Helman, L.; Krailo, M., Rare Tumors in Children: Progress Through Collaboration. *Journal of Clinical Oncology* **2015**, *33* (27), 3047-3054.
127. Smith, E. R.; Butler, W. E.; Barker, F. G., Craniotomy for Resection of Pediatric Brain Tumors in the United States, 1988 to 2000: Effects of Provider Caseloads and Progressive Centralization and Specialization of Care. *Neurosurgery* **2004**, *54* (3), 553-565.
128. Knops, R. R.; van Dalen, E. C.; Mulder, R. L.; Leclercq, E.; Knijnenburg, S. L.; Kaspers, G. J.; Pieters, R.; Caron, H. N.; Kremer, L. C., The volume effect in paediatric oncology: a systematic review. *Ann Oncol* **2013**, *24* (7), 1749-53.
129. Albright, A. L. M. D.; Sposto, R. P. D.; Holmes, E. M. S.; Zeltzer, P. M. M. D.; Finlay, J. L. M. D.; Wisoff, J. H. M. D.; Berger, M. S. M. D.; Packer, R. J. M. D.; Pollack, I. F. M. D., Correlation of Neurosurgical Subspecialization with Outcomes in Children with Malignant Brain Tumors. *Neurosurgery* **2000**, *47* (4), 879-887.
130. Chumas, P.; Kenny, T.; Stiller, C., Subspecialisation in neurosurgery—does size matter? *Acta Neurochirurgica* **2011**, *153* (6), 1231-1236.
131. Solheim, O.; Salvesen, O.; Cappelen, J.; Johannesen, T. B., The impact of provider surgical volumes on survival in children with primary tumors of the central nervous system—a population-based study. *Acta Neurochir (Wien)* **2011**, *153* (6), 1219-29; discussion 1229.
132. Solheim, O.; Cappelen, J., Bigger is bigger. Better is better. *Acta Neurochir (Wien)* **2011**, *153* (6), 1237-43; author reply 1245.
133. Young, A. E., Designing a safe and sustainable pediatric neurosurgical practice: the English experience. *Paediatric Anaesthesia* **2014**, *24* (7), 649-656.
134. Coppola, A.; Tramontano, V.; Basaldella, F.; Arcaro, C.; Squintani, G.; Sala, F., Intra-operative neurophysiological mapping and monitoring during brain tumour surgery in children: an update. **2016**, *32* (10), 1849-59.
135. McClain, C. D.; Soriano, S. G., Anesthesia for intracranial surgery in infants and children. *Current opinion in anaesthesiology* **2014**, *27* (5), 465-9.
136. NHS England, 2013/14 NHS Standard Contract for Paediatric Neurosciences: Neurosurgery. National Health Service.: **2013**.
137. Zebian, B.; Vergani, F.; Lavrador, J. P.; Mukherjee, S.; Kitchen, W. J.; Stagno, V.; Chamilos, C.; Pettorini, B.; Mallucci, C., Recent technological advances in pediatric brain tumor surgery. *CNS oncology* **2017**, *6* (1), 71-82.
138. Balogun, J. A.; Khan, O. H.; Taylor, M.; Dirks, P.; Der, T.; Carter Snead Iii, O.; Weiss, S.; Ochi, A.; Drake, J.; Rutka, J. T., Pediatric awake craniotomy and intra-operative stimulation mapping. *Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia* **2014**, *21* (11), 1891-4.
139. Bindra, R. S.; Wolden, S. L., Advances in Radiation Therapy in Pediatric Neuro-oncology. *Journal of child neurology* **2016**, *31* (4), 506-16.
140. Combs, S. E., Does Proton Therapy Have a Future in CNS Tumors? *Current treatment options in neurology* **2017**, *19* (3), 12.
141. Verma, V.; Mishra, M. V.; Mehta, M. P., A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. *Cancer* **2016**, *122* (10), 1483-501.
142. Leroy, R.; Benahmed, N.; Hulstaert, F.; Van Damme, N.; De Ruyscher, D., Proton Therapy in Children: A Systematic Review of Clinical Effectiveness in 15 Pediatric Cancers. *International Journal of Radiation Oncology, Biology, Physics* **2016**, *95* (1), 267-78.
143. Mizumoto, M.; Oshiro, Y.; Yamamoto, T.; Kohzaki, H.; Sakurai, H., Proton Beam Therapy for Pediatric Brain Tumor. *Neurologia medico-chirurgica* **2017**, *57* (7), 343-355.
144. Thorp, N. J.; Taylor, R. E., Management of central nervous system tumours in children. *Clinical Oncology* **2014**, *26* (7), 438-45.
145. Vitanza, N. A.; Cho, Y. J., Advances in the biology and treatment of pediatric central nervous system tumors. *Curr Opin Pediatr* **2016**, *28* (1), 34-9.
146. Zaky, W., Revisiting Management of Pediatric Brain Tumors with New Molecular Insights. *Cell* **2016**, *164* (5), 844-6.
147. Fountain, D. M.; Burke, G. A., Multidisciplinary rehabilitation for children with brain tumors: A systematic review. *Developmental neurorehabilitation* **2017**, *20* (2), 68-75.
148. Adcock, F.; Burke, G. A., Children with brain tumours: a critical reflection on a specialist coordinated assessment. *British Journal of Occupational Therapy* **2014**, *77* (8), 429-433.
149. Packer, R. J.; Gurney, J. G.; Punyko, J. A.; Donaldson, S. S.; Inskip, P. D.; Stovall, M.; Yasui, Y.; Mertens, A. C.; Sklar, C. A.; Nicholson, H. S.; Zeltzer, L. K.; Neglia, J. P.; Robison, L. L., Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study. *Journal of clinical oncology : Official journal of the American Society of Clinical Oncology* **2003**, *21* (17), 3255-61.

150. King, A. A.; Seidel, K.; Di, C.; Leisenring, W. M.; Perkins, S. M.; Krull, K. R.; Sklar, C. A.; Green, D. M.; Armstrong, G. T.; Zeltzer, L. K.; Wells, E.; Stovall, M.; Ullrich, N. J.; Oeffinger, K. C.; Robison, L. L.; Packer, R. J., Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study. *Neuro Oncol* **2017**, *19* (5), 689-698.
151. Hirpara, D. H., Bhatt, M. D. & Katrin, S., Utility of Long-Term Surveillance Neuroimaging Five Years Post-Diagnosis in the Management of Pediatric Brain Tumours. *Austin Pediatric Oncology* **2016**, *1* (1), 1-4.
152. Kaste, S. C., Oncological imaging: tumor surveillance in children. *Pediatric radiology* **2011**, *41* (02), 505-508.
153. Reaman, G. H., What, why, and when we image: considerations for diagnostic imaging and clinical research in the Children's Oncology Group. *Pediatric radiology* **2009**, *39* (1), 42-45.
154. Main, C.; Stevens, S. P.; Bailey, S.; Phillips, R.; Pizer, B.; Wheatley, K.; Kearns, P. R.; English, M.; Wilne, S.; Wilson, J. S., The impact of routine surveillance screening with magnetic resonance imaging (MRI) to detect tumour recurrence in children with central nervous system (CNS) tumours: protocol for a systematic review and meta-analysis. *Systematic Reviews* **2016**, *5* (1), 143-143.
155. Schulte, F.; Russell, K. B.; Cullen, P.; Embry, L.; Fay-McClymont, T.; Johnston, D.; Rosenberg, A. R.; Sung, L., Systematic review and meta-analysis of health-related quality of life in pediatric CNS tumor survivors. *Pediatr Blood Cancer* **2017**.
156. Barrera, M.; Atenafu, E. G.; Schulte, F.; Bartels, U.; Sung, L.; Janzen, L.; Chung, J.; Cataudella, D.; Hancock, K.; Saleh, A.; Strother, D.; McConnell, D.; Downie, A.; Hukin, J.; Zelcer, S., Determinants of quality of life outcomes for survivors of pediatric brain tumors. *Pediatr Blood Cancer* **2017**, *64* (9), e26481-n/a.
157. de Ruiter, M. A.; van Mourik, R.; Schouten-van Meeteren, A. Y.; Grootenhuys, M. A.; Oosterlaan, J., Neurocognitive consequences of a paediatric brain tumour and its treatment: a meta-analysis. *Developmental medicine and child neurology* **2013**, *55* (5), 408-17.
158. Robinson, K. E.; Kuttesch, J. F.; Champion, J. E.; Andreotti, C. F.; Hipp, D. W.; Bettis, A.; Barnwell, A.; Compas, B. E., A quantitative meta-analysis of neurocognitive sequelae in survivors of pediatric brain tumors. *Pediatr Blood Cancer* **2010**, *55* (3), 525-531.
159. Tallen, G.; Resch, A.; Calaminus, G.; Wiener, A.; Leiss, U.; Pletschko, T.; Friedrich, C.; Langer, T.; Grabow, D.; Driever, P. H.; Kortmann, R. D.; Timmermann, B.; Pietsch, T.; Warmuth-Metz, M.; Bison, B.; Thomale, U. W.; Krauss, J.; Mynarek, M.; von Hoff, K.; Ottensmeier, H.; Fruhwald, M.; Kramm, C. M.; Temming, P.; Muller, H. L.; Witt, O.; Kordes, U.; Fleischhack, G.; Gnekow, A.; Rutkowski, S., Strategies to improve the quality of survival for childhood brain tumour survivors. *European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society* **2015**, *19* (6), 619-39.
160. Eshelman-Kent, D.; Gilger, E.; Gallagher, M., Transitioning survivors of central nervous system tumors: challenges for patients, families, and health care providers. *J Pediatr Oncol Nurs* **2009**, *26* (5), 280-94.
161. Rothstein, D. H.; Li, V., Transitional care in pediatric neurosurgical patients. *Seminars in pediatric surgery* **2015**, *24* (2), 79-82.
162. ReKate, H. L., The Pediatric Neurosurgical Patient: The Challenge of Growing Up. *Seminars in Pediatric Neurology* **2009**, *16* (1), 2-8.
163. Cage, T. A.; Mueller, S.; Haas-Kogan, D.; Gupta, N., High-grade gliomas in children. *Neurosurgery clinics of North America* **2012**, *23* (3), 515-23.
164. Zacharoulis, S.; Ashley, S.; Moreno, L.; Gentet, J. C.; Massimino, M.; Frappaz, D., Treatment and outcome of children with relapsed ependymoma: a multi-institutional retrospective analysis. *Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery* **2010**, *26* (7), 905-11.
165. Gibson, F.; Soanes, L., *Cancer in Children and Young People*. John Wiley & Sons, Incorporated: New York, **2008**.
166. Armstrong, G. T.; Liu, Q.; Yasui, Y.; Huang, S.; Ness, K. K.; Leisenring, W.; Hudson, M. M.; Donaldson, S. S.; King, A. A.; Stovall, M.; Krull, K. R.; Robison, L. L.; Packer, R. J., Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. *J Natl Cancer Inst* **2009**, *101* (13), 946-58.
167. The Royal Children's Hospital Melbourne, Thinking ahead framework: planning care for children with life-limiting conditions. Department of Health and Human Services, Ed. State of Victoria: Melbourne, **2016**.
168. The Royal Children's Hospital Melbourne, Thinking ahead policy: planning care for children with life-limiting conditions. Department of Health and Human Resources, Ed. State of Victoria: Melbourne, **2016**.
169. The Royal Children's Hospital Melbourne, Thinking ahead discussion guide: planning care for children with life-limiting conditions. Resources, D. o. h. a. H., Ed. State of Victoria: Melbourne, **2016**.
170. Kuhlen, M.; Hoell, J.; Balzer, S.; Borkhardt, A.; Janssen, G., Symptoms and management of pediatric patients with incurable brain tumors in palliative home care. *European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society* **2016**, *20* (2), 261-9.
171. Vallerio, S. G.; Lijoi, S.; Bertin, D.; Pittana, L. S.; Bellini, S.; Rossi, F.; Peretta, P.; Basso, M. E.; Fagioli, F., End-of-life care in pediatric neuro-oncology. *Pediatr Blood Cancer* **2014**, *61* (11), 2004-11.
172. Zelcer, S.; Cataudella, D.; Cairney, A. L.; Bannister, S. L., Palliative care of children with brain tumors: A parental perspective. *Archives of Pediatrics & Adolescent Medicine* **2010**, *164* (3), 225-230.
173. Alabran, J. L.; Hooper, J. E.; Hill, M.; Smith, S. E.; Spady, K. K.; Davis, L. E.; Peterson, L. S.; Malempati, S.; Ryan, C. W.; Acosta, R.; Spunt, S. L.; Keller, C., Overcoming autopsy barriers in pediatric cancer research. *Pediatr Blood Cancer* **2013**, *60* (2), 204-209.
174. Baker, J. N.; Windham, J. A.; Hinds, P. S.; Gattuso, J. S.; Mandrell, B.; Gajjar, P.; West, N. K.; Hammarback, T.; Broniscer, A.; Bereaved parents' intentions and suggestions about research autopsies in children with lethal brain tumors. *J Pediatr* **2013**, *163* (2), 581-6.
175. Giordano, M.; Arraez, C.; Samii, A.; Samii, M.; Di Rocco, C., Neurosurgical tools to extend tumor resection in pediatric hemispheric low-grade gliomas: iMRI. *Child's Nervous System* **2016**, *32* (10), 1915-1922.
176. Giordano, M.; Samii, A.; Lawson McLean, A. C.; Bertalanffy, H.; Fahlbusch, R.; Samii, M.; Di Rocco, C., Intraoperative magnetic resonance imaging in pediatric neurosurgery: safety and utility. *Journal of Neurosurgery. Pediatrics* **2017**, *19* (1), 77-84.
177. Jenkinson, M. D.; Barone, D. G.; Bryant, A.; Vale, L.; Bulbeck, H.; Lawrie, T. A.; Hart, M. G.; Watts, C., Intraoperative imaging technology to maximise extent of resection for glioma. *Cochrane Database of Systematic Reviews* **2018**, January (1).
178. Swinney, C.; Li, A.; Bhatti, I.; Veeravagu, A., Optimization of tumor resection with intra-operative magnetic resonance imaging. *Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia* **2016**, *34*, 11-14.
179. Brindle, K. M.; Izquierdo-García, J. L.; Lewis, D. Y.; Mair, R. J.; Wright, A. J., Brain Tumor Imaging. *Journal of Clinical Oncology* **2017**, *35*.
180. Australian Childhood Cancer Registry and Cancer Council Queensland Australian Childhood Cancer Statistics Online. (Based on data from ACCR (1983–2014). CCQ Brisbane Australia **2018**. <https://cancerqld.org.au/research/queensland-cancer-statistics/accr/>.
181. Steliarova-Foucher, E.; Stiller, C.; Lacour, B.; Kaatsch, P., International Classification of Childhood Cancer, third edition. *Cancer* **2005**, *103* (7), 1457-67.
182. Aitken, J. F.; Youlden, D. R.; Moore, A. S.; Baade, P. D.; Ward, L. J.; Thursfield, V. J.; Valery, P. C.; Green, A. C.; Gupta, S.; Frazier, A. L., Assessing the feasibility and validity of the Toronto Childhood Cancer Stage Guidelines: a population-based registry study. *The Lancet Child & Adolescent Health* **2018**, *2* (3), 173-9.
183. Gupta, S.; Aitken, J. F.; Bartels, U.; Brierley, J.; Dolendo, M.; Friedrich, P.; Fuentes-Alabi, S.; Garrido, C. P.; Gatta, G.; Gospodarowicz, M.; Gross, T.; Howard, S. C.; Molyneux, E.; Moreno, F.; Pole, J. D.; Pritchard-Jones, K.; Ramirez, O.; Ries, L. A. G.; Rodriguez-Galindo, C.; Shin, H. Y.; Steliarova-Foucher, E.; Sung, L.; Supriyadi, E.; Swaminathan, R.; Torode, J.; Vora, T.; Kutluk, T.; Frazier, A. L., Paediatric cancer stage in population-based cancer registries: the Toronto consensus principles and guidelines. *The Lancet Oncology* **2016**, *17* (4), e163-e172.
184. Zhang, J.; Walsh, M. F.; Wu, G.; Edmonson, M. N.; Gruber, T. A.; Easton, J.; Hedges, D.; Ma, X.; Zhou, X.; Yergeau, D. A.; Wilkinson, M. R.; Vadodaria, B.; Chen, X.; McGee, R. B.; Hines-Dowell, S.; Nuccio, R.; Quinn, E.; Shurtleff, S. A.; Rusch, M.; Patel, A.; Becksfors, J. B.; Wang, S.; Weaver, M. S.; Ding, L.; Mardis, E. R.; Wilson, R. K.; Gajjar, A.; Ellison, D. W.; Pappo, A. S.; Pui, C.-H.; Nichols, K. E.; Downing, J. R., Germline mutations in predisposition genes in pediatric cancer. *New England Journal of Medicine* **2015**, *373* (24), 2336-46.
185. Plon, S. E.; Malkin, D., Childhood cancer and heredity. In: *Principles and practice of pediatric oncology*, Pizzo, P. A. P.; Poplack, D. G., Eds. Lippincott Williams & Wilkins: Philadelphia, PA, **2016**.
186. Gorlick, R.; Janeway, K.; Marina, N., Osteosarcoma. In: *Principles and practice of pediatric oncology*, 6th ed.; Pizzo, P. A.; Poplack, D. G., Eds. Lippincott Williams & Wilkins: Philadelphia, PA, **2016**.
187. Spector, L. G.; Pankratz, N.; Marcotte, E. L., Genetic and nongenetic risk factors for childhood cancer. *Pediatric Clinics of North America* **2015**, *62* (1), 11-25.
188. Australian Childhood Cancer Registry and Cancer Council Queensland Australian Childhood Cancer Statistics Online: Based on data from the ACCR (1983–2014). CCQ Brisbane Australia **2018**. <https://cancerqld.org.au/research/queensland-cancer-statistics/accr/>.
189. Jo, V. Y.; Doyle, L. A., Refinements in sarcoma classification in the current 2013 World Health Organization classification of tumours of soft tissue and bone. *Surgical Oncology Clinics of North America* **2016**, *25* (4), 621-43.
190. Thenappan, A.; Halaweish, I.; Mody, R. J.; Smith, E. A.; Geiger, J. D.; Ehrlich, P. F.; Jasty Rao, R.; Hutchinson, R.; Yanik, G.; Rabah, R. M.; Heider, A.; Stoll, T.; Newman, E. A., Review at a multidisciplinary tumour board impacts critical management decisions of pediatric patients with cancer. *Pediatric Blood & Cancer* **2017**, *64* (2), 254-8.
191. Iniesta, R. R.; Paciarotti, I.; Brougham, M. F.; McKenzie, J. M.; Wilson, D. C., Effects of pediatric cancer and its treatment on nutritional status: a systematic review. *Nutrition Reviews* **2015**, *73* (5), 276-95.
192. Ladas, E. J.; Rogers, P. C., Nutrition. In: *Supportive care in pediatric oncology: a practical evidence-based approach*, Fuesner, J. H.; Agrawal, A. K.; Hastings, C. A.; Eds. Springer: Berlin, **2015**.
193. Long, C. J.; Ginsberg, J. P.; Kolon, T. F., Fertility preservation in children and adolescents with cancer. *Urology* **2016**, *91*, 190-6.
194. Rodgers, C. C.; Laing, C. M.; Herring, R. A.; Tena, N.; Leonardelli, A.; Hockenberry, M.; Hendricks-Ferguson, V., Understanding effective delivery of patient and family education in pediatric oncology: a systematic review from the Children's Oncology Group. *Journal of Pediatric Oncology Nursing* **2016**, *33* (6), 432-46.
195. Rodgers, C. C.; Stegenga, K.; Withycombe, J. S.; Sachse, K.; Kelly, K. P., Processing information after a child's cancer diagnosis—how parents learn: a report from the Children's Oncology Group. *Journal of Pediatric Oncology Nursing* **2016**, *33* (6), 447-59.
196. Rossig, C.; Juergens, H.; Schrappe, M.; Moericke, A.; Henze, G.; von Stackelberg, A.; Reinhardt, D.; Burkhardt, B.; Woessmann, W.; Zimmermann, M.; Gadner, H.; Mann, G.; Schellong, G.; Mauz-Koerholz, C.; Dirksen, U.; Bielack, S.; Berthold, F.; Graf, N.; Rutkowski, S.; Calaminus, G.; Kaatsch, P.; Creutzig, U., Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria. *Pediatric Blood & Cancer* **2013**, *60* (10), 1574-81.
197. Zhou, L.; Nath, N.; Markovich, O.; Yuksel, A.; Roberts, A.; Catchpoole, D., The tumour bank of the Children's Hospital at Westmead. *Biopreservation and Biobanking* **2015**, *13* (2), 147-8.
198. Rush, A.; Spring, K.; Byrne, J. A., A critical analysis of cancer biobank practices in relation to biospecimen quality. *Biophysical Reviews* **2015**, *7* (4), 369-78.
199. Weldon, C. B.; Hamilton, T. E.; Shamberger, R. C., General principles of surgery. In: *Principles and practice of pediatric oncology*, 6th ed.; Pizzo, P. A., Poplack, D. G., Eds. Lippincott, Williams and Wilkins: Philadelphia, PA, **2016**.
200. Dasgupta, R.; Billmire, D.; Aldrink, J. H.; Meyers, R. L., What is new in pediatric surgical oncology? *Current Opinion in Pediatrics* **2017**, *29* (1), 3-11.
201. Ezekian, B.; Englum, B. R.; Gulack, B. C.; Rialon, K. L.; Kim, J.; Talbot, L. J.; Adibe, O. O.; Routh, J. C.; Tracy, E. T.; Rice, H. E., Comparing oncologic outcomes after minimally invasive and open surgery for pediatric neuroblastoma and Wilms tumour. *Pediatric Blood & Cancer* **2018**, *65* (1).
202. Bouty, A.; Burnand, K.; Nightingale, M.; Roberts, A.; Campbell, M.; O'Brien, M.; Heloury, Y., What is the risk of local recurrence after laparoscopic transperitoneal radical nephrectomy in children with Wilms tumours? Analysis of a local series and review of the literature. *Journal of Pediatric Urology* **2018**, *14* (4), 327.e1-327.e7.
203. Eriksen, K. O.; Johal, N. S.; Mushtaq, I., Minimally invasive surgery in management of renal tumours in children. *Translational Pediatrics* **2016**, *5* (4), 305-14.
204. van Dalen, E. C.; de Lijster, M. S.; Leijssen, L. G. J.; Michiels, E. M. C.; Kremer, L. C. M.; Caron, H. N.; Aronson, D. C., Minimally invasive surgery versus open surgery for the treatment of solid abdominal and thoracic neoplasms in children. *Cochrane Database of Systematic Reviews* **2015**, January (1).
205. Fuchs, J., The role of minimally invasive surgery in pediatric solid tumours. *Pediatric Surgery International* **2015**, *31* (3), 213-28.
206. Lombardi, C. P.; Raffaelli, M.; Boniardi, M.; De Toma, G.; Marzano, L. A.; Miccoli, P.; Minni, F.; Morino, M.; Pelizzo, M. R.; Pietrabissa, A.; Renda, A.; Valeri, A.; De Crea, C.; Bellantone, R., Adrenocortical carcinoma: effect of hospital volume on patient outcome. *Langenbeck's Archives of Surgery* **2012**, *397* (2), 201-7.

207. Axt, J. R.; Murphy, A. J.; Arbogast, P. G.; Lowvorn, H. N., 3rd, Volume-outcome effects for children undergoing resection of renal malignancies. *Journal of Surgical Research* **2012**, *177* (1), e27-33.
208. Youngwirth, L. M.; Adam, M. A.; Thomas, S. M.; Roman, S. A.; Sosa, J. A.; Scheri, R. P., Pediatric thyroid cancer patients referred to high-volume facilities have improved short-term outcomes. *Surgery* **2018**, *163* (2), 361-6.
209. Joseph, J. M.; Farron, A. M.; Renella, R.; Gapany, C., Can smaller-scale comprehensive cancer centers provide outstanding care in abdominal and thoracic pediatric solid tumour surgery? Results of a 14-year retrospective single-center analysis. *Annals of Surgical Oncology* **2014**, *21* (5), 1726-31.
210. Wang, B.; Xu, M.; Zheng, K.; Yu, X., Effect of unplanned therapy on the prognosis of patients with extremity osteosarcoma. *Scientific Reports* **2016**, *6*, 38783.
211. Wang, T.-I.; Wu, P.-K.; Chen, C.-F.; Chen, W.-M.; Yen, C.-C.; Hung, G.-Y.; Liu, C.-L.; Chen, T.-H., The prognosis of patients with primary osteosarcoma who have undergone unplanned therapy. *Japanese Journal of Clinical Oncology* **2011**, *41* (11), 1244-50.
212. Charoenlap, C.; Imanishi, J.; Tanaka, T.; Slavin, J.; Ngan, S. Y.; Chander, S.; Dowsey, M. M.; Goyal, C.; Choong, P. F. M., Outcomes of unplanned sarcoma excision: impact of residual disease. *Cancer Medicine* **2016**, *5* (6), 980-8.
213. Vandenberg, R. N.; Bierman, E. N.; Noord, M. V.; Rice, H. E.; Routh, J. C., Nephron-sparing surgery for Wilms tumour: a systematic review. *Urologic Oncology* **2016**, *34* (1), 24-32.
214. Ehrlich, P. F.; Hamilton, T. E.; Gow, K.; Barnhart, D.; Ferrer, F.; Kandel, J.; Glick, R.; Dasgupta, R.; Naranjo, A.; He, Y.; Perlman, E. J.; Kalapurakal, J. A.; Khanna, G.; Dome, J. S.; Geller, J.; Mullen, E., Surgical protocol violations in children with renal tumours provides an opportunity to improve pediatric cancer care: a report from the Children's Oncology Group. *Pediatric Blood & Cancer* **2016**, *63* (11), 1905-10.
215. Leroy, R.; Benahmed, N.; Hulstaert, F.; Van Damme, N.; De Ruysscher, D., Proton therapy in children: a systematic review of clinical effectiveness in 15 pediatric cancers. *International Journal of Radiation Oncology Biology Physics* **2016**, *95* (1), 267-78.
216. Laskar, S.; Pilar, A.; Khanna, N.; Puri, A.; Gulia, A.; Qureshi, S.; Chinnaswamy, G.; Vora, T.; Ramadwar, M., Interstitial brachytherapy for pediatric soft tissue sarcoma: evolving practice over three decades and long-term outcomes. *Pediatric Blood & Cancer* **2018**, *65* (9), e27112.
217. Chargari, C.; Haie-Meder, C.; Guerin, F.; Minard-Colin, V.; de Lambert, G.; Mazeron, R.; Escande, A.; Marsolat, F.; Dumas, I.; Deutsch, E.; Valteau-Couanet, D.; Audry, G.; Oberlin, O.; Martelli, H., Brachytherapy Combined With Surgery for Conservative Treatment of Children With Bladder Neck and/or Prostate Rhabdomyosarcoma. *International Journal of Radiation Oncology Biology Physics* **2017**, *98* (2), 352-9.
218. Saltzman, A. F.; Cost, N. G., Current treatment of pediatric bladder and prostate rhabdomyosarcoma. *Current Urology Reports* **2018**, *19* (1), 11.
219. Adamson, P. C.; Blaney, S. M.; Bagatell, R.; Skolnik, J. M.; Balis, F. M., General principles of chemotherapy. In: *Principles and practice of pediatric oncology*, 7th ed. P. A. Pizzo, P.; Poplack, D. G., Eds. Lippincott, Williams and Wilkins: Philadelphia, PA, **2016**.
220. Pincez, T.; Clément, N.; Lapouble, E.; Pierron, G.; Kamal, M.; Bieche, I.; Bernard, V.; Fréneaux, P.; Michon, J.; Orbach, D.; Aerts, I.; Pacquement, H.; Bourdeaut, F.; Jiménez, I.; Thébaud, E.; Oudot, C.; Vèrité, C.; Taqae, S.; Owens, C.; Doz, F.; Le Tourneau, C.; Delattre, O.; Schleiermacher, G., Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumours. *Pediatric Blood & Cancer* **2017**, *64* (6).
221. Majzner, R. G.; Heitzeneder, S.; Mackall, C. L., Harnessing the immunotherapy revolution for the treatment of childhood cancers. *Cancer Cell* **2017**, *31* (4), 476-85.
222. Schultz, L. M.; Majzner, R.; Davis, K. L.; Mackall, C., New developments in immunotherapy for pediatric solid tumours. *Current Opinion in Pediatrics* **2018**, *30* (1), 30-9.
223. Wilson, C. L.; Gawade, P. L.; Ness, K. K., Impairments that influence physical function among survivors of childhood cancer. *Children* **2015**, *2* (1), 1-36.
224. Ness, K. K.; Hudson, M. M.; Ginsberg, J. P.; Nagarajan, R.; Kaste, S. C.; Marina, N.; Whitton, J.; Robison, L. L.; Gurney, J. G., Physical performance limitations in the Childhood Cancer Survivor Study cohort. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* **2009**, *27* (14), 2382-9.
225. Robison, L. L.; Hudson, M. M., Survivors of childhood and adolescent cancer: life-long risks and responsibilities. *Nature Reviews Cancer* **2013**, *14*, 61.
226. Houghton, P. J., New insights into drug development for pediatric solid tumours: what preclinical data justify clinical trials in pediatric cancer? *Expert Review of Anticancer Therapy* **2013**, *13* (10), 1135-8.
227. Vern-Gross, T. Z.; Lam, C. G.; Graff, Z.; Singhal, S.; Levine, D. R.; Gibson, D.; Sykes, A.; Angheliescu, D. L.; Yuan, Y.; Baker, J. N., Patterns of end-of-life care in children with advanced solid tumour malignancies enrolled on a palliative care service. *Journal of Pain and Symptom Management* **2015**, *50* (3), 305-12.
228. Williams, R. F.; Fernandez-Pineda, I.; Gosain, A., Pediatric sarcomas. *The Surgical Clinics of North America* **2016**, *96* (5), 1107-25.
229. Gerrand, C.; Athanasou, N.; Brennan, B.; Grimer, R.; Judson, I.; Morland, B.; Peake, D.; Seddon, B.; Whelan, J., UK guidelines for the management of bone sarcomas. *Clinical Sarcoma Research* **2016**, *6*.
230. Durfee, R. A.; Mohammed, M.; Luu, H. H., Review of osteosarcoma and current management. *Rheumatology and Therapy* **2016**, *3* (2), 221-43.
231. Mirabello, L.; Yeager, M.; Mai, P. L.; Gastier-Foster, J. M.; Gorlick, R.; Khanna, C.; Patino-Garcia, A.; Sierrasesumaga, L.; Lecanda, F.; Andrulis, I. L.; Wunder, J. S.; Gokgoz, N.; Barkauskas, D. A.; Zhang, X.; Vogt, A.; Jones, K.; Boland, J. F.; Chanock, S. J.; Savage, S. A., Germline TP53 variants and susceptibility to osteosarcoma. *Journal of the National Cancer Institute* **2015**, *107* (7).
232. Wolpert, F.; Grotzer, M. A.; Niggli, F.; Zimmermann, D.; Rushing, E.; Bode-Lesniewska, B., Ewing's sarcoma as a second malignancy in long-term survivors of childhood hematologic malignancies. *Sarcoma* **2016**, *2016*, 11.
233. Applebaum, M. A.; Goldsby, R.; Neuhaus, J.; DuBois, S. G., Clinical features and outcomes in patients with secondary Ewing sarcoma. *Pediatric Blood & Cancer* **2013**, *60* (4), 611-5.
234. Grohar, P. J.; Janeway, K. A.; Mase, L. D.; Schiffman, J. D., Advances in the treatment of pediatric bone sarcomas. *American Society of Clinical Oncology Educational Book* **2017**, *37*, 725-35.
235. Choi, E. Y.; Gardner, J. M.; Lucas, D. R.; McHugh, J. B.; Patel, R. M., Ewing sarcoma. *Seminars in Diagnostic Pathology* **2014**, *31* (1), 39-47.
236. Reed, D. R.; Hayashi, M.; Wagner, L.; Binitie, O.; Steppan, D. A.; Brohl, A. S.; Shinohara, E. T.; Bridge, J. A.; Loeb, D. M.; Borinstein, S. C.; Isakoff, M. S., Treatment pathway of bone sarcoma in children, adolescents, and young adults. *Cancer* **2017**, *123* (12), 2206-18.
237. Hawkins, D. S.; Brennan, B.; Bölling, T.; Davidson, D. J.; Dirksen, U.; DuBois, S. G.; Hogendoorn, P. C. W.; Lessnick, S. L., Ewing sarcoma. In: *Principles and practice of pediatric oncology*, 6th ed.; Pizzo, P. A.; Poplack, D. G., Eds. Lippincott Williams & Wilkins: Philadelphia, PA, **2016**.
238. National Comprehensive Cancer Network. NCCN guidelines for treatment of cancer by site: bone cancer (version 1.2018). **2017**. https://www.nccn.org/professionals/physician_gls/default.aspx#bone.
239. Dyrop, H. B.; Vedsted, P.; Raedkjaer, M.; Safwat, A.; Keller, J., Imaging investigations before referral to a sarcoma center delay the final diagnosis of musculoskeletal sarcoma. *Acta Orthopaedica* **2017**, *88* (2), 211-6.
240. Kasalak, O.; Claudemans, A.; Overbosch, J.; Jutte, P. C.; Kwee, T. C., Can FDG-PET/CT replace blind bone marrow biopsy of the posterior iliac crest in Ewing sarcoma? *Skeletal Radiology* **2018**, *47* (3), 363-7.
241. Newman, E. N.; Jones R. L.; Hawkins D. S., An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing Sarcoma. *Pediatric Blood & Cancer* **2013**, *60* (7), 1113-7.
242. Kreyer, J.; Ranft, A.; Timmermann, B.; Juergens, H.; Jung, S.; Wiebe, K.; Boelling, T.; Schuck, A.; Vieth, V.; Streitburger, A.; Harges, J.; Heinemann, M.; Dirksen, U., Impact of the Interdisciplinary Tumour Board of the Cooperative Ewing Sarcoma Study Group on local therapy and overall survival of Ewing sarcoma patients after induction therapy. *Pediatric Blood & Cancer* **2018**, *6* (12), e27384.
243. Whelan, J.; Hackshaw, A.; McTiernan, A.; Grimer, R.; Spooner, D.; Bate, J.; Ranft, A.; Paulussen, M.; Juergens, H.; Craft, A.; Lewis, I., Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICES-92. *Clinical Sarcoma Research* **2018**, *8*, 6.
244. Strauss, S. J.; Whelan, J. S., Current questions in bone sarcomas. *Current Opinion in Oncology* **2018**, *30* (4), 252-9.
245. Frisch, S.; Timmermann, B., The evolving role of proton beam therapy for sarcomas. *Clinical Oncology (Royal College of Radiologists (Great Britain))* **2017**, *29* (8), 500-6.
246. Desai, N. B.; Laine, A. M.; Timmerman, R. D., Stereotactic ablative body radiotherapy (SABR) for oligometastatic cancer. *The British Journal of Radiology* **2017**, *90* (1070), 20160500.
247. Meazza, C.; Scanagatta, P., Metastatic osteosarcoma: a challenging multidisciplinary treatment. *Expert Review of Anticancer Therapy* **2016**, *16* (5), 543-56.
248. Imran, H.; Enders, F.; Krailo, M.; Sim, F.; Okuno, S.; Hawkins, D.; Neglia, J.; Randall, R. L.; Womer, R.; Mascarenhas, L.; Arndt, C. A. S., Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma. *Journal of Bone and Joint Surgery* **2009**, *91* (3), 604-12.
249. Vasquez, L.; Tarrillo, F.; Oscanoa, M.; Maza, I.; Geronimo, J.; Paredes, G.; Silva, J. M.; Sialer, L., Analysis of prognostic factors in high-grade osteosarcoma of the extremities in children: a 15-year single-institution experience. *Frontiers in Oncology* **2016**, *6*, 22.
250. Lin Patrick P.; Jaffe Norman; Herzog Cynthia E.; Costelloe Colleen M.; Deavers Michael T.; Kelly Jeana S.; Patel Shreyaskumar R.; Madewell John E.; Lewis Valerae O.; Cannon Christopher P.; Benjamin Robert S.; Yasko Alan W., Chemotherapy response is an important predictor of local recurrence in ewing sarcoma. *Cancer* **2007**, *109* (3), 603-11.
251. Hanafy, E.; Al Jabri, A.; Gadelkarim, G.; Dasaq, A.; Nazim, F.; Al Pakrah, M., Tumour histopathological response to neoadjuvant chemotherapy in childhood solid malignancies: is it still impressive? *Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research* **2018**, *66* (2), 289-97.
252. Heinemann, M.; Ranft, A.; Langer, T.; Jürgens, H.; Kreyer, J.; Vieth, V.; Schäfers, M.; Weckesser, M.; Simon, T.; Hassenpflug, W.; Corbacioglu, S.; Biela, S.; Mayer-Steinacker, R.; Kühne, T.; van den Berg, H.; Gelderblom, H.; Bauer, S.; Stegger, L.; Dirksen, U., Recurrence of Ewing sarcoma: Is detection by imaging follow-up protocol associated with survival advantage? *Pediatric Blood & Cancer* **2017**, e27011.
253. Marina, N. M.; Liu, Q.; Donaldson, S. S.; Sklar, C. A.; Armstrong, G. T.; Oeffinger, K. C.; Leisenring, W. M.; Ginsberg, J. P.; Henderson, T. O.; Neglia, J. P.; Stovall, M. A.; Yasui, Y.; Randall, R. L.; Geller, D. S.; Robison, L. L.; Ness, K. K., Longitudinal follow-up of adult survivors of Ewing sarcoma: a report from the Childhood Cancer Survivor Study. *Cancer* **2017**, *123* (13), 2551-60.
254. Lee, J. S.; DuBois, S. G.; Boscardin, W. J.; Wustrack, R. L.; Goldsby, R. E., Secondary malignant neoplasms among children, adolescents, and young adults with osteosarcoma. *Cancer* **2014**, *120* (24), 3987-93.
255. Rajaram, N.; Kamruzzaman, A.; Ness, K.; Marchese, V. G.; Sklar, C. A.; Mertens, A.; Yasui, Y.; Robison, L.; Marina, N., Twenty years of follow-up of survivors of childhood osteosarcoma. *Cancer* **2011**, *117* (3), 625-34.
256. Spraker-Perlman, H. L.; Barkauskas, D. A.; Krailo, M. D.; Meyers, P. A.; Schwartz, C. L.; Doski, J.; Gorlick, R.; Janeway, K. A.; Isakoff, M. S., Factors influencing survival after recurrence in osteosarcoma: A report from the Children's Oncology Group. *Pediatric Blood & Cancer* **2018**, *66* (1), e27444.
257. Rasper, M.; Jabar, S.; Ranft, A.; Jurgens, H.; Amler, S.; Dirksen, U., The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma. *Pediatric Blood & Cancer* **2014**, *61* (8), 1382-6.
258. Ferrari, S.; Luksch, R.; Hall, K. S.; Fagioli, F.; Prete, A.; Tamburini, A.; Tienghi, A.; DiGirolamo, S.; Paioli, A.; Abate, M. E.; Podda, M.; Cammelli, S.; Eriksson, M.; Brach del Prever, A., Post-relapse survival in patients with Ewing sarcoma. *Pediatric Blood & Cancer* **2015**, *62* (6), 994-9.
259. Egas-Bejar, D.; Huh, W. W., Rhabdomyosarcoma in adolescent and young adult patients: current perspectives. *Adolescent Health, Medicine and Therapeutics* **2014**, *5*, 115-25.
260. Dasgupta, R.; Fuchs, J.; Rodeberg, D., Rhabdomyosarcoma. *Seminars in Pediatric Surgery* **2016**, *25* (5), 276-83.
261. Borinstein, S. C.; Steppan, D.; Hayashi, M.; Loeb, D. M.; Isakoff, M. S.; Binitie, O.; Brohl, A. S.; Bridge, J. A.; Stavas, M.; Shinohara, E. T.; Meyer, W. H.; Reed, D. R.; Wagner, L. M., Consensus and controversies regarding the treatment of rhabdomyosarcoma. *Pediatric Blood & Cancer* **2018**, *65* (2).
262. Wexler, L. H.; Skapek, S. X.; Helman, L. J., Rhabdomyosarcoma. In: *Principles and practice of pediatric oncology*, 6th ed.; Pizzo, P. A., Poplack, D. G., Eds. Lippincott Williams & Wilkins: Philadelphia, PA., **2016**.
263. National Institute for Health and Care Excellence, Suspected cancer: recognition and referral. NICE, Ed. **2015**.
264. Tateishi, U.; Hosono, A.; Makimoto, A.; Nakamoto, Y.; Kaneta, T.; Fukuda, H.; Murakami, K.; Terauchi, T.; Suga, T.; Inoue, T.; Kim, E. E., Comparative

- study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. *Annals of Nuclear Medicine* **2009**, *23* (2), 155-61.
265. Eugene, T.; Corradini, N.; Carlier, T.; Dupas, B.; Leux, C.; Bodet-Milin, C., (1) (8)F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas. *Nuclear Medicine Communications* **2012**, *33* (10), 1089-95.
266. Federico, S. M.; Spunt, S. L.; Krasin, M. J.; Billup, C. A.; Wu, J.; Shulkin, B.; Gerald, M.; McCarville, M. B., Comparison of PET-CT and conventional imaging in staging pediatric rhabdomyosarcoma. *Pediatric Blood & Cancer* **2013**, *60* (7), 1128-34.
267. Panda, S. P.; Chinnaswamy, G.; Vora, T.; Prasad, M.; Bansal, D.; Kapoor, G.; Radhakrishnan, V.; Agarwala, S.; Laskar, S.; Arora, B.; Kaur, T.; Rath, G. K.; Bakhshi, S., Diagnosis and management of rhabdomyosarcoma in children and adolescents: ICMR consensus document. *Indian Journal of Pediatrics* **2017**, *84* (5), 393-402.
268. European Soft Tissue Sarcoma Study Group (EpSSG) RMS 2005: a protocol for non-metastatic rhabdomyosarcoma. <https://tinyurl.com/y97yzdrc> (accessed 02.07.2018).
269. Hiniker, S. M.; Donaldson, S. S., Recent advances in understanding and managing rhabdomyosarcoma. *F1000prime reports* **2015**, *7*, 59.
270. Lockney, N. A.; Friedman, D. N.; Wexler, L. H.; Sklar, C. A.; Casey, D. L.; Wolden, S. L., Late toxicities of intensity-modulated radiation therapy for head and neck rhabdomyosarcoma. *Pediatric Blood & Cancer* **2016**, *63* (9), 1608-14.
271. Vaarwerk, B.; van der Lee, J. H.; Breunis, W. B.; Orbach, D.; Chisholm, J. C.; Cozic, N.; Jenney, M.; van Rijn, R. R.; McHugh, K.; Gallego, S.; Glosli, H.; Devalck, C.; Gaze, M. N.; Kelsey, A.; Bergeron, C.; Stevens, M. C. G.; Oberlin, O.; Minard-Colin, V.; Merks, J. H. M., Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumour 95 study. *Cancer* **2018**, *124* (5), 1016-24.
272. Mallebranche, C.; Carton, M.; Minard-Colin, V.; Desfachelles, A. S.; Rome, A.; Brisse, H. J.; Mosseri, V.; Thebaud, E.; Pelletier, I.; Boutroux, H.; Gandemer, V.; Corradini, N.; Orbach, D., Relapse after rhabdomyosarcoma in childhood and adolescence: Impact of an early detection on survival. *Bulletin du Cancer* **2017**, *104* (7-8), 625-635.
273. Setty, B. A.; Stanek, J. R.; Mascarenhas, L.; Miller, A.; Bagatell, R.; Okcu, F.; Nicholls, L.; Lysecki, D.; Gupta, A. A.; Vincristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma. *Pediatric Blood & Cancer* **2018**, *65* (1).
274. Shern, J. F.; Yohe, M. E.; Khan, J., Pediatric rhabdomyosarcoma. *Critical Reviews in Oncogenesis* **2015**, *20* (3-4), 227-43.
275. Sarah, W.; Sylvie, F.; Hervé, B.; Véronique, M.; Daniel, O., Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second-line chemotherapy. *Pediatric Blood & Cancer* **2015**, *62* (11), 1935-41.
276. Buhtoiarov, I. N., Pediatric lymphoma. *Pediatrics in Review* **2017**, *39* (9), 410-423.
277. Allen, C. E.; Kamdar, K. Y.; Bollard, C. M.; Gross, T. G., Malignant non-Hodgkin lymphomas in children. In: *Principles and practice of pediatric oncology*, 6th ed. Pizzo, P. A. P., Poplack D. G., Eds. Lippincott Williams & Wilkins: Philadelphia, PA, **2016**.
278. Arico, M.; Mussolin, L.; Carraro, E.; Buffardi, S.; Santoro, N.; D'Angelo, P.; Lombardi, A.; Pierani, P.; Giraldi, E.; Mura, R.; Sala, A.; Garaventa, A.; Tondo, A.; Piglionne, M.; Lo Nigro, L.; Cesaro, S.; Perruccio, K.; Rosolen, A.; Basso, G.; Pillon, M., Non-Hodgkin lymphoma in children with an associated inherited condition: a retrospective analysis of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). *Pediatric Blood & Cancer* **2015**, *62* (10), 1782-9.
279. Yanik, E. L.; Shiels, M. S.; Smith, J. M.; Clarke, C. A.; Lynch, C. F.; Kahn, A. R.; Koch, L.; Pawlish, K. S.; Engels, E. A., Contribution of solid organ transplant recipients to the pediatric non-hodgkin lymphoma burden in the United States. *Cancer* **2017**, *123* (23), 4663-71.
280. Rosolen, A.; Perkins, S. L.; Pinkerton, C. R.; Guillerman, R. P.; Sandlund, J. T.; Patte, C.; Reiter, A.; Cairo, M. S., Revised International Pediatric Non-Hodgkin Lymphoma Staging System. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* **2015**, *33* (18), 2112-8.
281. Swerdlow, S. H.; Campo, E.; Pileri, S. A.; Harris, N. L.; Stein, H.; Siebert, R.; Advani, R.; Ghielmini, M.; Salles, G. A.; Zelenetz, A. D.; Jaffe, E. S., The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood* **2016**, *127* (20), 2375-90.
282. Allen, C. E.; Kelly, K. M.; Bollard, C. M., Pediatric lymphomas and histiocytic disorders of childhood. *Pediatric Clinics of North America* **2015**, *62* (1), 139-65.
283. Acker, S. N.; Linton, J.; Tan, G. M.; Garrington, T. P.; Bruny, J.; Hilden, J. M.; Hoffman, L. M.; Partrick, D. A., A multidisciplinary approach to the management of anterior mediastinal masses in children. *Journal Of Pediatric Surgery* **2015**, *50* (5), 875-8.
284. Patte, C.; Gerrard, M.; Auperin, A., Early treatment intensity has a major prognostic impact in the 'intermediate risk' childhood and adolescent B-cell lymphoma: results of the international FAB LMB 96 trial. *Blood* **2003**, *103* (11).
285. Sorge, C. E.; McDaniel, J. K.; Xavier, A. C., Targeted therapies for the treatment of pediatric non-hodgkin lymphomas: present and future. *Pharmaceuticals (Basel, Switzerland)* **2016**, *9* (2).
286. Bardi, E.; Csoka, M.; Garai, I.; Szegedi, I.; Muller, J.; Gyorke, T.; Kajary, K.; Nemes, K.; Kiss, C.; Kovacs, G., Value of FDG-PET/CT examinations in different cancers of children, focusing on lymphomas. *Pathology Oncology Research* **2014**, *20* (1), 139-43.
287. Eissa, H. M.; Allen, C. E.; Kamdar, K.; Simko, S.; Goradia, P.; Dreyer, Z.; Steuber, P.; McClain, K. L.; Guillerman, R. P.; Bollard, C. M., Pediatric Burkitt's lymphoma and diffuse B-cell lymphoma: are surveillance scans required? *Pediatric Hematology and Oncology* **2014**, *31* (3), 253-7.
288. Truong, Q.; Shah, N.; Knestrick, M.; Curley, B.; Hu, Y.; Craig, M.; Hamadani, M., Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission. *Clinical Lymphoma, Myeloma & Leukemia* **2014**, *14* (1), 50-5.
289. Sussman, J.; Varela, N. P.; Cheung, M.; Hicks, L.; Kraftcheck, D.; Mandel, J.; Fraser, G.; Jimenez-Juan, L.; Boudreau, A.; Sajkowski, S.; McQuillan, R., Follow-up care for survivors of lymphoma who have received curative-intent treatment. *Current Oncology (Toronto, Ont.)* **2016**, *23* (5), e499-e513.
290. Ehrhardt, M. J.; Sandlund, J. T.; Zhang, N.; Liu, W.; Ness, K. K.; Bhakta, N.; Chemaitilly, W.; Krull, K. R.; Brinkman, T. M.; Crom, D. B.; Kun, L.; Kaste, S. C.; Armstrong, G. T.; Green, D. M.; Srivastava, K.; Robison, L. L.; Hudson, M. M.; Mulrooney, D. A., Late outcomes of adult survivors of childhood non-Hodgkin lymphoma: a report from the St. Jude Lifetime Cohort Study. *Pediatric Blood & Cancer* **2017**, *64* (6).
291. Giulino-Roth, L.; Ricafort, R.; Kernan, N. A.; Small, T. N.; Trippett, T. M.; Steiner, P. G.; Prockop, S. E.; Scaradavou, A.; Chiu, M.; O'Reilly, R. J.; Boulard, F., Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. *Pediatric Blood & Cancer* **2013**, *60* (12), 2018-24.
292. Jourdain, A.; Auperin, A.; Minard-Colin, V.; Aladjidi, N.; Zsiros, J.; Coze, C.; Gandemer, V.; Bertrand, Y.; Leverger, G.; Bergeron, C.; Michon, J.; Patte, C., Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective 'Lymphomes Malins B' protocols. A Societe Francaise des Cancers de l'Enfant study. *Haematologica* **2015**, *100* (6), 810-7.
293. Nagpal, P.; Akl, M. R.; Ayoub, N. M.; Tomiyama, T.; Cousins, T.; Tai, B.; Carroll, N.; Nyrenda, T.; Bhattacharyya, P.; Harris, M. B.; Goy, A.; Pecora, A.; Suh, K. S., Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine. *Oncotarget* **2016**, *7* (41), 67551-67573.
294. Linabery, A. M.; Erhardt, E. B.; Richardson, M. R.; Ambinder, R. F.; Friedman, D. L.; Glaser, S. L.; Monnereau, A.; Spector, L. G.; Ross, J. A.; Grufferman, S., Family history of cancer and risk of pediatric and adolescent Hodgkin lymphoma: A Children's Oncology Group study. *International journal of cancer* **2015**, *137* (9), 2163-74.
295. Radhi, M.; Fulbright, J. M.; Ginn, K. F.; Guest, E. M., Childhood cancer for the primary care physician. *Primary Care* **2015**, *42* (1), 43-55.
296. Metzger, M. L.; Krasin, M. J.; Choi, J. K.; Hudson, M. M., Hodgkin lymphoma. In: *Principles and practice of pediatric oncology*, 6th. ed.; Pizzo, P. A.; Poplack, D. G., Eds. Lippincott Williams & Wilkins: Philadelphia, PA, **2016**.
297. Flerlage, J. E.; Kelly, K. M.; Beishuizen, A.; Cho, S.; Alarcon, P. A.; Dieckmann, U.; Drachtman, R. A.; Hoppe, B. S.; Howard, S. C.; Kaste, S. C.; Kluge, R.; Kurch, L.; Landman-Parker, J.; Lewis, J.; Link, M. P.; McCarten, K.; Punnett, A.; Stoevesandt, D.; Voss, S. D.; Wallace, W. H.; Mauz-Körholz, C.; Metzger, M. L., Staging Evaluation and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (CAVAYL): Methodology statement. *Pediatric Blood & Cancer* **2017**, *64* (7), e26421.
298. Cheson, B. D.; Fisher, R. I.; Barrington, S. F.; Cavalli, F.; Schwartz, L. H.; Zucca, E.; Lister, T. A., Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* **2014**, *32* (27), 3059-68.
299. Kostakoglu, L.; Cheson, B. D., Current role of FDG PET/CT in lymphoma. *European Journal of Nuclear Medicine and Molecular Imaging* **2014**, *41* (5), 1004-27.
300. Brockelmann, P. J.; Goergen, H.; Fuchs, M.; Kriz, J.; Semrau, R.; Baues, C.; Kobe, C.; Behringer, K.; Eichenauer, D. A.; von Tresckow, B.; Klimm, B.; Halbsguth, T.; Wongso, D.; Plutskow, A.; Haverkamp, H.; Dietlein, M.; Eich, H. T.; Stein, H.; Diehl, V.; Borchmann, P.; Engert, A., Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group. *British Journal of Haematology* **2015**, *171* (4), 547-56.
301. Luders, H.; Ruhl, U.; Marciniak, H.; Haerting, J.; Claviez, A.; Mann, G.; Schellong, G.; Wickmann, L.; Dorffel, W., The impact of central review and central therapy planning on the treatment of children and adolescents with Hodgkin lymphoma. *European Journal of Cancer (Oxford, England: 1990)* **2014**, *50* (2), 425-33.
302. Ferrari, C.; Niccoli Asabella, A.; Merenda, N.; Altini, C.; Fanelli, M.; Muggeo, P.; De Leonardi, F.; Perillo, T.; Santoro, N.; Rubini, G., Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment. *Medicine (Baltimore)* **2017**, *96* (5), e5973.
303. Isik, E. G.; Kuyumcu, S.; Kebudi, R.; Sanli, Y.; Karakas, Z.; Cakir, F. B.; Unal, S. N., Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of (18)FDG-PET/CT according to DeltaSUVmax, Deauville 5-point scale and IHP criteria. *Annals of Nuclear Medicine* **2017**, *31* (9), 660-8.
304. Kluge, R.; Kurch, L.; Georgi, T.; Metzger, M., Current Role of FDG-PET in Pediatric Hodgkin's Lymphoma. *Seminars in Nuclear Medicine* **2017**, *47* (3), 242-57.
305. Friedmann, A. M.; Wolfson, J. A.; Hudson, M. M.; Weinstein, H. J.; Link, M. P.; Billett, A.; Larsen, E. C.; Yock, T.; Donaldson, S. S.; Marcus, K.; Krasin, M. J.; Howard, S. C.; Metzger, M. L., Relapse after treatment of pediatric Hodgkin lymphoma: outcome and role of surveillance after end of therapy. *Pediatric Blood & Cancer* **2013**, *60* (9), 1458-63.
306. Voss, S. D., Surveillance imaging in pediatric Hodgkin Lymphoma. *Current Hematologic Malignancy Reports* **2013**, *8* (3), 218-25.
307. Voss, S. D.; Chen, L.; Constine, L. S.; Chauvenet, A.; Fitzgerald, T. J.; Kaste, S. C.; Slovis, T.; Schwartz, C. L., Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology Group. *Journal of Clinical Oncology* **2012**, *30* (21), 2635-40.
308. Patel, V.; Buckstein, M.; Perini, R.; Hill-Kayser, C.; Svoboda, J.; Plastaras, J. P., Computed tomography and positron emission tomography/computed tomography surveillance after combined modality treatment of supradiaphragmatic Hodgkin lymphoma: a clinical and economic perspective. *Leukemia & lymphoma* **2013**, *54* (10), 2168-76.
309. Dorffel, W.; Riepenhausen, M.; Luders, H.; Bramswig, J., Late effects following treatment of Hodgkin lymphoma during childhood and adolescence. Results of the Hodgkin Lymphoma Late Effects Research Project. *Klinische Padiatrie* **2016**, *228* (6-07), 286-93.
310. Harker-Murray, P. D.; Drachtman, R. A.; Hodgson, D. C.; Chauvenet, A. R.; Kelly, K. M.; Cole, P. D., Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma. *Pediatric Blood & Cancer* **2014**, *61* (4), 579-86.
311. Tulla, M.; Berthold, F.; Graf, N.; Rutkowski, S.; von Schweinitz, D.; Spix, C.; Kaatsch, P., Incidence, Trends, and Survival of Children With Embryonal Tumours. *Pediatrics* **2015**, *136* (3), e623-32.
312. Tsubota, S.; Kadomatsu, K., Origin and initiation mechanisms of neuroblastoma. *Cell and Tissue Research* **2018**, *372* (2), 211-21.
313. Kamihara, J.; Bourdeaut, F.; Foulkes, W. D.; Molenaar, J. J.; Mosse, Y. P.; Nakagawara, A.; Parareda, A.; Scollon, S. R.; Schneider, K. W.; Skalet, A. H.; States, L. J.; Walsh, M. F.; Diller, L. R.; Brodeur, G. M., Retinoblastoma and neuroblastoma predisposition and surveillance. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research* **2017**, *23* (13), e98-e106.
314. Ritenour, L. E.; Randall, M. P.; Bosse, K. R.; Diskin, S. J., Genetic susceptibility to neuroblastoma: current knowledge and future directions. *Cell and Tissue Research* **2018**, *372* (2), 287-307.
315. Tolbert, V. P.; Coggins, G. E.; Maris, J. M., Genetic susceptibility to neuroblastoma. *Current Opinion in Genetics & Development* **2017**, *42*, 81-90.
316. Sharma, R.; Mer, J.; Lion, A.; Vik, T. A., Clinical presentation, evaluation, and management of neuroblastoma. *Pediatrics in Review* **2018**, *39* (4), 194-203.
317. Matthay, K. K.; Maris, J. M.; Schleiermacher, G.; Nakagawara, A.; Mackall, C. L.; Diller, L.; Weiss, W. A., Neuroblastoma. *Nature Reviews. Disease Primers* **2016**, *2*, 16078.

318. Tolbert, V. P.; Matthay, K. K., Neuroblastoma: clinical and biological approach to risk stratification and treatment. *Cell and Tissue Research* **2018**, *372* (2), 195-209.
319. Fragkandrea, I.; Nixon, J. A.; Panagopoulou, P., Signs and symptoms of childhood cancer: a guide for early recognition. *American Family Physician* **2013**, *88* (3), 185-92.
320. Kraal, K.; Blom, T.; van Noesel, M.; Kremer, L.; Caron, H.; Tytgat, G.; van der Pal, H., Treatment and outcome of neuroblastoma with intraspinal extension: a systematic review. *Pediatric Blood & Cancer* **2017**, *64* (8).
321. Hamilton, W.; Hajioff, S.; Graham, J.; Schmidt-Hansen, M., Suspected cancer (part 1—children and young adults): visual overview of updated NICE guidance. *British Medical Journal* **2015**, *350*.
322. Meena, J. P.; Seth, R.; Chakrabarty, B.; Gulati, S.; Agrawala, S.; Naranje, P., Neuroblastoma presenting as opsoclonus-myoclonus: A series of six cases and review of literature. *Journal of Pediatric Neurosciences* **2016**, *11* (4), 373-7.
323. Bar-Sever, Z.; Bionasoni, L.; Shulkin, B.; Kong, G.; Hofman, M. S.; Lopci, E.; Manea, I.; Koziorowski, J.; Castellani, R.; Boubaker, A.; Lambert, B.; Pfluger, T.; Nadel, H.; Sharp, S.; Giammarile, F., Guidelines on nuclear medicine imaging in neuroblastoma. *European Journal of Nuclear Medicine and Molecular Imaging* **2018**, *45* (11), 2009-24.
324. Bleeker, G.; Tytgat, G. A.; Adam, J. A.; Caron, H. N.; Kremer, L. C.; Hoof, L.; van Dalen, E. C., 123I-Mibg scintigraphy and 18F-Fdg-Pet imaging for diagnosing neuroblastoma. *The Cochrane Database of Systematic Reviews* **2015**, (9), CD009263.
325. Xia, J.; Zhang, H.; Hu, Q.; Liu, S. Y.; Zhang, L. Q.; Zhang, A.; Zhang, X. L.; Wang, Y. Q.; Liu, A. G., Comparison of diagnosing and staging accuracy of PET (CT) and MIBG on patients with neuroblastoma: Systemic review and meta-analysis. *Journal of Huazhong University of Science and Technology* **2017**, *37* (5), 649-60.
326. Dhull, V. S.; Sharma, P.; Patel, C.; Kundu, P.; Agarwala, S.; Bakhsbi, S.; Bhatnagar, V.; Bal, C.; Kumar, R., Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy. *Nuclear Medicine Communications* **2015**, *36* (10), 1007-13.
327. Verly, I. R.; van Kuilenburg, A. B.; Abeling, N. G.; Goorden, S. M.; Fiocco, M.; Vaz, F. M.; van Noesel, M. M.; Zwaan, C. M.; Kaspers, G. L.; Merks, J. H.; Caron, H. N.; Tytgat, G. A., Catecholamines profiles at diagnosis: Increased diagnostic sensitivity and correlation with biological and clinical features in neuroblastoma patients. *European Journal of Cancer (Oxford, England: 1990)* **2017**, *72*, 235-43.
328. Campagna, G.; Rosenfeld, E.; Foster, J.; Vasudevan, S.; Nuchtern, J.; Kim, E.; Comander, S.; Naik-Mathuria, B., Evolving biopsy techniques for the diagnosis of neuroblastoma in children. *Journal of Pediatric Surgery* **2018**, *53* (11), 2235-9.
329. Mullassery, D.; Sharma, V.; Salim, A.; Jawaid, W. B.; Pizer, B. L.; Abernethy, L. J.; Losty, P. D., Open versus needle biopsy in diagnosing neuroblastoma. *Journal of Pediatric Surgery* **2014**, *49* (10), 1505-7.
330. Brodeur, G. M.; Hogarty, M. D.; Bagatell, R.; Mossé, Y. P.; Maris, J. M., Neuroblastoma. In: *Principles and practice of pediatric oncology*, 6th ed.; Pizzo, P. A.; Poplack, D. G., Eds. Lippincott Williams & Wilkins: Philadelphia, PA, **2016**.
331. Pinto, N. R.; Applebaum, M. A.; Volchenboum, S. L.; Matthay, K. K.; London, W. B.; Ambros, P. F.; Nakagawara, A.; Berthold, F.; Schleiermacher, G.; Park, J. R.; Valteau-Couanet, D.; Pearson, A. D.; Cohn, S. L., Advances in risk classification and treatment strategies for neuroblastoma. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* **2015**, *33* (27), 3008-17.
332. Cohn, S. L.; Pearson, A. D.; London, W. B.; Monclair, T.; Ambros, P. F.; Brodeur, G. M.; Faldum, A.; Hero, B.; lebara, T.; Machin, D.; Mosseri, V.; Simon, T.; Garaventa, A.; Castel, V.; Matthay, K. K., The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* **2009**, *27* (2), 289-97.
333. Monclair, T.; Brodeur, G.; Ambros, P.; Brisse, H.; Cecchetto, G.; Holmes, K.; Kaneko, M.; B London, W.; K Matthay, K.; Nuchtern, J.; von Schweinitz, D.; Simon, T.; Cohn, S.; Pearson, A., *The International Neuroblastoma Risk Group (INRG) staging system: An INRG task force report*. **2009**, *27*, 298-303.
334. Nakagawara, A.; Li, Y.; Izumi, H.; Muramori, K.; Inada, H.; Nishi, M., Neuroblastoma. *Japanese Journal of Clinical Oncology* **2018**, *48* (3), 214-41.
335. Murphy, J. M.; La Quaglia, M. P., Advances in the surgical treatment of neuroblastoma: a review. *European Journal of Pediatric Surgery: Official Journal of Austrian Association of Pediatric Surgery* **2014**, *24* (6), 450-6.
336. Yeung, F.; Chung, P. H.; Tam, P. K.; Wong, K. K., Is complete resection of high-risk stage IV neuroblastoma associated with better survival? *Journal of Pediatric Surgery* **2015**, *50* (12), 2107-11.
337. Mullassery, D.; Farrelly, P.; Losty, P. D., Does aggressive surgical resection improve survival in advanced stage 3 and 4 neuroblastoma? A systematic review and meta-analysis. *Pediatric Hematology and Oncology* **2014**, *31* (8), 703-16.
338. Englum, B. R.; Rialon, K. L.; Speicher, P. J.; Gulack, B.; Driscoll, T. A.; Kreissman, S. G.; Rice, H. E., Value of surgical resection in children with high-risk neuroblastoma. *Pediatric Blood & Cancer* **2015**, *62* (9), 1529-35.
339. Simon, T.; Niemann, C. A.; Hero, B.; Henze, G.; Suttorp, M.; Schilling, F. H.; Berthold, F., Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma. *Developmental Medicine and Child Neurology* **2012**, *54* (4), 347-52.
340. Casey, D. L.; Kushner, B. H.; Cheung, N. K.; Modak, S.; LaQuaglia, M. P.; Wolden, S. L., Local control with 21-Gy radiation therapy for high-risk neuroblastoma. *International Journal of Radiation Oncology Biology Physics* **2016**, *96* (2), 393-400.
341. Casey, D. L.; Pitter, K. L.; Kushner, B. H.; Cheung, N. V.; Modak, S.; LaQuaglia, M. P.; Wolden, S. L., Radiation therapy to sites of metastatic disease as part of consolidation in high-risk neuroblastoma: Can long-term control be achieved? *International Journal of Radiation Oncology Biology Physics* **2018**, *100* (5), 1204-9.
342. Ferris, M. J.; Danish, H.; Switchenko, J. M.; Deng, C.; George, B. A.; Goldsmith, K. C.; Wasilewski, K. J.; Cash, W. T.; Khan, M. K.; Eaton, B. R.; Esiashvili, N., Favorable local control from consolidative radiation therapy in high-risk neuroblastoma despite gross residual disease, positive margins, or nodal involvement. *International Journal of Radiation Oncology Biology Physics* **2017**, *97* (4), 806-12.
343. Wilson, J. S.; Gains, J. E.; Moroz, V.; Wheatley, K.; Gaze, M. N., A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. *European Journal of Cancer (Oxford, England: 1990)* **2014**, *50* (4), 801-15.
344. Kraal, K. C. J. M.; van Dalen, E. C.; Tytgat, G. A. M.; Van Eck-Smit, B. L. F., Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma. *Cochrane Database of Systematic Reviews* **2017**, (4).
345. Sharp, S. E.; Trout, A. T.; Weiss, B. D.; Gelfand, M. J., MIBG in neuroblastoma diagnostic imaging and therapy. *Radiographics: a Review Publication of the Radiological Society of North America, Inc* **2016**, *36* (1), 258-78.
346. Willegaingon, J.; Crema, K. P.; Oliveira, N. C.; Pelissoni, R. A.; Coura-Filho, G. B.; Sapienza, M. T.; Buchpiguel, C. A., Pediatric 131I-MIBG therapy for neuroblastoma: whole-body 131I-MIBG clearance, radiation doses to patients, family caregivers, medical staff, and radiation safety measures. *Clinical Nuclear Medicine* **2018**, *43* (8), 572-8.
347. Chu, B. P.; Horan, C.; Basu, E.; Dauer, L.; Williamson, M.; Carrasquillo, J. A.; Pandit-Taskar, N.; Modak, S., Feasibility of administering high-dose (131I) I-MIBG therapy to children with high-risk neuroblastoma without lead-lined rooms. *Pediatric Blood & Cancer* **2016**, *63* (5), 801-7.
348. Hoy, S. M., Dinutuximab: a review in high-risk neuroblastoma. *Targeted Oncology* **2016**, *11* (2), 247-53.
349. Yalçın, B.; Kremer, L. C. M.; van Dalen, E. C., High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. *Cochrane Database of Systematic Reviews* **2015**, (10).
350. Whittle, S. B.; Smith, V.; Doherty, E.; Zhao, S.; McCarty, S.; Zage, P. E., Overview and recent advances in the treatment of neuroblastoma. *Expert Reviews in Anticancer Therapy* **2017**, *17* (4), 369-86.
351. Kembhavi, S. A.; Shah, S.; Rangarajan, V.; Qureshi, S.; Popat, P.; Kurkure, P., Imaging in neuroblastoma: an update. *The Indian Journal of Radiology & Imaging* **2015**, *25* (2), 129-36.
352. Owens, C.; Li, B. K.; Thomas, K. E.; Irwin, M. S., Surveillance imaging and radiation exposure in the detection of relapsed neuroblastoma. *Pediatric Blood & Cancer* **2016**, *63* (10), 1786-93.
353. Federico, S. M.; Brady, S. L.; Pappo, A.; Wu, J.; Mao, S.; McPherson, V. J.; Young, A.; Furman, W. L.; Kaufman, R.; Kaste, S., The role of chest computed tomography (CT) as a surveillance tool in children with high-risk neuroblastoma. *Pediatric Blood & Cancer* **2015**, *62* (6), 976-81.
354. Applebaum, M. A.; Desai, A. V.; Glade Bender, J. L.; Cohn, S. L., Emerging and investigational therapies for neuroblastoma. *Expert Opinion on Orphan Drugs* **2017**, *5* (4), 355-68.
355. Norsker, F. N.; Rechnittzer, C.; Cederkvist, L.; Tryggvadottir, L.; Madanat-Harjuoja, L. M.; Ora, I.; Thorarinsdottir, H. K.; Vettenranta, K.; Bautz, A.; Schroder, H.; Hasle, H.; Winther, J. F., Somatic late effects in 5-year survivors of neuroblastoma: a population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia (ALICCS) study. *International Journal of Cancer* **2018**, *143* (12), 3083-96.
356. Cohen, L. E.; Gordon, J. H.; Popovsky, E. Y.; Gunawardene, S.; Duffey-Lind, E.; Lehmann, L. E.; Diller, L. R., Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems. *Bone Marrow Transplantation* **2014**, *49* (4), 502-8.
357. Elzembely, M. M.; Dahlberg, A. E.; Pinto, N.; Leger, K. J.; Chow, E. J.; Park, J. R.; Carpenter, P. A.; Baker, K. S., Late effects in high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell rescue. *Pediatric Blood & Cancer* **2019**, *66* (1), e27421.
358. Morgenstern, D. A.; Barone, G.; Moreno, L.; Anderson, J.; Brock, P.; Elliott, M.; Gaze, M.; Gray, J.; Makin, G.; Squire, R.; Tweddle, D.; Ramanujachar, R.; Wheeler, K.; Pearson, A. D. J., Options for the treatment of patients with relapsed/progressive high-risk neuroblastoma. *Children's Cancer and Leukaemia Group*, **2015**.
359. Moreno, L.; Rubie, H.; Varo, A.; Le Deley, M. C.; Amoroso, L.; Chevance, A.; Garaventa, A.; Gambart, M.; Bautista, F.; Valteau-Couanet, D.; Georger, B.; Vassal, G.; Paoletti, X.; Pearson, A. D., Outcome of children with relapsed or refractory neuroblastoma: a meta-analysis of ITCC/SIOPEP European phase II clinical trials. *Pediatric Blood & Cancer* **2017**, *64* (1), 25-31.
360. Kalish, J. M.; Doros, L.; Helman, L. J.; Hennekam, R. C.; Kuiper, R. P.; Maas, S. M.; Maher, E. R.; Nichols, K. E.; Plon, S. E.; Porter, C. C.; Rednam, S.; Schultz, K. A. P.; States, L. J.; Tomlinson, G. E.; Zelley, K.; Druley, T. E., Surveillance recommendations for children with overgrowth syndromes and predisposition to Wilms tumours and hepatoblastoma. *Clinical Cancer Research: an Official Journal of the American Association for Cancer Research* **2017**, *23* (13), e115-e122.
361. Mussa, A.; Molinatto, C.; Baldassarre, G.; Riberi, E.; Russo, S.; Larizza, L.; Riccio, A.; Ferrero, G. B., Cancer risk in Beckwith-Wiedemann syndrome: a systematic review and meta-analysis outlining a novel (Epi)genotype specific histotype targeted screening protocol. *The Journal of pediatrics* **2016**, *176*, 142-149.e1.
362. Trobaugh-Lotrario, A. D.; Lopez-Terrada, D.; Li, P.; Feusner, J. H., Hepatoblastoma in patients with molecularly proven familial adenomatous polyposis: clinical characteristics and rationale for surveillance screening. *Pediatric Blood & Cancer* **2018**, *65* (8), e27103.
363. Meyers, R. L.; Trobaugh-Lotrario, A. D.; Malogolowkin, M. H.; Katzenstein, H. M.; López-Terrada, D. H.; Finegold, M. J., Liver tumours. In: *Principles and practice of pediatric oncology*, 6th ed. Pizzo, P. A.; Poplack, D. G., Eds. Lippincott Williams & Wilkins: Philadelphia, PA, **2016**.
364. Turcotte, L. M.; Georgieff, M. K.; Ross, J. A.; Feusner, J. H.; Tomlinson, G. E.; Malogolowkin, M. H.; Krailo, M. D.; Miller, N.; Fonstad, R.; Spector, L. G., Neonatal medical exposures and characteristics of low birth weight hepatoblastoma cases: a report from the Children's Oncology Group. *Pediatric Blood & Cancer* **2014**, *61* (11), 2018-23.
365. Czauderna, P.; Lopez-Terrada, D.; Hiyama, E.; Haberle, B.; Malogolowkin, M. H.; Meyers, R. L., Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. *Current Opinion in Pediatrics* **2014**, *26* (1), 19-28.
366. Hiyama, E., Pediatric hepatoblastoma: diagnosis and treatment. *Translational Pediatrics* **2014**, *3* (4), 293-9.
367. LaQuaglia, M. J.; LaQuaglia, M. P., Chapter 95 - Hepatic tumours in childhood. In: *Blumgart's surgery of the liver, biliary tract and pancreas, 2-volume set, 6th ed.*, Jarnagin, W. R., Ed. Content repository only: Philadelphia, **2017**, pp 1378-1397.
368. Sharma, D.; Subbarao, G.; Saxena, R., Hepatoblastoma. *Seminars in Diagnostic Pathology* **2017**, *34* (2), 192-200.
369. Lungren, M. P.; Towbin, A. J.; Roebuck, D. J.; Monroe, E. J.; Gill, A. E.; Thakor, A.; Towbin, R. B.; Cahill, A. M.; Matthew Hawkins, C., Role of interventional radiology in managing pediatric liver tumours: Part 1: Endovascular interventions. *Pediatric Radiology* **2018**, *48* (4), 555-64.
370. Towbin, A. J.; Meyers, R. L.; Woodley, H.; Miyazaki, O.; Weldon, C. B.; Morland, B.; Hiyama, E.; Czauderna, P.; Roebuck, D. J.; Tiao, G. M., **2017** PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT). *Pediatric Radiology* **2018**, *48* (4), 536-54.
371. Yikilmaz, A.; George, M.; Lee, E. Y., Pediatric hepatobiliary neoplasms: an overview and update. *Radiologic clinics of North America* **2017**, *55* (4), 741-66.
372. Matthew Hawkins, C.; Towbin, A. J.; Roebuck, D. J.; Monroe, E. J.; Gill, A. E.; Thakor, A. S.; Towbin, R. B.; Cahill, A. M.; Lungren, M. P., Role of

- interventional radiology in managing paediatric liver tumours: part 2: percutaneous interventions. *Pediatric Radiology* **2018**, 48 (4), 565-80.
373. Czauderna, P.; Garnier, H., Hepatoblastoma: current understanding, recent advances, and controversies. *F1000Research* **2018**, 7, 53.
374. Meyers, R. L.; Maibach, R.; Hiayama, E.; Haberle, B.; Krailo, M.; Rangaswami, A.; Aronson, D. C.; Malogolowkin, M. H.; Perilongo, G.; von Schweinitz, D.; Ansari, M.; Lopez-Terrada, D.; Tanaka, Y.; Alaggio, R.; Leuschner, I.; Hishiki, T.; Schmid, I.; Watanabe, K.; Yoshimura, K.; Feng, Y.; Rinaldi, E.; Saraceno, D.; Derosa, M.; Czauderna, P., Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumours International Collaboration. *The Lancet Oncology* **2017**, 18 (1), 122-31.
375. Cancer Research UK Clinical Trials Unit Paediatric Hepatic International Tumour Trial. <https://www.birmingham.ac.uk/research/activity/mds/trials/crc/ctu/trials/phitt/index.aspx> (accessed 20.07.2018).
376. Fonseca, A.; Gupta, A.; Shaikh, F.; Ramphal, R.; Ng, V.; McGilvray, I.; Gerstle, J. T., Extreme hepatic resections for the treatment of advanced hepatoblastoma: Are planned close margins an acceptable approach? *Pediatric Blood & Cancer* **2018**, 65 (2).
377. Trobaugh-Lotrario, A. D.; Meyers, R. L.; Tiao, G. M.; Feusner, J. H., Pediatric liver transplantation for hepatoblastoma. *Translational Gastroenterology and Hepatology* **2016**, 1, 44.
378. Michael, K.; Patrick, T.; Abbas, R.; Ronald, C.; Christine, O. M.; John, G., Effects of an early referral system on liver transplantation for hepatoblastoma at Texas Children's Hospital. *Pediatric Transplantation* **2016**, 20 (4), 515-22.
379. Trobaugh-Lotrario, A. D.; Meyers, R. L.; O'Neill, A. F.; Feusner, J. H., Unresectable hepatoblastoma: current perspectives. *Hepatic Medicine: Evidence and Research* **2017**, 9, 1-6.
380. Semeraro, M.; Branchereau, S.; Maibach, R.; Zsiros, J.; Casanova, M.; Brock, P.; Domerg, C.; Aronson, D. C.; Zimmermann, A.; Lathier, V.; Childs, M.; Roebuck, D.; Perilongo, G.; Czauderna, P.; Brugieres, L., Relapses in hepatoblastoma patients: clinical characteristics and outcome--experience of the International Childhood Liver Tumour Strategy Group (SIOPEL). *European Journal of Cancer (Oxford, England: 1990)* **2013**, 49 (4), 915-22.
381. Rojas, Y.; Guillermin, R. P.; Zhang, W.; Vasudevan, S. A.; Nuchtern, J. G.; Thompson, P. A., Relapse surveillance in AFP-positive hepatoblastoma: re-evaluating the role of imaging. *Pediatric Radiology* **2014**, 44 (10), 1275-80.
382. Agarwala, S.; Gupta, A.; Bansal, D.; Vora, T.; Prasad, M.; Arora, B.; Kapoor, G.; Chinnaswamy, G.; Radhakrishnan, V.; Laskar, S.; Kaur, T.; Dhaliwal, R. S.; Rath, G. K.; Bakshi, S., Management of Hepatoblastoma: ICMR Consensus Document. *Indian Journal of Pediatrics* **2017**, 84 (6), 456-64.
383. Trobaugh-Lotrario, A. D.; Meyers, R. L.; Feusner, J. H., Outcomes of Patients With Relapsed Hepatoblastoma Enrolled on Children's Oncology Group (COG) Phase I and II Studies. *Journal of Pediatric Hematology/Oncology* **2016**, 38 (3), 187-90.
384. Dome, J. S.; Huff, V., Wilms tumour predisposition. In: Gene Reviews., **2016**. <https://www.ncbi.nlm.nih.gov/books/NBK1116/>.
385. Dumoucel, S.; Gauthier-Villars, M.; Stoppa-Lyonnet, D.; Parisot, P.; Brisse, H.; Philippe-Chomette, P.; Sarnacki, S.; Boccon-Gibod, L.; Rossignol, S.; Baumann, C.; Aerts, I.; Bourdeaut, F.; Doz, F.; Orbach, D.; Pacquement, H.; Michon, J.; Schleiermacher, G., Malformations, genetic abnormalities, and Wilms tumour. *Pediatric Blood & Cancer* **2014**, 61 (1), 140-4.
386. Fernandez, C. V.; Geller, J. L.; Ehrlich, P. F.; Hill, A. D.; Kalapurakal, J. A.; Dome, J. S., Renal tumours. In: *Principles and practice of pediatric oncology*, 6th ed.; Pizzo, P. A.; Poplack, D. G., Eds. Lippincott Williams & Wilkins: Philadelphia, PA, **2016**.
387. Robertson, J. C.; Jorcyk, C. L.; Oxford, J. T., DICER1 Syndrome: DICER1 mutations in rare cancers. *Cancers* **2018**, 10 (5).
388. Chu, A.; Heck, J. E.; Ribeiro, K. B.; Brennan, P.; Boffetta, P.; Buffler, P.; Hung, R. J., Wilms' tumour: a systematic review of risk factors and meta-analysis. *Paediatric and Perinatal Epidemiology* **2010**, 24 (5), 449-69.
389. Brzezinski, J.; Shuman, C.; Choufani, S.; Ray, P.; Stavropoulos, D. J.; Basran, R.; Steele, L.; Parkinson, N.; Grant, R.; Thorner, P.; Lorenzo, A.; Weksberg, R., Wilms tumour in Beckwith-Wiedemann Syndrome and loss of methylation at imprinting centre 2: revisiting tumour surveillance guidelines. *European Journal of Human Genetics: EJHG* **2017**, 25 (9), 1031-9.
390. Szychot, E.; Apps, J.; Pritchard-Jones, K., Wilms' tumour: biology, diagnosis and treatment. *Translational Pediatrics* **2014**, 3 (1), 12-24.
391. Irtan, S.; Ehrlich, P. F.; Pritchard-Jones, K., Wilms tumour: 'state-of-the-art' update. **2016**. *Seminars in Pediatric Surgery* **2016**, 25 (5), 250-6.
392. Lopes, R. I.; Lorenzo, A., Recent advances in the management of Wilms' tumour. *F1000Research* **2017**, 6, 670.
393. van den Heuvel-Eibrink, M. M.; Hol, J. A.; Pritchard-Jones, K.; van Tinteren, H.; Furtwängler, R.; Verschuur, A. C.; Vujanic, G. M.; Leuschner, I.; Brok, J.; Rube, C.; Smets, A. M.; Janssens, G. O.; Godzinski, J.; Ramirez-Villar, G. L.; de Camargo, B.; Segers, H.; Collini, P.; Gessler, M.; Bergeron, C.; Spreafico, F.; Graf, N.; on behalf of the International Society of Paediatric Oncology — Renal Tumour Study, G., Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG **2016** protocol. *Nature Reviews Urology* **2017**, 14, 743.
394. Prasad, M.; Vora, T.; Agarwala, S.; Laskar, S.; Arora, B.; Bansal, D.; Kapoor, G.; Chinnaswamy, G.; Radhakrishnan, V.; Kaur, T.; Rath, G.; Bakshi, S.; Rath, G. K., Management of Wilms tumour: ICMR consensus document. *Indian Journal of Pediatrics* **2017**, 84 (6), 437-45.
395. Brok, J.; Lopez-Yurda, M.; Tinteren, H. V.; Treger, T. D.; Furtwängler, R.; Graf, N.; Bergeron, C.; van den Heuvel-Eibrink, M. M.; Pritchard-Jones, K.; Olsen, O. E.; de Camargo, B.; Verschuur, A.; Spreafico, F., Relapse of Wilms' tumour and detection methods: a retrospective analysis of the 2001 Renal Tumour Study Group-International Society of Paediatric Oncology Wilms' tumour protocol database. *The Lancet. Oncology* **2018**, 19 (8), 1072-81.
396. Brok, J.; Treger, T. D.; Gooskens, S. L.; van den Heuvel-Eibrink, M. M.; Pritchard-Jones, K., Biology and treatment of renal tumours in childhood. *European Journal of Cancer* **2016**, 68, 179-195.
397. McHugh, K.; Roebuck, D. J., Pediatric oncology surveillance imaging: two recommendations. Abandon CT scanning, and randomize to imaging or solely clinical follow-up. *Pediatric Blood & Cancer* **2014**, 61 (1), 3-6.
398. Dumba, M.; Jawad, N.; McHugh, K., Neuroblastoma and nephroblastoma: a radiological review. *Cancer Imaging* **2015**, 15, 5.
399. Neu, M.; Russo, A.; Wingerter, A.; Alt, F.; Theruvath, J.; El Malki, K.; Kron, B.; Dittrich, M.; Lotz, J.; Stein, R.; Beetz, R.; Faber, J., Prospective analysis of long-term renal function in survivors of childhood Wilms tumour. *Pediatric Nephrology* **2017**, 32 (10), 1915-25.
400. Lee, J. S.; Padilla, B.; DuBois, S. G.; Oates, A.; Boscardin, J.; Goldsby, R. E., Second malignant neoplasms among children, adolescents and young adults with Wilms tumour. *Pediatric Blood & Cancer* **2015**, 62 (7), 1259-64.
401. Armstrong, G. T.; Chen, Y.; Yasui, Y.; Leisenring, W.; Gibson, T. M.; Mertens, A. C.; Stovall, M.; Oeffinger, K. C.; Bhatia, S.; Krull, K. R.; Nathan, P. C.; Neglia, J. P.; Green, D. M.; Hudson, M. M.; Robison, L. L., Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. *New England Journal of Medicine* **2016**, 374 (9), 833-42.
402. Dome, J. S.; Graf, N.; Geller, J. I.; Fernandez, C. V.; Mullen, E. A.; Spreafico, F.; Van den Heuvel-Eibrink, M.; Pritchard-Jones, K., Advances in Wilms tumour treatment and biology: progress through international collaboration. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* **2015**, 33 (27), 2999-3007.
403. Skalet, A. H.; Gombos, D. S.; Gallie, B. L.; Kim, J. W.; Shields, C. L.; Marr, B. P.; Plon, S. E.; Chevez-Barrios, P., Screening children at risk for retinoblastoma: consensus report from the American Association of Ophthalmic Oncologists and Pathologists. *Ophthalmology* **2018**, 125 (3), 453-8.
404. Hurwitz, R. L.; Shields, C. L.; Shields, J. A.; Chévez-Barrios, P.; Gombos, D. S.; Hurwitz, M. Y.; Chintagumpala, M. M., Retinoblastoma. In: *Principles and practice of pediatric oncology*, 6th ed. Pizzo, P. A.; Poplack, D. G., Eds. Lippincott Williams & Wilkins: Philadelphia, PA, **2016**.
405. Abramson, D. H.; Beaverson, K.; Sangani, P.; Vora, R. A.; Lee, T. C.; Hochberg, H. M.; Kirsztot, J.; Ranjithan, M., Screening for retinoblastoma: presenting signs as prognosticators of patient and ocular survival. *Pediatrics* **2003**, 112 (6 Pt 1), 1248-55.
406. Dimaras, H.; Corson, T. W., Retinoblastoma, the visible CNS tumour: A review. *Journal of Neuroscience Research* **2018**, 97 (1), 29-44.
407. Canadian Retinoblastoma Society, National Retinoblastoma Strategy Canadian Guidelines for Care: Strategie thérapeutique du retinoblastome guide clinique canadien. *Canadian Journal of Ophthalmology* **2009**, 44 Suppl 2, S1-88.
408. Jenkinson, H., Retinoblastoma: diagnosis and management--the UK perspective. *Archives of Disease in Childhood* **2015**, 100 (11), 1070-5.
409. Dimaras, H.; Corson, T. W.; Cobrinik, D.; White, A.; Zhao, J.; Munier, F. L.; Abramson, D. H.; Shields, C. L.; Chantada, G. L.; Njuguna, F.; Gallie, B. L., Retinoblastoma. *Nature Reviews Disease Primers* **2015**, 1, 15021.
410. Karcioglu, Z. A., Fine needle aspiration biopsy (FNAB) for retinoblastoma. *Retina*. **2002**, 22, 707-710.
411. Linn Murphree, A., Intraocular retinoblastoma: the case for a new group classification. *Ophthalmology Clinics* **2005**, 18 (1), 41-53.
412. Mallipatna, A. C.; Gallie, B. L.; ChévezBarrios, P., Retinoblastoma. In: *AJCC cancer staging manual*. Amin, M. B.; Edge, S.; Greene, F., Eds. Springer International Publishing: Chicago, **2016**.
413. Daniels, A. B.; Mukai, S., Modern surgical techniques in the management of retinoblastoma. *International Ophthalmology Clinics* **2017**, 57 (1), 195-218.
414. Cassoux, N.; Lumbroso, L.; Levy-Gabriel, C.; Aerts, I.; Doz, F.; Desjardins, L., Retinoblastoma: update on current management. *Asia-Pacific Journal of Ophthalmology* **2017**, 6 (3), 290-5.
415. van Dijk Jennifer; Oostrom Kim J.; Huisman Jaap; Moll Annette C.; Cohen-Kettenis Peggy T.; Ringens Peter J.; Imhof Saskia M., Restrictions in daily life after retinoblastoma from the perspective of the survivors. *Pediatric Blood & Cancer* **2010**, 54 (1), 110-5.
416. Lili, Z.; Tao, G.; Yi, S., Quality of life in children with retinoblastoma after enucleation in China. *Pediatric Blood & Cancer* **2018**, 65 (7), e27024.
417. Wong, J. R.; Morton, L. M.; Tucker, M. A.; Abramson, D. H.; Seddon, J. M.; Sampson, J. N.; Kleinerman, R. A., Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy. *Journal of Clinical Oncology* **2014**, 32 (29), 3284-90.
418. Hill, J. A.; Gedleh, A.; Lee, S.; Hougham, K. A.; Dimaras, H., Knowledge, experiences and attitudes concerning genetics among retinoblastoma survivors and parents. *European Journal of Human Genetics* **2018**, 26 (4), 505-17.
419. Allen-Rhoades, W.; Whittle, S. B.; Rainusso, N., Pediatric solid tumours in children and adolescents: an overview. *Pediatrics in Review* **2018**, 39 (9), 444-53.
420. Pierce, J. L.; Frazier, A. L.; Amatruda, J. F., Pediatric germ cell tumours: a developmental perspective. *Advances in Urology* **2018**, 9059382.
421. Frazier, A. L.; Amatruda, J. F., *Pediatric germ cell tumours: biology, treatment, survivorship*. Springer: Heidelberg, **2014**.
422. Johnson, K. J.; Ross, J. A.; Poynter, J. N.; Linabery, A. M.; Robison, L. L.; Shu, X. O., Paediatric germ cell tumours and congenital abnormalities: a Children's Oncology Group study. *British Journal of Cancer* **2009**, 101 (3), 518-21.
423. Pettersson, A.; Richiardi, L.; Nordenskjold, A.; Kaijser, M.; Akre, O., Age at surgery for undescended testis and risk of testicular cancer. *New England Journal of Medicine* **2007**, 356 (18), 1835-41.
424. Poynter, J. N.; Richardson, M.; Roesler, M.; Krailo, M.; Amatruda, J. F.; Frazier, A. L., Family history of cancer in children and adolescents with germ cell tumours: a report from the Children's Oncology Group. *British Journal of Cancer* **2018**, 118, 121.
425. Lin, X.; Wu, D.; Zheng, N.; Xia, Q.; Han, Y., Gonadal germ cell tumours in children: A retrospective review of a 10-year single-center experience. *Medicine* **2017**, 96 (26), e7386.
426. Frazier, L.; Olson, T. A.; Schneider, D. T.; Perlman, E.; Amatruda, J. F., Germ cell tumours. In: *Principles and practice of pediatric oncology*, 6th ed.; Pizzo, P. A.; Poplack, D. G., Eds. Lippincott Williams & Wilkins: Philadelphia, PA, **2016**.
427. Öztürk, Ç.; Fleer, J.; Hoekstra, H. J.; Hoekstra-Weebers, J. E. H. M., Delay in diagnosis of testicular cancer; a need for awareness programs. *PLoS One* **2015**, 10 (11), e0141244.
428. Grantham, E. C.; Caldwell, B. T.; Cost, N. G., Current urologic care for testicular germ cell tumours in pediatric and adolescent patients. *Urological Oncology* **2016**, 34 (2), 65-75.
429. Hubbard, G.; Macmillan, I.; Canny, A.; Forbat, L.; Neal, R. D.; O'Carroll, R. E.; Haw, S.; Kyle, R. G., Cancer symptom awareness and barriers to medical help seeking in Scottish adolescents: a cross-sectional study. *BMC Public Health* **2014**, 14, 1117.
430. Hubbard, G.; Stoddart, I.; Forbat, L.; Neal, R. D.; O'Carroll, R. E.; Haw, S.; Rauchhaus, P.; Kyle, R. G., School-based brief psycho-educational intervention to raise adolescent cancer awareness and address barriers to medical help-seeking about cancer: a cluster randomised controlled trial. *Psycho-oncology* **2016**, 25 (7), 760-71.
431. Pasquale, M. D.; Crocoli, A.; Conte, M.; Indolfi, P.; D'Angelo, P.; Boldrini, R.; Terenziani, M.; Inserra, A., Mediastinal germ cell tumours in pediatric patients: a report from the Italian Association of Pediatric Hematology and Oncology. *Pediatric Blood & Cancer* **2016**, 63 (5), 808-12.
432. Shaikh, F.; Murray, J.; Amatruda, J.; Coleman, N.; Nicholson, J.; Hale, J.; Pashankar, F.; Stoneham, S.; Poynter, J.; Olson, T.; Billmire, D.; Stark, D.;

- Rodriguez-Galindo, C.; Frazier, A., Paediatric extracranial germ-cell tumours. *Lancet Oncology* **2016**, *17* (e149-62).
433. Frazier, A. L.; Hale, J. P.; Rodriguez-Galindo, C.; Dang, H.; Olson, T.; Murray, M. J.; Amatruda, J. F.; Thornton, C.; Arul, G. S.; Billmire, D.; Shaikh, F.; Pashankar, F.; Stoneham, S.; Krailo, M.; Nicholson, J. C., Revised risk classification for pediatric extracranial germ cell tumours based on 25 years of clinical trial data from the United Kingdom and United States. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology* **2015**, *33* (2), 195-201.
434. Frazier, A. L.; Hale, J. P.; Rodriguez-Galindo, C.; Dang, H.; Olson, T.; Murray, M. J.; Amatruda, J. F.; Thornton, C.; Arul, G. S.; Billmire, D.; Shaikh, F.; Pashankar, F.; Stoneham, S.; Krailo, M.; Nicholson, J. C., Revised risk classification for pediatric extracranial germ cell tumours based on 25 years of clinical trial data from the United Kingdom and United States. *Journal of Clinical Oncology* **2015**, *33* (2), 195-201.
435. Billmire, D. F.; Rescorla, F. J.; Ross, J. H.; Schlatter, M. G.; Dicken, B. J.; Krailo, M. D.; Rodriguez-Galindo, C.; Olson, T. A.; Cullen, J. W.; Frazier, A. L., Impact of central surgical review in a study of malignant germ cell tumours. *Journal of Pediatric Surgery* **2015**, *50* (9), 1502-5.
436. Agarwala, S.; Mitra, A.; Bansal, D.; Kapoor, G.; Vora, T.; Prasad, M.; Chinnaswamy, G.; Arora, B.; Radhakrishnan, V.; Laskar, S.; Kaur, T.; Dhaliwal, R. S.; Rath, G. K.; Bakshi, S., Management of pediatric malignant germ cell tumours: ICMR consensus document. *Indian Journal of Pediatrics* **2017**, *84* (6), 465-72.
437. Msaouel, P.; Bilen, M. A.; Zhang, M.; Campbell, M.; Wang, J.; Tu, S., Recent developments in the management of germ cell tumours. *Current Opinion in Oncology* **2017**, *29* (3), 172-8.
438. Frazier, A. L.; Stoneham, S.; Rodriguez-Galindo, C.; Dang, H.; Xia, C.; Olson, T. A.; Murray, M. J.; Amatruda, J. F.; Shaikh, F.; Pashankar, F.; Billmire, D.; Krailo, M.; Stark, D.; Brougham, M. F. H.; Nicholson, J. C.; Hale, J. P., Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: a report of the Malignant Germ Cell International Consortium. *European Journal of Cancer (Oxford, England: 1990)* **2018**, *98*, 30-7.
439. Huang, J.; Tan, Y.; Zhen, Z.; Lu, S.; Sun, F.; Zhu, J.; Wang, J.; Liao, R.; Sun, X., Role of post-chemotherapy radiation in the management of children and adolescents with primary advanced malignant mediastinal germ cell tumours. *PLoS One* **2017**, *12* (8), e0183219.
440. Grabski, D. F.; Pappo, A. S.; Krasin, M. J.; Davidoff, A. M.; Rao, B. N.; Fernandez-Pineda, I., Long-term outcomes of pediatric and adolescent mediastinal germ cell tumours: a single pediatric oncology institutional experience. *Pediatric Surgery International* **2017**, *33* (2), 235-44.
441. Shaikh, F.; Nathan, P. C.; Hale, J.; Uleryk, E.; Frazier, L., Is there a role for carboplatin in the treatment of malignant germ cell tumours? A systematic review of adult and pediatric trials. *Pediatric Blood & Cancer* **2013**, *60* (4), 587-92.
442. Pashankar, F.; Frazier, A. L.; Krailo, M.; Xia, C.; Pappo, A. S.; Malogolowkin, M.; Olson, T. A.; Rodriguez-Galindo, C., Treatment of refractory germ cell tumours in children with paclitaxel, ifosfamide, and carboplatin: A report from the Children's Oncology Group AGCT0521 study. *Pediatric Blood & Cancer* **2018**, *65* (8), e27111.
443. Faure-Contier, C.; Orbach, D.; Cropet, C.; Baranzelli, M. C.; Martelli, H.; Thebaud, E.; Verite, C.; Rome, A.; Fasola, S.; Corradini, N.; Rocourt, N.; Frappaz, D.; Kalfa, N.; Patte, C., Salvage therapy for refractory or recurrent pediatric germ cell tumours: the French SFCE experience. *Pediatric Blood & Cancer* **2014**, *61* (2), 253-9.
444. Badalian-Very, G.; Vergilio, J. A.; Degar, B. A.; MacConaill, L. E.; Brandner, B.; Calicchio, M. L.; Kuo, F. C.; Ligon, A. H.; Stevenson, K. E.; Kehoe, S. M.; Garraway, L. A.; Hahn, W. C.; Meyerson, M.; Fleming, M. D.; Rollins, B. J., Recurrent BRAF mutations in Langerhans cell histiocytosis. *Blood* **2010**, *116* (11), 1919-23.
445. Egeler, R. M.; Katewa, S.; Leenen, P. J. M.; Beverley, P.; Collin, M.; Ginhoux, F.; Arceci, R. J.; Rollins, B. J., Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci. *Pediatric Blood & Cancer* **2016**, *63* (10), 1704-12.
446. Grana, N., Langerhans cell histiocytosis. *Cancer Control: Journal of the Moffitt Cancer Center* **2014**, *21* (4), 328-34.
447. DiCaprio, M. R.; Roberts, T. T., Diagnosis and management of langerhans cell histiocytosis. *The Journal of the American Academy of Orthopaedic Surgeons* **2014**, *22* (10), 643-52.
448. Badalian-Very, G.; Vergilio, J. A.; Fleming, M.; Rollins, B. J., Pathogenesis of Langerhans cell histiocytosis. *Annual Review of Pathology* **2013**, *8*, 1-20.
449. Papadopoulou, M.; Panagopoulou, P.; Papadopoulou, A.; Hatzipantelis, E.; Efstratiou, I.; Galli-Tsinopoulou, A.; Papadopoulou-Alataki, E., The multiple faces of Langerhans cell histiocytosis in childhood: A gentle reminder. *Molecular Clinical Oncology* **2018**, *8* (3), 489-92.
450. Allen, C. E.; Ladisch, S.; McClain, K. L., How I treat Langerhans cell histiocytosis. *Blood* **2015**, *126* (1), 26-35.
451. Allen, C. E.; Merad, M.; McClain, K. L., Langerhans-Cell Histiocytosis. *New England Journal of Medicine* **2018**, *379* (9), 856-68.
452. Jezierska, M.; Stefanowicz, J.; Romanowicz, G.; Kosiak, W.; Lange, M., Langerhans cell histiocytosis in children - a disease with many faces. Recent advances in pathogenesis, diagnostic examinations and treatment. *Postępy dermatologii i alergologii* **2018**, *35* (1), 6-17.
453. Haupt, R.; Minkov, M.; Astigarraga, I.; Schafer, E.; Nanduri, V.; Jubran, R.; Egeler, R. M.; Janka, G.; Micic, D.; Rodriguez-Galindo, C.; Van Gool, S.; Visser, J.; Weitzman, S.; Donadieu, J., Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. *Pediatric Blood & Cancer* **2013**, *60* (2), 175-84.
454. Zinn, D. J.; Chakraborty, R.; Allen, C. E., Langerhans Cell Histiocytosis: Emerging Insights and Clinical Implications. *Oncology (Williston Park, N.Y.)* **2016**, *30* (2), 122-32, 139.
455. Phillips, M.; Allen, C.; Gerson, P.; McClain, K., Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. *Pediatric Blood & Cancer* **2009**, *52* (1), 97-101.
456. Heisig, A.; Sorensen, J.; Zimmermann, S. Y.; Schoning, S.; Schwabe, D.; Kvasnicka, H. M.; Schwentner, R.; Hutter, C.; Lehrnbecher, T., Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature. *Oncotarget* **2018**, *9* (31), 22236-22240.
457. Kolenova, A.; Schwentner, R.; Jug, G.; Simonitsch-Klupp, I.; Kornauth, C.; Plank, L.; Horakova, J.; Bodova, I.; Sykora, T.; Geczova, L.; Holter, W.; Minkov, M.; Hutter, C., Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH. *Blood Advances* **2017**, *1* (6), 352-6.
458. Kotecha, R.; Venkatramani, R.; Jubran, R. F.; Arkader, A.; Olch, A. J.; Wong, K., Clinical outcomes of radiation therapy in the management of Langerhans cell histiocytosis. *American Journal of Clinical Oncology* **2014**, *37* (6), 592-6.
459. Nanduri, V. R.; Pritchard, J.; Levitt, G.; Glaser, A. W., Long-term morbidity and health related quality of life after multi-system Langerhans cell histiocytosis. *European Journal of Cancer* **2006**, *42* (15), 2563-2569.
460. Chow, T. W.; Leung, W. K.; Cheng, F. W. T.; Kumta, S. M.; Chu, W. C. W.; Lee, V.; Shing, M. M. K.; Li, C. K., Late outcomes in children with Langerhans cell histiocytosis. *Archives of Disease in Childhood* **2017**, *102* (9), 830-835.
461. Veys, P. A.; Nanduri, V.; Baker, K. S.; He, W.; Bandini, G.; Biondi, A.; Dalissier, A.; Davis, J. H.; Eames, G. M.; Egeler, R. M.; Filipovich, A. H.; Fischer, A.; Jurgens, H.; Krance, R.; Lanino, E.; Leung, W. H.; Matthes, S.; Michel, G.; Orchard, P. J.; Pieczonka, A.; Ringden, O.; Schlegel, P. G.; Sirvent, A.; Vettenranta, K.; Eapen, M., Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. *British Journal of Haematology* **2015**, *169* (5), 711-8.
462. Kotecha, R. S.; Kees, U. R.; Cole, C. H.; Gottardo, N. G., Rare childhood cancers—an increasing entity requiring the need for global consensus and collaboration. *Cancer Medicine* **2015**, *4* (6), 819-24.
463. Ferrari, A.; Schneider, D. T.; Bisogno, G.; Orbach, D.; Villarroel, M.; Giron, V.; Rodriguez-Galindo, C.; Sorbara, S.; Magni, C.; Chiaravalli, S.; Casanova, M.; Cecchetto, G.; Godzinski, J.; Bien, E.; Stachowicz-Stencel, T.; Brennan, B.; Reguerre, Y.; Sultan, I.; Brecht, I. B., The challenge of very rare childhood cancers in developed and developing countries. *Expert Opinion on Orphan Drugs* **2017**, *5* (4), 331-41.
464. Pappo, A. S.; Furman, W. L.; Schultz, K. A.; Ferrari, A.; Helman, L.; Krailo, M. D., Rare tumours in children: progress through collaboration. *Journal of Clinical Oncology* **2015**, *33* (27), 3047-54.
465. Rodriguez-Galindo, C.; Krailo, M.; Frazier, L.; Chintagumpala, M.; Amatruda, J.; Katzenstein, H.; Malogolowkin, M.; Spector, L.; Pashankar, F.; Meyers, R.; Tomlinson, G., Children's Oncology Group's 2013 blueprint for research: rare tumours. *Pediatric Blood & Cancer* **2013**, *60* (6), 1016-21.
466. Greer, M.-L. C.; Voss, S. D.; States, L. J., Pediatric cancer predisposition imaging: focus on whole-body MRI. *Clinical Cancer Research* **2017**, *23* (11), e6-e13.
467. Gröbner, S. N.; Worst, B. C.; Weischenfeldt, J.; Buchhalter, I.; Kleinheinz, K.; Rudneva, V. A.; Pfister, S. M., The landscape of genomic alterations across childhood cancers. *Nature* **2018**, *555*, 321.
468. Chen, X.; Pappo, A.; Dyer, M. A., Pediatric solid tumour genomics and developmental pliancy. *Oncogene* **2015**, *34* (41), 5207-15.
469. Wedekind, M. F.; Wagner, L. M.; Cripe, T. P., Immunotherapy for osteosarcoma: Where do we go from here? *Pediatric Blood & Cancer* **2018**, e27227.
470. Lawlor, E. R.; Sorensen, P. H., Twenty Years On – What do we really know about Ewing sarcoma and what is the path forward? *Critical Reviews in Oncogenesis* **2015**, *20* (3), 155-71.
471. Dziuba, I.; Kurzawa, P.; Dopierala, M.; Larque, A. B.; Januszkiewicz-Lewandowska, D.; Rhabdomyosarcoma in children - current pathology and molecular classification. *Polish Journal of Pathology: Official Journal of the Polish Society of Pathologists* **2018**, *69* (1), 20-32.
472. Kashi, V. P.; Hatley, M. E.; Galindo, R. L., Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems. *Nature Reviews. Cancer* **2015**, *15* (7), 426-39.
473. Fletcher, J. I.; Ziegler, D. S.; Trahair, T. N.; Marshall, G. M.; Haber, M.; Norris, M. D., Too many targets, not enough patients: rethinking neuroblastoma clinical trials. *Nature Reviews. Cancer* **2018**, *18* (6), 389-400.
474. Cairo, M. S.; Pinkerton, R., Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science. *British Journal of Haematology* **2016**, *173* (4), 507-30.
475. Mauz-Korholz, C.; Stroter, N.; Baumann, J.; Botzen, A.; Korholz, K.; Korholz, D., Pharmacotherapeutic management of pediatric lymphoma. *Paediatric Drugs* **2018**, *20* (1), 43-57.
476. Olson, T. A.; Murray, M. J.; Rodriguez-Galindo, C.; Nicholson, J. C.; Billmire, D. F.; Krailo, M. D.; Dang, H. M.; Amatruda, J. F.; Thornton, C. M.; Arul, G. S.; Stoneham, S. J.; Pashankar, F.; Stark, D.; Shaikh, F.; Gershenson, D. M.; Covens, A.; Hurteau, J.; Stenning, S. P.; Feldman, D. R.; Grimison, P. S.; Huddart, R. A.; Sweeney, C.; Powles, T.; Lopes, L. F.; dos Santos Agular, S.; Chinnaswamy, G.; Khaleel, S.; Abouelnaga, S.; Hale, J. P.; Frazier, A. L., Pediatric and adolescent extracranial germ cell tumours: the road to collaboration. *Journal of Clinical Oncology* **2015**, *33* (27), 3018-28.

Paediatric Integrated Cancer Service

Telephone +61 3 9345 4433

Email pics.admin@rch.org.au

Website www.pics.org.au